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ABSTRACT 
GENETIC MAPPING AND MECHANISM OF ACTION OF RAT MAMMARY 
CARCINOMA SUSCEPTIBILITY QUANTITATIVE TRAIT LOCUS MCSl B 
Aaron D. denDekker 
January 9,2013 
Breast cancer is a complex disease that involves genetic, epigenetic, and 
environmental components. High and moderate penetrant genes have been identified that 
affect risk to developing breast cancer; however, these risk alleles are present in a small 
percentage of breast cancer cases. Low penetrant modifier genes have risk-associated 
alleles that are common in the population. Although these genes have lower penetrance, 
it is expected that the majority of genetic risk to developing breast cancer is controlled by 
common genetic variation. Studying mechanisms of common genetic variants on breast 
cancer risk is difficult due to their small individual effects and overlapping contribution 
of other risk factors; thus, animal models are commonly used. The rat mammary 
,£arcinoma ~usceptibility quantitative trait locus (QTL) Mcsl b was identified between 
mammary carcinoma-resistant Copenhagen (COP) and susceptible Wistar Furth (WF) 
rats on chromosome 2. This rat QTL is an ortholog of a human breast cancer-associated 
locus identified on human chromosome 5q; therefore, the rat Mcsl b model can be used to 
identify mechanisms and causative factors contributing to breast cancer risk associated 
with human breast cancer-associated locus 5q. 
VI 
The goal of the work presented in this dissertation is to identify quality candidate 
breast cancer risk genetic elements associated with the rat Mcsl b locus. This project 
utilized a well-defined rat mammary carcinogenesis system and congenic rat model to 
fine map and characterize the rat Mcsl b locus. My studies reduced the number of 
candidate genes by narrowing the rat Mcslb locus from a 13 megabase (Mb) to a 1 Mb 
containing nine annotated transcripts. I determined that Mcsl b-conferred mammary 
carcinoma resistance is being controlled by a cell type within the mammary gland. This 
is an important finding because mammary carcinogenesis is dependent on both mammary 
gland-extrinsic and -intrinsic factors. I also found that the transcript Mier3 is 
differentially expressed between resistant and susceptible rat mammary glands with or 
without carcinogen exposure providing genetic evidence that Mier 3 is a strong mammary 
carcinoma susceptibility gene. Taken together, these results provide insight into the 
mechanism by which Mier3 controls mammary carcinogenesis and implicate human 
MIER3 as a potential target for breast cancer prevention. 
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CHAPTER I 
GENES, ENVIRONMENT, AND BREAST CANCER 
General Introduction 
Breast Cancer Statistics 
Breast cancer is the leading cause of cancer death in the United States in women 
aged 20-59 and is the second most diagnosed cancer in women in the US (Siegel et aI., 
2012). Additionally, with the exception to skin cancer, breast cancer is the most common 
cancer diagnosed in women worldwide (Mathers et aI., 2008). In the US, it was 
estimated that near 230,000 new cases of invasive breast cancer were diagnosed and that 
almost 40,000 women died of breast cancer in 2012 (American Cancer Society, 2011). 
Breast cancer deaths in women rose 0.4% per year from 1975 to 1990. However, in 
recent years, early detection, increased awareness, better treatments, and decreased use of 
hormone replacement therapies have led to a decrease in breast cancer death rates with a 
2.2% decrease per year from 1990 to 2007 (American Cancer Society, 2011). Still, breast 
cancer remains a major health concern for many women and current risk estimates are 
that lout of8 women in the US will develop breast cancer (Altekruse SF, 2010). 
Breast cancer also affects men; however, male breast cancer only accounts for 
approximately 1 % of breast cancers diagnosed in the US (American Cancer Society, 
2011). Due to its rarity, much less is known about the male form of breast cancer. 
Incidence of male breast cancer has risen from I in 100,000 men being diagnosed with 
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breast cancer in the late 1970's to 1.2 in 100,000 from 2000-2004 (Onami et al., 2010). 
However, breast cancer death rates in men have fallen 3.3% since 2000; likely due to 
increased awareness and better diagnoses (American Cancer Society, 2011; Anderson 
and Devesa, 2005). 
Breast Cancer Risk 
Breast cancer IS a complex disease and the risk of developing it has 
environmental, genetic, and epigenetic components. The most important factors affecting 
risk to developing breast cancer are age and female gender (American Cancer Society, 
2011). As noted, approximately 12% (1 in 8) of US women are predicted to be diagnosed 
with breast cancer based on lifetime risk, and this probability increases as a woman gets 
older (Altekruse SF, 2010; American Cancer Society, 2011). This estimate is based on 
epidemiology of population incidence. However, these estimates may not be accurate for 
many individual women. Risk for an individual may be higher or lower depending on 
various risk factors including age, family history and reproductive history as well as other 
heritable and non-heritable factors (Gail et al., 1989). 
Radiation exposure is one of the most potent exogenous factors known to increase 
chances for developing breast cancer (Land et al., 2003; Ronckers et al., 2005). Although 
exposure to high doses of ionizing radiation is less common, many women are exposed to 
low-dose radiation through mammograms and routine low-dose exposure has been 
associated with an increase in breast cancer risk especially in women already with an 
increased familial risk (Pijpe et al., 2012). Additionally, other non-heritable risk factors 
have been identified e.g., living near nuclear power sites (chronic radiation exposure) and 
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shift work cycles (prolonged exposure to light at night) but these risks aren't fully 
understood (Boice et aI., 2003; Bonde et aI., 2012; Hill et aI., 2011). 
Inherited genetic susceptibility to cancer is now considered an established fact 
(Fletcher and Houlston, 2010). Mutations in several high-risk genes have been identified, 
e.g. BRCAI and BRCA2, that increase a woman's chances of developing breast cancer by 
51-75% and 33-54%, respectively (Antoniou et aI., 2003). Screening for mutations in 
these genes is, under certain circumstances, more routinely conducted; however, 
mutations in these genes account for approximately 3-5% of female breast cancer cases, 
leaving the majority of alleles contributing to breast cancer susceptibility unknown 
(Campeau et aI., 2008; Narod and Salmena, 2011). Conversely, common genetic 
modifiers have a small independent effect but can act cumulatively to exert a greater 
influence on disease development (Jostins and Barrett, 2011; Pharoah et aI., 2008). 
Therefore, the majority of genetic risk to breast cancer development is likely attributable 
to common genetic variation (Fletcher and Houlston, 2010; Lee et aI., 2011). 
Predicting Breast Cancer Risk 
Accurate prediction of an individual's breast cancer risk is vital to developing 
better prevention and treatment strategies. The ability to predict the development of 
disease in an individual has been useful in improving strategies for breast cancer 
prevention; e.g. increased frequency of mammograms for high risk breast cancer patients 
(Jostins and Barrett, 2011). However, breast cancer etiology is complex, which makes 
accurate individual risk assessment problematic for many women. Individual risk for 
developing breast cancer is currently assessed using the Gail model. Gail and colleagues 
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developed a risk-assessment model based on a set of risk factors: age at menarche, age at 
first live birth, number of previous biopsies, and number of first-degree relatives with 
breast cancer (Costantino et aI., 1999; Gail et aI., 1989). An interactive tool has been 
developed by the National Cancer Institute (NCI) and the National Surgical Adjuvant 
Breast and Bowel Project (NSABP) based on the Gail model. This tool is used by 
physicians to assess risk for an individual with a limited family history 
(http://www.cancer.gov/bcrisktool/). 
The Gail model provides an efficient method to project the likelihood to develop 
breast cancer for most individual women; however, it has limitations. First, the Gail 
model only accounts for first degree relatives with breast cancer potentially 
underestimating risk in the 50% of families with cancer in the paternal lineage (Euhus et 
aI., 2002; Evans and Howell, 2007). Also, the Gail model does not take into account the 
age of onset of breast cancer of the affected relative, thereby, possibly overestimating risk 
in women with an affected relative who developed breast cancer late in life. Last, 
although it has been modified to account for ethnic background, the Gail model focuses 
primarily on non-genetic risk factors. Heritable factors are recognized to have significant 
roles in complex disease risk and this is underscored by the importance of accounting for 
family history in risk assessment (Bevier et aI., 2011; Costantino et aI., 1999; Gail et aI., 
1989; Lalloo and Evans, 2012). 
At present, the effects of risk-predisposing genes are difficult to evaluate; thus, a 
better understanding of genetics and the molecular mechanisms that influence breast 
cancer susceptibility is necessary to better predict an individual's risk for developing 
breast cancer. Several low- to moderate-penetrance breast cancer risk alleles have been 
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identified (Easton et aI., 2007; Turnbull et aI., 2010). Relative risk conferred by alleles at 
individual loci is small, but risk alleles are hypothesized to act multiplicatively. It has 
been estimated that risk of developing breast cancer is approximately six times as great 
among women carrying 14 risk alleles as among those carrying no risk alleles at these 
loci (Pharoah et aI., 2008). Although there is little clinical use for single, low-penetrance 
genes, the cumulative effects of these alleles may be useful to separate high risk 
individual women from those at lower risk (Pharoah et aI., 2008). As previously 
mentioned, the genetic contribution to breast cancer development is not fully understood. 
However, new technologies and approaches are available that will allow for the discovery 
of common genetic risk alleles and it is believed that assessing individual breast cancer 
risk based on genetic factors will be achieved in the near future (Jostins and Barrett, 
2011). 
Breast Cancer Risk Factors: Breast Cancer as a Complex Disease 
Estrogen Exposure and Breast Cancer 
As stated earlier, the most widely recognized risk factors to breast cancer 
development are female gender and increasing age (American Cancer Society, 2011). 
Women develop breast cancer at a rate one hundred times that of men and these rates 
increase as women age. This is interpreted as a representation of accumulated exposure 
to ovarian hormones in the form of estrogens and progesterone (Pike et aI., 1993). It is 
thought that women exposed longer to estrogen due to early menarche, late menopause or 
hormone replacement therapy exhibit an increase in breast cancer risk (Kelsey et aI., 
1993; Pike et al., 1993). It was first discovered in 1896 that oophrectomy could 
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effectively regress breast carcinomas (Beatson, 1896). Later observations indicated that 
women who experienced early menarche or late menopause exhibited higher incidence of 
breast cancer (Kelsey et aI., 1993). Also, women who had their first child early (before 
age 18) had a lower incidence of breast cancer than women who had children later in life 
(35 years of age) (Kelsey et aI., 1993; MacMahon et aI., 1970; Pike et aI., 1983). More 
recently, it has been shown that oophrectomy in women before 35 years of age reduces 
breast cancer risk by 75% (Kronenberg and Williams, 2008). Taken together, this 
suggests a pivotal role for endogenous estrogens in the development of breast cancer. 
Estrogen exposure is now considered one of the most important factors 
determining breast cancer risk. Estrogens primarily function to control the estrous cycle 
but have roles in a variety of other processes. There are three forms of estrogen produced 
in the body: estrone (El), estradiol (E2), and estriol (E3). These are made and secreted 
primarily by the ovary but can also be made in other tissues. Of these E2 is the most 
potent as El and E3 bind estrogen receptors a and P (ERa and ERP) with lower affinity 
. compared to E2. However, Eland E3 can be converted to E2. Significantly, E2 is 
secreted by the breast epithelium and adipose and serum E2 levels have been correlated 
with an increase in breast cancer incidence (Kronenberg and Williams, 2008). During the 
1940s, hormone replacement therapy (HR T) was instituted into clinical practice for the 
treatment of menopausal symptoms by administration of exogenous estrogens. 
Subsequent studies of groups of women receiving HRT demonstrated that the relative 
risk (RR) of developing breast cancer for women receiving therapy was elevated 
(RR=2.0) compared to that of the general population (RR=1.3) (Hoover et aI., 1976). 
Breast cancer risk due to HR T was debated for many years citing contradictory studies; 
6 
however, studies conducted by the Women's Health Initiative (WHI) and the Million 
Women Study (MWS) indicate that continued HRT increases breast cancer risk (Beral, 
2003; Rossouw et aI., 2002). Data from the MWS showed the effect of combined 
progesterone-estrogen therapy was greater (RR=2.00, [95% Confidence Interval (CI) 
1.88-2.12], P<O.OOOI) compared to estrogen alone (1.30 [1.21-1.40], P<O.OOOI) when 
compared to women never receiving HRT (Beral, 2003). Women in the WHI 
randomized control study receiving combined estrogen-progesterone therapy also had an 
increase incidence in breast cancer compared to those receiving a placebo (Hazard Ratio 
(HR)= 1.62 [95% CI 1.00-1.59], P<0.05) (Rossouw et aI., 2002). 
Estrogens have been extensively studied to understand the action by which they 
influence breast cancer. Estrogens promote rapid proliferation of mammary epithelial 
cells, which increases the probability that mutations will become fixed and propagated, 
thereby promoting tumor formation (Preston-Martin et aI., 1993). The "canonical" 
estrogen signaling pathway occurs through estrogens binding ERa and ER~. Estrogens 
diffuse passively through cell and nuclear membranes and bind to ERa and ER~ 
(Kronenberg and Williams, 2008). Once an estrogen receptor is bound to an estrogen 
ligand, it undergoes a conformational change and binds to specific DNA sequences called 
estrogen response elements (EREs) to drive transcription of target genes. ERE-bound 
ERs interact with basal transcription factors and co-activator proteins, which stabilize 
basal transcription factor binding and initiate transcription (Klinge, 2000). The products 
of these genes act to promote cell growth and differentiation. 
ERa and ER~ exhibit similar binding affinities for E2, the predominate estrogen 
in premenopausal women, and both ER subtypes have been shown to bind to EREs 
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similarly (Kuiper et aI., 1997; Paech et aI., 1997). Both receptors form homodimers in 
response to ligand binding; however, studies have shown that they can also form 
heterodimers in vitro and in vivo, and that ER~ reduces ERa transcriptional activity (Hall 
and McDonnell, 1999; Pettersson et aI., 2000; Pettersson et aI., 1997). Also, recent 
findings have shown that ER~ can recruit a corepressor complex to the ERa gene 
promoter resulting in reduced expression of ERa (Bartella et aI., 2012). This implies that 
ER~ is acting as an internal regulator of ERa activity. Indeed, ERa expression is often 
higher compared to ER~ in invasive mammary tumors (Leygue et aI., 1998). 
ERs are the active components controlling estrogen signaling and have, thus, 
become popular targets for breast cancer treatment. There are several classes of hormone 
treatment options for breast cancer therapy. Selective estrogen-receptor modulators 
(SERMs), such as tamoxifen and raloxifene, are synthetic agonist/antagonists of the ER. 
In the mammary gland, both of these drugs bind ER as antagonists to prevent ER-
mediated transcription. Alternatively, tamoxifen is an ER agonist in uterus and bone 
while raloxifene acts as an agonist in bone only (Dutertre and Smith, 2000). Other 
chemotherapeutics also act on the ER, such as fulvestrant, an ER antagonist that 
abolishes estrogen-specific gene transcription by degrading the ER (Flemming et aI., 
2009). Aromatase inhibitors (AI), on the other hand, operate indirectly by inhibiting the 
activity of aromatase, the enzyme responsible for converting androgens into estrogens, 
thereby reducing estrogen availability for ER binding (Mokbel, 2002). 
Tamoxifen is the most widely used treatment for ER-positive breast cancers in 
pre- and post-menopausal women. Although tamoxifen is an effective therapeutic, it has 
some disadvantages and limitations. For one, tamoxifen has been shown to increase the 
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chance of endometrial cancer by acting as an agonist in the uterus and endometrium 
(Fisher et aI., 1994; Gottardis et aI., 1988). Also, many breast tumors are unresponsive to 
tamoxifen as they have lost the ability to express ERa (Ring and Dowsett, 2004). One of 
the biggest problems clinicians face when treating with tamoxifen is that many patients 
develop resistance to the drug and relapse (Cui et aI., 2012; Osborne et aI., 2005). Often, 
tumors in these patients continue to express a functionally normal ER yet they grow 
independently of estrogen action. Amplification and over-expression of the growth factor 
receptor HER2 is thought to be a major mechanism contributing to endocrine resistance 
in many cases (Osborne et aI., 2005). Additionally, it is believed that tamoxifen 
resistance in some breast cancers may is due to changes in expression of co-activators 
and co-repressors (Dobrzycka et aI., 2003). For example, the co-repressor Metastatic 
tumor antigen 1 (MTA1) interacts directly with ER and histone deacetylases (HDACs) to 
inhibit ERE transcriptional activity and promote hormone-independent growth. Further, 
MTA1 over-expression correlates with a reduced response to tamoxifen (O'Malley and 
Kumar, 2009). In addition, mis-expression of many of these co-regulators is associated' 
with many cancer types. It is not clear whether this dysregulation is a cause or 
consequence of the pathology; however, co-regulators of ER action appear to be 
important factors in breast cancer pathogenesis. 
Estrogens also function to promote breast carcinogenesis independent of the 
canonical ER-signaling pathway. Several mechanisms have been identified that are 
independent of estrogen receptor activity. For example, Liehr et al. have shown that 4-
hydroxylated estrogen metabolites playa central role in the genotoxic activity of estrogen 
via generation of free radicals, which correlates with increased cancer risk (Liehr, 1990; 
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Liehr and Roy, 1990). Second, estrogen metabolites, catechol estrogen quinones, are 
formed via cytochrome P450 activation. These electrophilic quinine metabolites form 
depurinating adducts on DNA thereby inducing point mutations (Cavalieri et aI., 2002). 
Normally, metabolism of these catechol estrogens by O-methylation, glutathionation, 
glucuronidation, or sulfation renders these inactive; however, studies have shown that 
when levels of catechol estrogen metabolites are increased they cannot be sufficiently 
metabolically inactivated, and this associates with an increase in breast cancer incidence 
(Rogan et ai., 2003). In addition, Barrett and colleagues demonstrated that 
diethylstilbestrol (DES), a synthetic estrogen previously used for the treatment of 
menopause, interferes with microtubule organization at low doses (Tsutsui et ai., 1983). 
Their data indicate that DES does not prevent cell division but, rather, interferes with 
microtubule organization sufficiently to cause non-dysjunction at mitosis resulting in 
aneuploidy (Tsutsui et ai., 1983). Therefore, endogenous estrogens may also be affecting 
carcinogenesis through this pathway. 
Various genetic modifiers have been identified that affect estrogen action in the 
context of breast cancer susceptibility. Common variants have been identified in, ESR2, 
the gene encoding ERP (Maguire et ai., 2005). Gene targeting association studies along 
with in vitro studies suggest these variants may be involved in increasing risk for breast 
cancer. Interestingly, an ultra-rapid metabolizing allele for CYP2C19, CYP2C19*17, has 
been identified that associates with a lower risk for breast cancer (Justenhoven et ai., 
2009). Additionally, deletion alleles of CYP2C19, were identified at an increased 
frequency in familial breast cancer cases from a cohort of Northern Finnish women 
(Pylkas et ai., 2012). CYP2C19 is a gene encoding an enzyme involved in the catabolism 
10 
of E2 implying that increased catabolism of E2 reduces estrogen levels and subsequently 
reduces breast cancer risk. Correspondingly, haploinsufficiency of CYP2C19 may retard 
estrogen catabolism and, thereby, increase risk for breast cancer. What is more, copy 
number variants (CNVs) have recently been discovered in familial breast cancer cases 
that affect genes in estrogen signaling pathways (Pylkas et aI., 2012). Taken together, the 
effects of estrogen signaling in breast cancer development are very complex. Unraveling 
these mechanisms will be useful in determining the role of estrogens in breast cancer and 
may lead to better diagnoses and treatments. 
Progesterone and Breast Cancer 
Progesterone is another steroid hormone involved in mammary gland 
development (Kronenberg and Williams, 2008). Like estrogens, progesterone passively 
diffuses into the cell and binds to either of its cognate receptors, A or B (PR-A or PR-B, 
respectively) and is able to activate gene transcription (Kronenberg and Williams, 2008). 
It rs believed that estrogens and progesterone act in concert to promote ductal branching 
and development of mammary terminal end buds (TEBs), while estrogen is responsible 
for overall growth of mammary ducts emanating from the nipple (Ruan et aI., 2005; 
Singletary and McNary, 1992). Although progesterone is associated with mammary duct 
outgrowth, studies have also shown that PR-deficient animals develop normal mammary 
glands (Kleinberg et aI., 1990; Lydon et aI., 1995). This suggests that progesterone may 
be involved in ductal morphogenesis by acting through an alternative mechanism. 
Although the mechanism by which progesterone is acting is not fully understood, it is 
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held that progesterone plays a role in promoting mammary gland development (Lydon et 
aI., 1995; Ruan et aI., 2005). 
Progesterone is also known to attenuate estrogen action via three separate 
mechanisms (Kronenberg and Williams, 2008). First, progesterone can reduce synthesis 
of ERa (Hsueh et aI., 1976; Tseng and Gurpide, 1975). Second, progesterone can 
activate transcription of the gene coding for 17P-hydroxysteroid dehydrogenase (17P-
HSD), an enzyme involved in the enzymatic inactivation of E2 to the weakly estrogenic 
E1 (Casey et aI., 1994). Third, progesterone induces transcription of estrogen 
sulfotransferases; enzymes that catalyze the conjugation of sulfate groups to E2 and E1 
rendering the estrogens inactive (Falany and Falany, 1996). Therefore, although 
progesterone promotes mammary gland development, it could playa role in reducing the 
deleterious effects of estrogen action. 
Based on these observations, one may expect progesterone to reduce the pro-
tumorigenic effects of estrogen. Not surprisingly, breast tumors that express ER and PR 
are much more sensitive to endocrine chemotherapies compared to ER- and PR-negative 
tumors (American Cancer Society, 2(11). However, the role of progesterone in breast 
cancer risk is confounding. The WHI and the MWS Study found that women taking 
estrogen plus progestin replacement therapy exhibited higher breast cancer incidence than 
those taking estrogen alone (Chlebowski et aI., 2010; Chlebowski et aI., 2003; Travis et 
aI., 2(10). Additionally, postmenopausal women with prior hysterectomy that received 
equine conjugated estrogen alone had a lower incidence of breast cancer compared to the 
placebo group (Anderson et aI., 2(12). This implicates progesterone with a role in 
promoting breast cancer development. 
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The mechanism by which progesterone and PR affect mammary cell proliferation 
and cancer development is not fully understood. In vitro studies have shown that 
progesterone induces cell proliferation by activating protein kinases such as MAPK, 
Akt/PI3K, and c-Src (Boonyaratanakornkit et aI., 2001; Migliaccio et aI., 1998; Saitoh et 
aI., 2005); however, the role this plays in human (i.e. whole animal) physiology is not 
clear and further studies are needed to determine how it effects mammary carcinogenesis. 
What is more, PR expression is driven by ERa but can also be expressed independently 
of ERa (Horwitz et aI., 1982; Lange, 2008). Therefore, it is difficult to ascertain the 
effects of progesterone alone from those of estrogen (Lange, 2008). Regardless, while 
the distinct role of progesterone and PR in breast carcinogenesis is unclear, breast tumor 
PR status is routinely used as a prognostic indicator for response to adjuvant 
chemotherapy and PR-targeted therapies are in use to treat breast cancer (Lange, 2008). 
Exogenous Environmental Effects on Breast Cancer Development 
As described, breast cancer is influenced by both exogenous and endogenous 
environmental chemical carcinogens. The prime example of a physical carcinogen is 
irradiation. Less common than estrogen exposure, ionizing radiation is the strongest 
known exogenous environmental factor affecting breast cancer development (Ronckers et 
aI., 2005). This is based on breast cancer incidence rates in atomic bomb survivors and 
patients receiving prolonged radiotherapy (Land et aI., 2003; Ronckers et aI., 2005). The 
effects of living near nuclear power plants and exposure to low-level ionizing radiation 
sources remains a concern, but has not been extensively studied (Boice et aI., 2003). 
Unrelated to radiation, there has been increasing interest in "light at night" as a risk factor 
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since exposure to light at night due to night shift work correlates with both disruption in 
melatonin secretion and increased breast cancer incidence (Bonde et aI., 2012; Hill et aI., 
2011). Also, exposure to radiofrequency/microwave radiation emissions (RF) from 
wireless communications has become a concern due to the increasing use of mobile 
communication devices. This is thought to playa role in numerous pathologies including 
breast cancer development; however, these areas are relatively new and are not fully 
understood (Hardell and Sage, 2008). 
Many different classes of exogenous chemical carcinogens have been identified 
that associate with breast cancer risk. Some of these act though the estrogen signaling 
pathway. Xenoestrogens, such as polychlorinated biphenyls (PCBs), bisphenol A (BPA) 
and phthalates are structurally different from endogenous estrogens but are able to bind 
ERs and activate mitotic events (Darbre and Charles, 2010; Fernandez and Russo, 2010; 
Kester et aI., 2000; Tsutsui et aI., 2000). Phytoestrogens, such as genestein, are natural 
plant-derived xenostrogens. They are structurally similar to endogenous mammalian 
estrogens and are able to act in a similar manner through the canonical signaling pathway 
(Martin et aI., 1978). Yet, reported effects on phytoestrogens on breast cancer risk are 
conflicting due to studies that have shown protective as well as detrimental effects 
(Darbre and Charles, 2010; Martin et aI., 1978; Safe, 1997; Zhang and Chen, 2011). 
Other chemical carcinogens are able to act to promote breast cancer development 
through estrogen-independent means. Some of the most prominent are polycyclic 
aromatic hydrocarbons (P AHs) and their nitrated metabolites (nitro-P AHs), which cause 
genotoxic effects (Mersch-Sundermann et aI., 1993). For example, PAHs such as 
benzo(a)pyrene (B[a]P) and 7,12-dimethylbenz(a)anthracene (DMBA) are metabolized to 
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form reactive diol epoxide intermediates that directly bind DNA and induce mutations 
(Todorovic et aI., 1997). B[a]P is one of the most well-studied PAHs and it is found in 
many places because it is a byproduct of incomplete combustion of organic matter, e.g., 
cigarette smoke, car exhaust, and industrial smoke stack exhaust (Lawther and Waller, 
1976; Phillips, 1999). DMBA is a synthetic organ-specific PAH also used as a laboratory 
carcinogen (Christou et aI., 1995; Miyata et aI., 2001). DMBA induces expression of 
eYPiBi in a mammary gland-specific manner (Christou et aI., 1987). Thus, CYPIBl, is 
the primary P450 enzyme metabolizing DMBA in the mammary gland. CYPIBl, along 
with epoxide hydrolase, converts DMBA to its carcinogenic diol-epoxide form, which 
makes it ideal to induce carcinogenesis in the mammary gland (Christou et aI., 1987; 
Christou et aI., 1995; Miyata et aI., 1999). DMBA is routinely used as an experimental 
mutagen for research purposes because it models PAH-induced carcinogenesis (Modi et 
aI., 2012). 
Lifestyle-based Factors and Breast Cancer Risk . 
Many different lifestyle-based environmental factors are also contributors to 
breast cancer risk. Tobacco smoke has long been accepted as modifiable lifestyle risk 
factor for many different cancer types although there is limited evidence for its role in 
breast cancer (American Cancer Society, 2012). Obesity and alcohol consumption are 
two other factors that have been identified as risk predictors for developing breast cancer 
(American Cancer Society, 2011; Cannichael, 2006; Hankinson et aI., 1995; Pelucchi et 
aI., 2011). 
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In post-menopausal women, obesity is positively associated with an increased 
incidence of breast cancer and has also been shown to confer a poorer prognosis 
(Carmichael, 2006; Hankinson et aI., 1995). However, studies on pre-menopausal 
women have had conflicting results as some data suggest an inverse relationship between 
weight and breast cancer outcome. Regardless, weight gain and obesity associate with 
poor outcomes in both pre- and post-menopausal women (Carmichael, 2006). 
Adipocytes exhibit increased aromatase expression, the enzyme responsible for 
converting androgens to estrogen (Bulun et aI., 2012; Santen et aI., 2009). Thus, it has 
been postulated that increased estrogen is produced in the breast adipose tissue thereby 
promoting breast cancer development (Bulun et aI., 2012). 
Alcohol consumption increases endogenous estrogen levels and positively 
correlates with breast density and breast cancer incidence (Boyd et aI., 1995; Hankinson 
et aI., 1995). Although alcohol consumption associates with increased incidence of 
breast and other types of cancers, there are also data that suggest beneficial effects from 
alcohol, especially in red wine (de Lorimier, 2000). However, the mechanisms for this 
have not been extensively studied and are currently inconclusive. 
Additionally, the consumption of "well-done" or charred meat has been identified 
as a risk factor to a variety of cancers, including the breast (Zheng and Lee, 2009). 
Heterocyclic amines (HCAs) are the most abundant mutagen found in overcooked meat. 
Studies have identified associations between high-temperature cooked meat intake, HCA 
exposure and breast cancer incidence (De Stefani et aI., 1997; Sinha et aI., 2000; Zheng et 
aI., 1998; Zheng and Lee, 2009). Women who consistently eat overcooked meat have a 
4.6-fold higher RR (95% CI=1.36-15.70) of developing breast cancer compared to 
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women who consume rare or medium-done meat. (Zheng et aI., 1998). Further studies 
found increased levels of 2-amino-1-methyl-6-phenylimidazo( 4,5-b )pyridine (PhIP), the 
most common HCA found in over-cooked meat, to correlate with an increase in breast 
cancer incidence; however, there was no significant effect associated with other HCAs 
(Sinha et aI., 2000). In addition to HCAs, overcooked meat may also contain other 
mutagens such as P AHs including the ubiquitous B[ a]P (Zheng and Lee, 2009). Other 
studies suggest that breast cancer risk associated with HCA exposure may be modified by 
common polymorphisms in genes coding for enzymes responsible for metabolizing 
HCAs, thereby strengthening the role of genetics in breast cancer risk (Deitz et aI., 2000; 
Zheng et aI., 1999; Zheng et aI., 2002). 
Breast Cancer Genetics and Susceptibility Genes 
The etiology of breast cancer is driven by multiple components that include 
environmental factors, physiological host factors, and inherited genetic components. 
Genes influencing complex diseases are inherited according to Mendelian principles. 
However, while Mendelian disorders are monogenic, complex diseases are controlled by 
multiple alleles (Badano and Katsanis, 2002). Genes associated with disease provide a 
genetic predisposition to development of the disease; however, the outcome is determined 
by gene-gene interactions and gene-environment interactions (Hunter, 2005; Marian, 
2012). At present, the interplay between hereditary and environmental factors is not fully 
understood (Hunter, 2005). Although it remains difficult to quantify the magnitude of the 
effect of each of the components on breast cancer etiology, as outlined above, progress is 
being made to begin to estimate the contribution of the genetic components. 
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Women with a family history of breast cancer have an increased breast cancer risk 
(American Cancer Society, 2011; Bevier et aI., 2011; Collaborative Group on Hormonal 
Factors in Breast Cancer, 2001). RR increases with increasing numbers of first degree 
relatives diagnosed with breast cancer with RR=1.80 (99% CI=1.69 - 1.91), 2.93 (2.36 -
3.64) and 3.90 (2.03 - 7.49) for one, two, or three affected first degree relatives, 
respectively (Collaborative Group on Hormonal Factors in Breast Cancer, 2001). Having 
an affected second-degree relative increases risk to a lesser degree, with RR=1.27 (95% 
CI=1.09 - 1.47) and 1.26 (1.05 - 1.50) for either a maternal or paternal grandmother 
affected, respectively. Further, there is a RR=1.60 (1.24 - 2.07) for two affected second 
degree female relatives (Bevier et aI., 2011). Recent epidemiological studies have 
revealed that having a brother diagnosed with breast cancer increases a woman's RR to 
2.48 (95% CI=1.44 - 4.27), which is more than having an affected sister (RR=1.87, 1.80-
1.95). This may suggest that male breast cancer has a higher genetic basis than female 
breast cancer (Bevier et aI., 2011). Clearly, the inherited component affecting breast 
cancer risk is significant. Moreover, estimates based on breast cancer studies in twins 
suggest that the inherited genetic component in the etiology of breast cancer accounts for 
at least 30% of risk (Lichtenstein et aI., 2000). However, Peto (2000) contested that this 
is an underestimate and that the actual contribution is much higher. 
The inherited genetic component of breast cancer in a population consists of both 
highly penetrant genes at a low frequency and those genes that occur at a high frequency, 
but have a low penetrance. High risk alleles have been identified in three genes; BRCA 1, 
BRCA2 and TP53 (Lalloo and Evans, 2012). Mutations in these genes are highly 
penetrant, conferring a 40-85% increase in lifetime risk for developing breast cancer. 
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Additionally, moderately penetrant alleles have been identified in genes such as PALB2, 
BRIPl, ATM, and CHEK2 (Meijers-Heijboer et aI., 2002; Rahman et aI., 2007; Seal et aI., 
2006; Vahteristo et aI., 2002). Variants in these moderately-penetrant alleles confer a 20-
40% increase in breast cancer susceptibility (Lalloo and Evans, 2012). 
Many mutations and variants in highly- and moderately-penetrant genes are 
characteristic of specific ethnic backgrounds; therefore, frequencies of these alleles vary 
across populations due to founder effects and population sizes. For example, mutations 
in CHEK2 exist in ~ 1 % of Dutch, Finnish and Ashkanazi Jewish populations, while 
PALB2 mutations have been identified in Finnish and French-Canadian populations 
(Erkko et aI., 2007; Foulkes et aI., 2007; Nevanlinna and Bartek, 2006). In addition, 
BRCAlI2 mutations have been identified in Ashkanazi Jewish women at frequencies 10-
50 times higher than those in the general population (Neuhaus en et aI., 1996; Oddoux et 
aI., 1996; Roa et aI., 1996; Struewing et aI., 1995). Although variation in these highly-
and moderately-penetrant alleles contribute significantly to breast cancer susceptibility, 
the total population frequency is low with combined frequencies of approximately 0.4% 
for BRCAlIBRCA21TP53 and <0.6% for PALB21BRIlPIATMICHEK2 (Lalloo and Evans, 
2012). Furthermore, less than half of familial breast cancer patients exhibit predisposing 
mutations in these genes (Ford et aI., 1995; Ford et aI., 1998; Smith et aI., 2006). 
Population-based estimates indicate mutations in high-penetrance genes account 
for 25% or less of the heritable component of breast cancer susceptibility (Easton, 1999). 
This suggests that the majority of heritable risk of developing breast cancer is attributable 
to additive, dominant, and interactive effects of low-penetrance genes. However, the 
number and properties of these genes are not known. Much of the work performed to 
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identify low-penetrance breast cancer genes has focused primarily on case-control studies 
targeting potential candidate genes involved in cancer related pathways (de long et aI., 
2002; Nathanson and Weber, 2001). Unfortunately, results of these studies have yet to be 
validated in larger population-based studies (Wooster and Weber, 2003). 
Although useful, risk models that include family history, such as the Gail model, 
are limited in power. It has been calculated, accounting for no genetic factors, that 62% 
of breast cancer cases can be predicted to occur in 50% of the population at high risk and 
15% can be predicted in the 10% of the population at highest risk. However, if all of the 
low-penetrance alleles were known, the ability to predict breast cancer in 50% of the 
population at high risk would increase from 62% to ~90%. This would present the 
opportunity to detect breast cancer earlier (Pharoah et aI., 2002). Therefore, identifying 
and characterizing common, low-penetrance breast cancer genes will strengthen breast 
cancer screening and prevention programs. 
Common Human Genetic Variation and Breast Cancer 
Genetic variation between individuals occurs at a myriad of sites across the 
human genome. These variants fall into two broad classes based on their nucleotide 
composition: single nucleotide polymorphisms (SNPs) and structural variants (Frazer et 
aI., 2009). As the name implies, SNPs are variants at a single base position. To date, 
more than 12 million SNPs have been catalogued (2005). Structural variants are 
insertion-deletions (indels), inversions, block substitutions, and copy number variants 
(Frazer et aI., 2009). The ability to effectively detect structural variants has been lacking; 
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therefore, much is still not known about the frequency of these variants and their 
association with human disease. However, current estimates point toward structural 
variants accounting for 20% of all genetic variation (Frazer et aI., 2009). 
Human genetic variants are defined by their minor allele frequency (MAF), which 
is, simply, the lowest allele frequency that a particular variant is observed in a population. 
Common variants are defined as having a MAF of 1 % or higher. SNPs are observed 
more often than structural variants among individuals and it is estimated that 
approximately 7 million SNPs have a MAF of 5% or higher with the rest being between 
1 % and 5% (Barrett and Cardon, 2006; Frazer et aI., 2009). These SNPs can be used to 
mark common variation that is hypothesized to underlie genetic susceptibility to 
developing breast cancer (Fletcher and Houlston, 2010; Frazer et aI., 2009; Lee et aI., 
2011 ). 
Identifying common genetic variants that contribute to disease requires the ability 
to screen and analyze thousands of variants in a large cohort of individuals in diseased 
and non.:diseased populations. With the advent of high throughput genotyping 
technologies, population-based genome-wide association studies (GW AS), which assess 
thousands of SNPs in thousands of individuals, is possible. In another technological 
advancement, next-generation sequencing techniques that allow for sequencing of large 
regions of genomic DNA in large sample populations can be incorporated into GW ASs. 
By comparing the genotypes of diseased to non-diseased members of a popUlation, novel 
genetic determinants may be identified that associate with disease risk. GW ASs are now 
employed to identify novel common genetic variants that associate with an increased 
susceptibility or resistance to developing breast cancer. Since 2008, 23 breast cancer risk 
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OW AS reports have been published using libraries of common polymorphisms to assay 
genetic variation in human populations (Hindorff et aI., 2009). Several common SNPs 
have been identified in OW AS that associate with increased incidence of breast cancer 
and these SNPs are located in regions containing novel potential breast cancer 
susceptibility genes (Easton et aI., 2007; Turnbull et aI., 2010). Particularly, a OWAS 
by Easton et al. identified five independent loci that showed a strong correlation with 
increased breast cancer incidence (P<10-7) (Easton et aI., 2007). Of these five loci, four 
contain plausible potential causative genes, i.e. FGFR2, MAP3K1, TNRC9, and LSP 1. 
Although these genes are plausible candidates, further study is necessary to confirm 
genes contributing to differences in susceptibility. 
Further, additional SNPs are often in linkage disequilibrium (LD) with variants 
that show a positive association to risk. Put differently, particular SNP alleles will 
frequently be found together in LD and one of these SNPs can be genotyped to "tag" the 
other SNPs in LD. As a consequence, SNPs used in genome-wide screens may only 
mark a region carrying an allele associated with a disease phenotype while the causative 
SNP may be unknown. In other words, the causal variant may not be the one tested in the 
OW AS. Moreover, tagging SNPs tested in a OW AS may also be in LD with common 
structural variants, the majority of which have not yet been identified. This underscores 
one of the limitations of OW AS: there is no simple way of moving beyond statistical 
association to understanding the functional relationship between a genetic locus and a 
complex disease phenotype (Frazer et aI., 2009). 
Another limitation of OW AS is the prospective lack of sufficient statistical power. 
Many OW AS have been conducted using sample sizes of 2,000 to 5,000 individuals and 
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have the statistical power to identify common variants an odds ratio (OR) of 1.5 or higher 
(Altshuler et aI., 2008). To detect variants with an OR of 1.1, studies would require 
60,000 individuals to be tested. Although, some of the common genetic variants already 
identified have per allele OR of <1.30 (Ahmed et aI., 2009; Antoniou et aI., 2010; Cox et 
aI., 2007; Easton et aI., 2007; Garcia-Closas et aI., 2008b; Milne et aI., 2009; Stacey et 
aI., 2008; Thomas et aI., 2009; Turnbull et aI., 2010) it is likely that many low-penetrance 
alleles may have been missed due to the small affect on susceptibility. Additionally, 
novel or rare variants may also be missed by GW AS. Thus, although GW AS have been 
useful in identifying some common genetic variants associated with breast cancer 
susceptibility, new approaches are needed to effectively study common, low-penetrant 
alleles and their effect on disease susceptibility. 
Gene-Environment Interactions 
Further complicating studies of breast cancer susceptibility is the combined action 
of risk-predisposing genes and environmental factors. Aside from studies on genetic 
variants in detoxifying metabolic enzymes, relatively little is known about the majority of 
genetic risk alleles and their potential interactions with the environment (Masson et aI., 
2005). Recent studies have implicated potential interactions between FGFR2 variants 
and hormone replacement therapy; however, these data are inconsistent (Prentice et aI., 
2009; Travis et aI., 2010). Additionally, a study was published on potential interactions 
between ten environmental risk factors (age at menarche, parity, age at first birth, 
breast feeding, menopausal status, age at natural menopause, hormone replacement 
therapy, body-mass index, height, alcohol consumption) and twelve breast cancer 
23 
susceptibility-associated SNPs (Travis et aI., 2010). No strong interaction was identified 
between any of the 120 possibilities. However, the majority of women in this study were 
post-menopausal, and therefore, these data may miss gene-environment interactions 
occurring in younger women. Also, moderate modulations may be occurring that are not 
being detected. Detecting a gene-environment interaction requires a four-fold larger 
sample size than does a main effect; thus, for a RR=-1.5 thousands of cases and controls 
or tens of thousands of GW AS cases would need to be assessed (Thomas, 2010). This 
study examined 7610 women with breast cancer and 10,196 controls; although a large 
sample size, the authors acknowledge it may be insufficient to identify moderate effects 
(Travis et aI., 2010). Furthermore, these studies are somewhat limited in that they 
exclude certain environmental components; i.e. pollutants such as BP A, PHCs and PCBs. 
Exposure to these environmental pollutants is becoming more common and it is relevant 
to assess the effect of exogenous chemical exposure in the environment on breast cancer-
predisposing alleles. 
Animal Models of Breast Cancer Susceptibility 
Mouse Models for Breast Cancer Research 
Human studies provide the most direct way of studying breast cancer 
susceptibility. However, different approaches are needed to identify the effects of low-
penetrant alleles. Human cell lines are routinely used to study breast cancer 
development, progression and metastasis (Burdall et aI., 2003). They have a number of 
advantages; they are easy to handle and represent a potential unlimited self-replicating 
source that can be grown in almost infinite quantities. In addition, they exhibit a 
24 
relatively high degree of homogeneity and are easily replaced from frozen stocks if lost 
through contamination. There are disadvantages though, as cell lines are prone to 
genotypic and phenotypic drift due to continual culture. This occurs as subpopulations 
may arise over time by the selection of specific, more rapidly growing clones within a 
population leading to phenotypic changes (Bahia et aI., 2002; Osborne et aI., 1987). In 
addition to cell growth rate, changes have been observed in hormone receptor content, 
karyotype and clonogenicity, despite the cells appearing morphologically identical. 
However, the most important weakness for susceptibility studies is that cell lines are 
usually derived from tumors and have adapted to growth in culture. Although cell culture 
tries to create a close-to-physiology milieu by adding appropriate amounts of salt, 
glucose, amino acids, vitamins, and serum, the lack of tissue architecture and 
heterogeneous population of cell types often abolishes cell-cell interaction, secretion, and 
other functions based on tissue context (Pan et aI., 2009). As stated, cells in culture are 
prone to genotypic and phenotypic drifting. Thereby cell lines can lose tissue-specific 
functions and acquire a molecular phenotype quite different from cells in vivo. Thus, cell 
lines are limited in scope and cannot fully replicate the disease phenotype. Although they 
can be used to study specific molecular targets in transformed cells they are not an 
effective model to study breast cancer susceptibility. 
Use of animal models has been an effective approach for studying human 
diseases. Various model organisms have been successfully used to study aspects of 
different human diseases in vivo. The most widely used animal models of breast cancer 
are the mouse and the rat. Mouse models have the benefit that more genetic manipulation 
techniques exist for them compared to the rat. Many transgenic models have been 
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developed taking advantage of the long terminal repeat (L TR) of the mouse mammary 
tumor virus (MMTV) (Hutchinson and Muller, 2000). The MMTV-LTR is active in the 
mammary gland and was shown to be able to promote expression of genes in a mammary 
gland-specific manner (Cardiff and Kenney, 2007). The MMTV -Polyoma virus middle T 
antigen MMTV/PyV mT mouse model is one of the most widely used experimental 
animal models used to study mammary tumor development and metastasis. In this 
model, the mT antigen derived from PyV was placed under the transcriptional control of 
the MMTV-LTR (Guy et aI., 1992a). The mT antigen was identified to induce multifocal 
tumors in mammary glands through activation of various signaling molecules such as Src 
family kinases and phosphatidylinositol 3' kinase (PI3K) in mice (Guy et aI., 1992a). 
This mouse model develops polyc1onal tumors aggressively within 7-8 weeks with a high 
degree of lung metastasis (Marcotte and Muller, 2008). The MMTV/PyV mT mouse 
model is often used in combination with gene knockouts to examine the influence they 
may have during mammary carcinogenesis or metastasis. 
Another widely used transgenic mouse model is the HER21neu or ErbB2 mouse. 
HER2 codes for a tyrosine kinase growth factor receptor and is the human ortholog of the 
rat neu oncogene that was identified to increase neuroblastoma development (Coussens et 
aI., 1985; Schechter et aI., 1985). Since it was identified in humans, HER2 has been 
identified to be overexpressed in 20-30% of human breast cancers and has become a 
prime therapy target for treating breast cancer (Wang et aI., 2000). The mouse ortholog 
of HER21neu is ErbB2. ErbB2 was identified to be an oncogene in studies using 
transgenic mice that overexpressed activated neu under the control of an MMTV 
promoter. While mammary epithelial expression of activated neu is sufficient to induce 
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mammary tumorigenesis, few activating mutations in HER2 have been identified in 
humans, suggesting it exerts oncogenic effects through overexpression of the wild-type 
Her2 receptor (Lemoine et aI., 1990). The ErbB2 transgenic mouse model of breast 
cancer was developed with a trans gene carrying the wild-type ErbB2 proto-oncogene 
under the control of the MMTV promoter (Guy et aI., 1992b). Overexpression of wild-
type ErbB2 results in multi focal tumors, but they occur with a longer latency compared to 
the MMTV-PyV mouse model of breast cancer. Further, MMTV-ErbB2-induced 
mammary tumors are less metastatic than MMTV-PvV-induced tumors (Guy et aI., 
1992b). Regardless, the ErbB2 transgenic mouse model has been used extensively to 
examine the role of the ErbB2 proto-oncogene in mammary tumor development. In 
addition, the MMTV system has been extensively used to study other proto-oncogenes, 
e.g., c-myc and cyclin Dl (Stewart et aI., 1984; Wang et aI., 1994). Overall, the use of 
the MMTV transgenic mouse system has led to a greater understanding of the genetic 
machinery of mammary carcinogenesis. 
In addition to transgenic mouse models, gene knockout mice are regularly used 
and these have been combined with 'knock-in' and conditional tissue-specific gene 
targeting technologies allowing for a wide range of approaches to study human disease 
(Hutchinson and Muller, 2000; Maddison and Clarke, 2005). These studies involve 
deleting or inserting specific genes of interest into a targeted region using targeted 
recombination. Moreover, the development of the Cre-Lox system has allowed for 
conditional and/or temporal deletion of target genes (Maddison and Clarke, 2005). With 
this method, specific regions of DNA, e.g. whole genes, exons, promoters, are flanked by 
specific pieces of DNA termed 10xP sites oriented in the same direction. When crossed 
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with mice carrying the Cre recombinase gene, Cre expression carries out 10xP-specific 
recombination in a topoisomerase-like manner; thereby cleaving out the intervening 
sequence between the two 10xP sites (Maddison and Clarke, 2005). When Cre is under 
the control of a tissue- or development-specific promoter, the knockout is directed to 
specific sites and/or at specific points in development. Also, inducible systems have been 
developed to control expression of genes when administered a specific inducer. Gossen 
and Bujard developed the tetracycline (tet)-dependent transcriptional activation system 
allowing spatial and temporal control of effector gene expression through the use of a 
tissue-specific transactivator (Gossen and Bujard, 1992). When an effector gene is under 
the control of the tet system, expression is activated only when the mouse is administered 
tetracycline in the diet. Therefore, gene expression can be easily turned on or off. 
Moreover, Cre can be placed within a tet-dependent system making it inducible (Gossen 
and Bujard, 1992; Maddison and Clarke, 2005). This way, the knockout only occurs 
once the mouse has been administered tetracycline. However, the Cre-Lox system has 
been found to have "off target" effects where Cre acts on lox-like sites causing 
inadvertent deletion (Maddison and Clarke, 2005). Regardless, the Cre-Lox and the tet-
inducible systems have been useful in dissecting pathways of genes involved in a host of 
diseases. 
A genetic "tool box" has been developed for the mouse making it a useful model 
to study the genetic and molecular aspects of human disease. The mouse has been 
instrumental in identifying mechanisms of specific genes involved in mammary 
carcinogenesis and this has increased our knowledge of these genes in human breast 
cancer. There are additional models and technologies not mentioned that are being 
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employed to study many human diseases including breast cancer. Furthermore, new 
technologies for using the mouse continue to be developed. 
Rat Models of Breast Cancer Susceptibility 
Although mice are widely used to study mammary carcinogenesis, there are some 
key differences between mice and humans in the pathology of mammary and breast 
tumors that each species develops. First, ~50% of breast carcinomas arising in humans 
are ERa positive and thus are hormonally responsive while mouse mammary tumors are 
almost exclusively ERa negative and hormone independent (Marcotte and Muller, 2008). 
Also, human mammary gland tissue is primarily made up of connective tissue, while 
mouse mammary gland stroma consists mainly of adipocytes (Marcotte and Muller, 
2008). Thus, mouse model studies on mammary carcinogenesis are lacking in their 
ability to translate to human breast cancer. 
The laboratory rat is preferable for the study of breast cancer susceptibility 
because the pathology of rat mammary cancer is more similar to human breast cancer. 
Although mouse models clearly have merit in understanding human disease, rats are 
more similar to humans than mice in their normal physiology and pathogenesis. Both 
rats and humans develop tumors that arise in epithelial cells lining the mammary gland 
duct have similar histopathology, and both develop the same proportion of hormone-
dependent and endocrine therapy, e.g., tamoxifen, -responsive carcinomas (Gould, 1995). 
This is contrary to the mouse where most mammary tumors are hormonally refractive and 
many tumors are of endothelial cell origin (Gould, 1995). Additionally, while a majority 
of mammary tumors that form in mice are induced by MMTV, rats and humans do not 
form mammary tumors with a known viral etiology (Gould, 1995). Finally, and most 
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importantly for mammary gland susceptibility studies, rats and humans both have a 
natural genetic variation in mammary and breast carcinoma susceptibility (Dunning and 
Curtis, 1952; Dunning et aI., 1947; Gould, 1995; Isaacs, 1986; Isaacs, 1988). These 
similarities make the rat an ideal model to study natural variation in development of 
. . 
mammary carcmogeneSlS. 
Various rat models have been developed to study breast cancer susceptibility. 
Age and gender are the most widely accepted risk factors affecting breast cancer 
development and this has been attributed to ovarian hormone exposure. Dunning et al. 
discovered that the ACI rat strain was susceptible to estrogen-induced mammary cancers 
(Dunning and Curtis, 1952; Dunning et aI., 1947; Dunning et aI., 1953; Shull et aI., 
1997). Conversely, Copenhagen (COP) rats are almost completely resistant to developing 
estrogen-induced mammary tumors. In this regard, ACI and COP rats are commonly 
used together to study estrogen action in the rat. Specifically, ACI female X COP male 
and COP female X ACI female intercrosses were performed to generate Fla and FIb 
progeny, respectively. Fl progeny were administered E2 to induce carcinogenesis and 
tested for mammary carcinoma susceptibility. Data indicated no significant difference in 
tumor incidence between F 1 a, FIb or homozygous ACI rats. However, latency to 
appearance of the first E2-induced mammary tumor was significantly prolonged in both 
Fl populations compared to ACI homozygous rats (Shull et aI., 2001). Further, siblings 
from Fla and FIb progeny were mated to each other to generate F2a and F2b progeny, 
respectively, and Fla and FIb males were mated back to ACI females to generate 
backcrosses a (BCa) and BCb progeny, respectively. Using these lines a locus was 
mapped on chromosome 5 that conferred susceptibility to estrogen-induced mammary 
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carCInoma development. This method was further utilized to identify multiple 
quantitative trait loci (QTLs) in the ACI rat responsible for estrogen-induced mammary 
carcinoma susceptibility (Gould et al., 2004; Kurz et al., 2008; Shull et al., 2001). 
Other rat lines have varying propensities for developing exogenous non-estrogen 
carcinogen-induced mammary carcinomas. The Wistar Furth (WF) rat strain was 
identified to be susceptible to developing spontaneous, radiation-, oncogene-, and 
carcinogen-induced mammary carcinomas (Gould, 1986; Moore et al., 1983). 
Conversely, the COP rat strain is susceptible to ionizing radiation and oncogene-induced 
mammary carcinogenesis, but is almost completely resistant to developing chemical 
carcinogen-induced mammary tumors (Isaacs, 1988). Studies using ionizing radiation on 
(WF X COP) Fl rats detected random allelic imbalances throughout the genome leading 
to development of mammary tumors with no preferential loss for either the WF or COP 
parental alleles (Haag et al., 1996). This indicates that neither the WF nor COP allele 
confer resistance to radiation-induced mammary carcinogenesis. Additionally, both WF 
and COP females treated with a v-H-ras oncogene-containing retrovirus directly infused 
into the mammary gland develop similar tumor incidences (Wang et al., 1991). As 
previously mentioned, COP rats are resistant to estrogen-induced tumors; however, 
hormonal promotion enhanced the penetrance of the ras oncogene on mammary tumor 
formation in both COP and WF female rats in a similar manner (Wang et al., 1991). 
Although the COP and WF rats showed similar tumor incidence from ras oncogene 
induction, COP tumors were more differentiated and less invasive than WF tumors 
(Wang et al., 1991). This suggests that although oncogene activation in situ was able to 
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ultimately overcome the resistance phenotype, COP rats still exhibit a less malignant 
phenotype compared to WF rats. 
Mammary Carcinoma Susceptibility Quantitative Trait Loci 
Mammary Carcinoma Susceptibility Alleles 
The rat is not as easily genetically manipulated as the mouse. Until recently, 
chemical or random-insertional mutagenesis screens had been employed in the rat to 
identify causative genes for specific phenotypes (Aitman et aI., 2008). Now, transgenic 
rat models are available and it is possible to generate knockout lines (Aitman et aI., 2008; 
Geurts et aI., 2009). However, these approaches are biased towards particular genes of 
interest or involve disrupting the genetic architecture by random insertion of foreign 
DNA into the chromosome. Although these methods may be used for validating or 
studying the effects of specific genes, they are not suited for forward genetics studies 
focused on identifying genotypes responsible for disease susceptibility phenotypes. 
Instead, congenic rat lines have been developed that allow one to study mammary 
carcinoma susceptibility in a "natural" context. Congenic lines take advantage of varying 
susceptibility phenotypes between different rat strains. Congenic rat lines for mammary 
carcinoma susceptibility studies are developed by introgressing alleles from a resistant 
strain onto a susceptible strain by first identifying an allele of interest in an F 1 population 
and then continuously backcrossing to a recipient strain. By genotyping and selecting for 
the donor allele of interest, the donor allele is retained and introgressed onto the genotype 
of the recipient background strain (FibJUre 1) (Markel et aI., 1997). Lines with different 
segments of the donor allele can be tested to map a genetic locus to define the allele of 
interest. 
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Figure 1: Congenic Breeding Scheme. Homozygous susceptible male rats (WF) are 
bred to female resistant rats (COPIWKy/BN) to create an FI heterozygous population. 
FI progeny are genotyped for the allele of interest. FI males containing the allele of 
interest are backcrossed to WF females to produce the N2 population. At each 
subsequent generation the litters are genotyped and males carrying the allele of interest 
are backcrossed again to WF females . At the N8 generation, speed congenics are 
potentially viable to use for mapping as the background genotype is >99%. However, 
backcrossing to NIO is common. At NIO (or N8) heterozygous male and female 
littermates are inbred and the offspring are genotyped to identify pups homozygous for 
the target allele. These homozygotes are inbred continuously to fix the line for the allele 
of interest. 0 , . and • represent resistant female, susceptible male, and susceptible 
female rats, respectively. The gray shade of a circle or square depicts the genotype 
percentage of the background genome in heterozygous offspring; i.e. as the percentage of 
the background genome becomes more WF, the shade becomes darker gray . • , L\I, and 
~ inside a circle or square represent the target allele when it is homozygous WF, 
homozygous COP, and heterozygous, respectively. 
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Work by our group employs congenic strains developed with resistant alleles 
COP and Wistar Kyoto (WKy) donor strains on a WF background denoted as WF.COP 
and WF.WKy congenic lines, respectively. In contrast to WF rats, COP and WKy rats 
have been shown to be almost completely resistant to developing mammary carcinomas 
induced by the chemical carcinogens DMBA and N-Nitroso-N-methylurea (NMU) (Haag 
et aI., 1992; Isaacs, 1986). 
WF.WKy and WF.COP have been used to identify novel independent loci 
affecting mammary carcinoma susceptibility (Cotroneo et aI., 2006; Haag et aI., 2003; 
Lan et aI., 2001; Samuelson et aI., 2003). These QTLs have been denoted as mammary 
farcinoma ~usceptibility (Mes) loci. The first Mes locus, Mesl, was found in a DMBA-
induced carcinogenesis study on female progeny from a (WF X COP)Fl X WF backcross 
(Hsu et aI., 1994). Since then, WF.COP and WF.WKy congenic lines have been used to 
identify other Mes loci: Mes2, Mes3, and Mes4, all found in WF.COP congenics, and 
Mes5, Mes6, Mes7 and Mes8, found in WF.WKy congenics (Lan et aI., 2001; Shepel et 
aI., 1998). Each strain, COP or WKy, has three QTLs that increase and one that 
decreases susceptibility to developing DMBA-induced mammary tumors. Only one QTL 
in each strain overlaps with a QTL at the same genetic locus in the other strain. These 
are COP Mes2 and WKy Mes6. This illustrates the genetic diversity of mammary 
carcinoma genetic susceptibility as both of these strains are highly resistant to developing 
DMBA-induced mammary carcinomas. 
Mammary Carcinoma Susceptibility Locus lb (Mcslb) 
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As stated above, (WF X COP)F1 X WF backcrosses were used to identify the 
Mesi locus. Rats were divided into groups based on susceptibility: resistant (R), 
undetermined (U), and susceptible (S). Rats from Rand S groups were genotyped using 
micro satellite markers and the locus conferring resistance was determined to be on the 
proximal end of chromosome 2 (Hsu et al., 1994). Resistant congenic F1 rats were 
backcrossed to WF rats and progeny were genotyped to identify shorter regions of the 
interval to fine map the Mesilocus. Results ofphenotyping showed that the Mesilocus 
contained 3 independent loci that each reduced DMBA-induced tumor incidence by 
~60% compared to homozygous WF controls (Haag et al., 2003). These were termed 
Mesia, Mesib, and Mesie (Figure 2). Interestingly, one of these loci, Mesib, contains a 
region orthologous to a human locus identified in a GWAS of breast cancer susceptibility 
(Easton et al., 2007). 
Easton et al. (2007) reported the identification and validation of five novel breast 
cancer susceptibility loci in a 3-stage breast cancer GWAS (Easton et al., 2007). One of 
these SNPs, rs8893J2, has MAF of 0.38 with an allelic OR of 1.13 (95% CI=1.10 - 1.16) 
and associates with an increase in breast cancer incidence (P=7 x 10-2°). Additionally, 
SNP rs8893J2 localizes to a region on human chromosome 5 and is in LD with 6 other 
SNPs contained within a 280 kb haplotype block (Figure 3)(Barrett et al., 2005). 
Importantly, this human haplotype block is orthologous to a region within the rat Mes i b 
locus. There are three transcripts annotated to the human locus delineated by the 280 kb 
haplotype block; MAP3Ki, MIER3, and C50RF35 (Figure 3). These transcripts are also 
annotated to the rat Mesib locus. In addition there are 7 more transcripts annotated that 
lie nearby, but outside the 280 kb haplotype block on the human locus, that are also 
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Figure 2: Chromosome 2 genetic map of Mcsl-congenic and -recombinant rat lines. Rat 
lines are designated with capital letters . . , indicates the presence of two COP alleles 
for congenic lines resulting in reduced mammary tumor development (one to four 
carcinomas/rat); D indicates the presence of two COP alleles for congenic lines 
incapable of conferring resistance to tumor development (six to eight carcinomas/rat). D, 
indicates areas of unknown genotype because of recombination. Three independent 
regions of chromosome 2 were capable of conferring resistance to mammary cancer 
development in COP-homozygous congenic rats. These genomic regions are shown 
as Mcsl a, Mcsl b, and Mcsl c. The chromosome markers used to identify the congenic 
rats are listed to thefar right of the figure with genetic distances in centiMorgans (cM) to 
the left of the marker names. The Mcsl QTL I-LaD interval is also shown between 
D2Mit29 and D2Uwm13. 
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Figure 3: 280 Kb haplotype block containing breast cancer-associated SNP rs889312. 
Transcripts are shown in blue with exons designated as vertical bars. Above, the location 
of the tagging SNP rs889312 is shown in red, other SNPs in LD with rs889312 are 
shown in black. Below, pairwise r2 values for LD are shown; light blue represents lower 
disequilibrium, white is intermediate, and red represents strong disequilibrium. An l 
threshold of 0.80 was used to determine SNPs in LD in this block. 
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contained in the rat Mcslb locus; GPBPl, IL31RA, IL6ST, DDX4, ANKRD55, ACTBL2, 
and SLC38A9. MAP3Kl has been described as the most likely candidate gene due to its 
role as a protein kinase and involvement in promoting cell growth and proliferation; still, 
any of these genes could be involved in affecting breast cancer susceptibility in humans. 
Furthermore, any of the SNPs or combination of variants in LD with rs889312 could be 
causative to affect breast cancer susceptibility. Therefore, each SNP must be studied to 
identify the causative variant. The original study identifying this human locus consisted 
of an initial two-stage GWAS on 4,398 breast cancer cases and 4,316 controls, followed 
by a third stage testing 21,860 cases and 22,578 controls from 22 studies (Easton et aI., 
2007). Testing individual SNPs in LD with rs889312 in this population would offer a 
better view of the genetic composition associated with this phenotype; however, this 
provides no insight into their function. Studying the molecular mechanisms by which 
these SNPs are operating in a human population is not realistic. Therefore, the WF.COP 
Mcsl b congenic rat line is a good model to study this locus in the context of breast cancer 
susceptibili ty. 
There are over 50 transcripts annotated within the rat Mcs 1 b locus. It is 
anticipated that the causative gene is conserved between humans and rats which reduces 
the number of viable gene candidates to be tested. Nonetheless, all of the transcripts 
annotated to the current rat Mcsl b locus must be treated as potentially causative; thus, all 
genes must be tested. It is useful, then, to attempt to reduce the number of genes to be 
tested by narrowing the current rat Mcs 1 b locus by means of positional mapping. The rat 
genome has been sequenced and many microsatellite and SNP markers are available to 
effectively map Mcslb to a narrower interval. Testing genes in the rat may identify the 
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causative gene involved at the human locus. Related to this, the Mcs 1 b rat model can 
also be used to study the cellular and physiological phenotypes affecting mammary 
carcinogenesis associated with this locus. On the whole, aMes 1 b rat genetic model could 
help determine mechanisms controlling human breast cancer that are associated with the 
locus demarcated by SNP rs889312 and expand our current understanding of breast 
cancer etiology. 
Dissertation Overview 
Overall Goal 
The work presented in this dissertation is focused on using congenic WF.COP 
Mcslb rat lines to study mammary carcinoma susceptibility. I made use of the varying 
propensity for developing mammary tumors between WF.COP Mcslb congenic female 
rats and homozygous WF female rats. The overall goal was to narrow the genetic 
interval and to identify potential gene candidates. Mapping the Mcslb locus to a shorter 
interval reduces the number of potential gene candidates and focuses on identifying the 
causative gene(s). Identification of the causative gene(s) could lead to development of 
novel genetic tests for better diagnosis as well as novel targets for prevention and 
treatment of breast cancer. In addition, I began to identify the cellular mechanism by 
which rat Mcsl b affects mammary carcinogenesis and tumor development. By 
elucidating the means by which this susceptibility locus is working, we will increase the 
current understanding of breast cancer etiology. 
Hypothesis and Research Aims 
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I hypothesized that the rat Mcsl b locus contains genetic elements controlling 
molecular and cellular phenotypes that translate into mammary carcinoma susceptibility 
phenotypes. By completing aim one; I successfully delimited the rat Mcslb locus to a 
region of 1.1 Mb containing three genes. In aim two, I identified that the mammary 
carcinogenesis susceptibility allele is acting in a mammary gland cell-autonomous 
manner. In aim three, I show that the transcript Mier 3 is a candidate modifier gene 
controlling mammary carcinogenesis based on its differential transcript expression 
between susceptible and resistant rat strains. These data will help us better understand 
breast cancer etiology and may lead to better diagnoses and treatments of human breast 
cancer. 
42 
CHAPTER II 
RAT MCS1B IS WITHIN Al MB REGION OF RAT CHROMOSOME 2 
Introduction 
The rat Mesilocus was originally identified on the proximal end of chromosome 
2 in (WF x COP)F1 x WF backcrosses using DMBA to induce mammary carcinomas 
(Hsu et aI., 1994). Previously, the Mesilocus was physically confirmed and positionally 
mapped using congenic lines containing unique segments of the Mesl predicted QTL 
interval. Female rats from these lines were tested using the same DMBA carcinogenesis 
protocol and revealed that the locus contained three independent susceptibility loci that 
conferred resistance to developing mammary carcinomas. These QTLs were termed 
MesIa, Mesib and MesIc (Haag et aI., 2003)(Figure 2). 
The Mesl b locus is of particular interest because it is orthologous to a human 
locus associated with increased breast cancer incidence that was identified in a GW AS 
(Easton et aI., 2007). The human breast cancer risk-associated allele was tagged with 
SNP rs8893I2 which lies within a 280 kb LD block on human chromosome 5. This LD 
block contains three annotated transcripts; MAP3KI, MIER3, and C50RF35 (Figure 3). 
The rat ortholog to this locus is contained in the Mes I b congenic line T interval, which 
was mapped to a region delimited from marker D2UwmI7 to D2Meo42 (Chr2: 32051319 
- 45248161). This locus contains over 50 annotated transcripts, including Map3kl, 
Mier3, and C50rj35. Mapping rat Mesl b to a narrower region will reduce the number of 
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candidate genetic elements to be functionally tested and minimize the work required for 
comparative genetic studies. 
Many QTLs are multigenic or affected by more than one genetic element. For 
that reason, two or more elements may potentially act in concert to affect susceptibility. 
Narrowing the interval may provide insight into the function of this locus. Accordingly, I 
attempted to map the Mcslb locus to a tighter interval using a congenic mapping 
approach previously used to segregate and identify three independent loci contained 
within the original Mcsl locus (Haag et aI., 2003). This approach will reduce the genetic 
elements to be functionally tested as well as potentially identify complex genetic 
interactions or additional risk alleles within the line T Mcs 1 b interval. 
The advantages of the rat over a mouse model have been noted. However, there 
are other rat-centric methods that could be employed, e.g., transgenic rat models, rather 
than the congenic approach used in these studies. Many genes are annotated to the rat 
Mcsl b locus, as it is currently defined, and these could be tested in a transgenic rat model 
by introducing the genes as transgenes under the control of an artificial promoter. 
However, this approach would be extremely labor-intensive requiring the development of 
over 50 transgenic lines. Further, gene regulatory elements cannot be cloned into 
traditional transgenic cassettes. This is critical, since we do not know the transcript 
profile of the hypothesized candidate gene. In this regard, bacterial artificial 
chromosome (BAC) transgenic rats may be useful. BAC transgenics allow for up to 400 
kb of foreign DNA to be cloned so that all the regulatory elements may be included. For 
this reason, BAC transgenes are expressed in a more spatially, temporally, and 
physiologically accurate manner. The current Mcsl b locus is delineated to a ~ 15 Mb 
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interval containing 50 transcripts; thus, much like traditional transgenics, the BAC 
trans gene method would also require many lines to be developed to tile across the region. 
Moreover, if there are multiple components involved, using a BAC transgenic may 
"hide" these effects. Another shortcoming of this method is that the BAC transgene is 
incorporated randomly in the genome. Although regulatory elements and surrounding 
DNA are included, this technique disregards possible long range effects, e.g., distal 
enhancers and long range cis regulatory elements, thereby altering the context. 
Although laborious and time-consuming, the congenic rat model is the preferred 
approach. It is powerful in that it is unbiased with regard to the cause of action, i.e., the 
heritable element(s) controlling the susceptibility phenotype may be non-protein coding 
regulatory elements that control expression or processing, causative elements may be in 
cis of secondary element, or they may be multigenic and require multiple factors. 
Overall, congenics allow one to study the action of the Mcsl b locus in its native 
physiologically-relevant environment. For these reasons, I continued to use the 
previously-described congenic approach for these studies. 
Until now, the rat Mcsl b region has been genotyped using microsatellite markers. 
The genome sequence for the rat is available and groups are attempting to develop SNP 
maps of the rat genome (Nijman et al., 2008; Saar et al., 2008). However, the annotated 
sequence is based on the Brown Norway (BN) strain, and the COP and WF genomes 
were not included in SNP and haplotype studies; therefore, there are no well-documented 
polymorphisms between the COP and WF lines in the Mcslb region. Identifying new 
polymorphisms between the WF and COP strains will provide better markers to more 
accurately map the Mcslb locus. Moreover, within the 280 kb haplotype block 
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containing the human Mcslb ortholog, SNP rs889312 is in LD with 6 other annotated 
SNPs: rs12697152, rs1910020, rs1862625, rs1862626, rs4700485, and rs961847 (Figure 
3). Any of the SNPs lying in the 280 kb LD block could be causative. However, it is not 
clear which of these SNPs, if any, is the causative variant responsible for conferring 
breast cancer susceptibility. Rat orthologs to the 7 human SNPs lying within the LD 
block are not known. Consequently, identifying novel polymorphisms between the WF 
and COP rat lines could potentially lead to identifying the causative SNP controlling 
mammary carcinoma susceptibility and comparative genetics could be used to accurately 
identify the causative SNP in the human genome. 
Overall, identifying novel polymorphisms between the WF and COP strains will 
add to the current knowledge of these strains and can be used for the mapping studies 
described herein. These SNPs are potentially useful in that they may shed light on the 
causative element responsible for the difference in mammary carcinoma susceptibility 
between these two rat lines and identify the causative variant in the human genome. 
Fine-mapping this region in the rat will reduce the number of potential gene candidates 
that must be functionally evaluated. As stated, this approach is powerful in that it is 
unbiased with regards to the cause of action, i.e., the heritable element(s) controlling the 
susceptibility phenotype may be a regulatory element(s) controlling expression or 
processing of a transcript. In addition, these elements may lie within or outside of the 
protein coding region of the gene. Indeed, all of the SNPs in the human breast cancer-
associated haplotype block lie outside of the transcribed regions of any of the annotated 
transcripts. Furthermore, this approach may uncover complex genetic interactions and/or 
potential additional mammary carcinoma susceptibility loci that lie within the region. 
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Design and Methods 
Resequencing 
WF and COP rats were euthanized and splenectomized using a protocol approved 
by the University of Louisville Institutional Animal Care and Use Committee (IACUC). 
Spleens were frozen until DNA was isolated. DNA was isolated using a Gentra Tissue 
DNA Extraction Kit (Gentra, Minneapolis, MN) and PCR amplified using AccuPrime 
Taq polymerase (Life Technologies, Grand Island, NY) at specific regions defined in an 
article by Cuppen and colleagues (Nijman et aI., 2008) or compiled in the STAR 
Consortium SNP database (http://www.snp-star.eu/). These PCR products were purified 
using a QIAquick PCR Purification Kit (QIAGEN, Valencia, CA) and sequenced using 
the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies). Sequencing 
reaction products were purified with 5 I.d Agencourt AMPure XP beads and 80% ethanol. 
Beads were washed once with 80% ethanol and subsequently eluted in molecular biology 
grade water. Sequence products were submitted for analysis to the University of 
Louisville Center for Genetics & Molecular Medicine DNA Core using an ABI PRISM 
3130XL Sequence Detection System (Life Technologies). 
Additionally, random regions across the Mcslb locus were selected to be 
amplified and sequenced to identify polymorphisms. Using the UCSC genome browser, 
regions exhibiting stretches of di- and tri-nucleotide repeats were selected and primers 
were designed using Primer3 (Rozen and Skaletsky, 2000) oligonucleotide design 
software. Primers were obtained from Integrated DNA Technologies (IDT, Coralville, 
IA). Using these primers, genomic DNA (gDNA) was PCR amplified and run on high-
resolution agarose gels to identify potential micro satellite polymorphisms between WF 
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and COP sequence. Additionally, long spans were selected randomly across the Meslb 
locus and PCR amplified and sequenced to identify potential SNPs between WF and COP 
sequence. Sequence reads were analyzed using DNAStar Sequence Analysis software 
(DNA Star, Madison, WI). 
Congenic Strain Breeding 
The congenic breeding method was detailed above (Figure I). The rat WF.COP 
Mes 1 b congenic lines T and B were used to generate new recombinant lines and 
potentially isolate the SNP(s) and/or gene(s) involved in the breast cancer susceptibility 
phenotype. These lines, containing varying pieces of the rat Mesl b locus, will be tested 
using the DMBA mammary carcinoma susceptibility assay. The line T Meslb locus was 
delineated to ~13 Mb interval at D2UwmI7:g2UL2-30 (Chr2:32051320-44932309) and 
confers a reduction in mammary tumor development (Figure 2) (Haag et at, 2003). Line 
B was delineated a Chr2 region from marker D2Mit29 to marker D2Rat201 Figure 2. In 
addition to Meslb, the Line B COP interval contains Mesla and MesIc; however, the 
recombinant lines at the distal end may be used to narrow the Mesl b locus. 
Inbred WF male and female rats were obtained from Harlan Sprague Dawley, Inc. 
(Indianapolis, IN). All housing and breeding was performed in the Research Resources 
Center Animal Facility at the University of Louisville under protocols approved by the 
University of Louisville Animal Care and Use Committee. Line T male and female rats 
at the NIO generation or beyond were bred with inbred homozygous WF female or male 
rats, respectively, at 12 weeks of age. Progeny were genotyped for unique recombinant 
intervals of the Meslb locus. Novel recombinant rats were backcrossed with inbred 
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homozygous WF rats to obtain heterozygous progeny. Heterozygous male and female 
progeny were inbred to obtain progeny homozygous for the unique recombinant allele. 
WF.BN-RN02 animals were generated in a similar manner by initially breeding 
BN female rats (Harlan Sprague Dawley, Indianapolis, IN) to a WF male rat to obtain an 
FI generation. An FI generation male was backcrossed to inbred (homozygous) WF 
female rats and progeny were screened for the Mcslb locus using the markers mentioned. 
WF.BN animals were bred out to the N6 generation. Mammary carcinoma susceptibility 
phenotype studies were performed as described. 
Genotype Analysis 
Progeny from crosses between congemc and homozygous WF rats were 
genotyped using an approved protocol. A tail clipping of each pup was taken at 1-2 
weeks of age. DNA was extracted from tail clip samples using a Gentra Tissue DNA 
Extraction Kit, diluted and PCR amplified using primers for informative micro satellite 
markers. Multiple markers were tested spanning the length of the original line T locus 
from D2Rat194 to D2Rat201 (Table 1). Microsatellite markers were analyzed by PCR 
amplification using the GeneAmp Fast PCR system (Life Technologies) and separation 
on 3% high-resolution agarose gels in TBE buffer. SNP markers were analyzed by either 
PCR amplification followed by sequence analysis by the University of Louisville Center 
for Genetics & Molecular Medicine DNA Core. 
Phenotype Analysis 
At 50-55 days of age nUlliparous female homozygous WF and female congenic 
rats were administered DMBA (Acros, Pittsburgh, PA) at 65 mg/kg body weight by 
gavage. DMBA was suspended in sesame oil at a concentration of 20 mg/ml, heated in 
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Tabi" 1: 
Informative microsattelite markers used to narrow Mcslh locus to 1.8 Mh interval 
Samuelson I.ah TD Public TD Position* Forward Primer Se9uence 
D2Rat194 D2Rat194 29237360-29237535 TAATIGCAACAGGTCAGGGC 
D2Uwm17 D2Uwml7 3205131973205163 A AC,cTACAATGCCTAGCAAC 
D2Mco43 D2Mco43 32836549-32836763 AACCACTlTI'AGAAI'GTfAATCAG 
D2GotIl D2Gotli 33838802-33839075 CCTGGTCTCTGTCTCTGTCTCA 
D2Rat195 D2Ratl95 33957192-33957523 TIGCTGTITCTi\GT,\TGTGCAGG 
D2Rat12 D2Rat12 39101957-39102109 CC AGTCCCTC AGAAGGAACA 
D2Mgh2 D2Mgh2 39829003-39829053 GAAATGGGGAGTCAGAGAAGG 
D2Rat199 D2Ratl99 41032096-4103220 I TCAGGTATCTCCTATGGGGG 
D2Rat142 D2Rat142 42318356-42318464 CACAAATGCATGTGTGCCTI 
D2Ratl6 D2Rat16 43376467-43376635 CTGCATGTGTIAAATCATTAGTCA 
g2ULl-5 12324219t 43485572-43485628 AGACAi\TCCCCCACAGACA!' 
g2liL2-27 I 2324060t 44195286-44195382 TAAATGTGGTITCCTITGCT 
g2liL2-29 NA 44325512-44325564 CATAACAGCAA.GAAGCATCA 
D2Mc042 D2Mc042 45247893-45248161 GAGGAGTATATI'AGTlTGGGCTG 
g2UL2-30 I 2324220t 44932096-44932309 ATTCAATTCCAACAATCCTC 
D2Rat200 D2Rat200 48762858-48762979 AGGGTGGTITGAAGCCAUIT 
D2Rat201 D2Rat201 49691463-49691646 GCAACCACAAAAGGAGAAGG 
D2Rat202 D2Rat202 51821000-51821161 TGGCTIAGCATAATCTCAGCA 
Abbreviations: WF, Wistar Furth; COP, Copenhagen 
Genotypes detem1ined using 3°'0 high-resolution agarose gel 
* Position based 011 Rattus norvegicus Chromosome 2, genome bulid version 3.4 
tMarkcr IDs in NCill database 
Reverse Primer Se9ucnce 
GAGTGGATITGAGAGCAGCTG 
CCAACAGGACTITAGTCATTG 
CGATCCn'CATGGGGCTAACACI' 
TCCTITAGCCTICCTITTGG 
CCCATGCACACAAGTATGAA 
GCAACCACATTITCAGAATIGA 
TTrCTfGTTTACCTCTGTCTGGG 
GAG CGC TCA 'ITG erc TeT CT 
CAAAGCCTITGA TIGTGCAA 
ACTICACGATCCAGTCTGGG 
GAGAAGGl'GCA'l'GTTCCAAA 
TCAACGTAGCTGAAA TIGTG 
OOAAAAGAACAACrGTITGG 
ATGGGCTGGCTAGTGAGAAAGTl' 
CATITTCAAGCCTTACAGGT 
CAGGA'ITGAACAGCAAGCAG 
GCTAAC'l'AGAATGC ATlTCAAAATr 
CGCCCAGCTCACATTAATTT 
boiling water to dissolve and cooled to room temperature. For each congenic line, 15-25 
female rats were used for phenotype analysis. At 15 weeks post DMBA administration, 
rats were euthanized and the total number of mammary carcinomas measuring2:3x3 mm 
in diameter were counted per rat. Spleens were removed to confirm genotype. Statview 
(SAS Institute, Cary, NC) statistical analysis software was utilized for analysis. Data are 
presented as means ± SD. Nonparametric Mann-Whitney tests were performed for 
analysis within congenic groups. 
Haplotype Block Analysis 
Human haplotype blocks and SNPs in LD are based on the GRCh371hg19 human 
genome assembly and were identified using the LD and Tagger functions in Haploview 
v.4.2 (www.broad.mit.edu/mpglhaploview/), respectively (Barrett et aI., 2005). 
Sequences for human haplotype blocks were identified using the UCSC Genome Browser 
(genome.ucsc.edu/). Syntenic analysis was performed using the Convert function of the 
browser to determine the rat ortholog for the human haplotype block associated with each 
SNP (Kent et aI., 2002). 
Results 
Line T Backcrosses Result in Novel WF.COP Mcslb Congenic Rat Strains/Lines 
Mapping the Mcsl b QTL to a shorter syntenic interval reduces future comparative 
genetics work and abbreviates the list of potential candidate genes to be tested. To fine 
map the locus five congenic lines were generated by backcrossing Mcs 1 b line T and line 
B (Figure 2) to homozygous WF rats. These were termed F3, U2, W2, N3, and 14 
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(Figure 4). Each of these lines contain a unique COP rat Chr2 segment of the Mcslb 
candidate region from D2Uwm17:D2Rat201 (Chr2: 32051319 - 49691646) on a 
susceptible WF genetic background (Table 2, Figure 4). Lines W2 and U2 contained a 
COP allele spanning from marker D2Uwm17 to marker D2Rat142. Line N3 contained a 
COP allele spanning from marker D2Uwm17 to marker g2ULl-5. Line 14 contained a 
COP allele spanning from marker g2 Uwm65-18 to marker bUwm15-3. 
When a unique recombinant animal was identified from a backcross, it was bred 
to a homozygous WF animal to generate additional heterozygous rats. Progeny were 
genotyped and pups lacking the recombinant allele were not used. Once enough male 
and female rats carrying the allele of interest had been generated they were inbred to 
produce homozygous rats. These homozygous rats were inbred from here forth to expand 
and maintain the line. 
Mammary Carcinoma Susceptibility Phenotypes of Congenic Lines F3, U2, W2, 14 and 
N3 Shorten Mcslb to a 2 Mb Interval 
Mcs phenotypes were determined using tumor multiplicity at 15 weeks following 
DMBA induction of mammary carcinogenesis. As anticipated, the lines exhibited 
varying propensities to developing DMBA-induced mammary carcmomas. Rats 
homozygous for the F3, U2, and W2 COP allele developed 9.6 ± 4.1 (N=32), 5.7 ± 
3.9(N=6) and 6.0 ± 1.8 (N=18) tumors per rat, respectively, while littermate homozygous 
WF control rats developed 8.8 ± 3.5 (N=32), 6.3 ± 2.2 (N=12) and 5.9 ± 3.2 (N=9), 
respectively (Table 2). These numbers suggest that there is no difference between rats 
carrying the U2 and W2 COP alleles and rats having the WF allele in this interval. 
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Figure 4: Rat Chr 2 map ofWF.COP lines delimiting Mcslb to 1.8 Mb. Markers used 
to genotype WF.COP congenics are listed in relative positions on the y-axis. Lines are 
labeled with letter-number combinations and designated with filled dark-gray bars to 
indicate Mcsl b-resistant alleles. Lines that are drawn with unfilled bars represent COP 
intervals incapable of conferring decreased susceptibility or resistance to mammary 
carcinoma development. The filled light-gray bars at ends of each congenic segment are 
intervals of unknown genotype. Lines T and K are shown again for reference. 
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Table 2: 
Mammary carcinoma multiplicity phenotypes (mean mammary carcinomas per rat ± SD) by genotype for WF.COP Chr 2 
congenic lines used to map Mcs1b to 0.75 Mb 
coP/coP 
WF.COP Chr2 region Line N WF/WF N P value 
(COP/WF) 
D2Uwm171g2UL2-30 Tt 3.5 ± 2.2 21 8.3±3.3 19 0.001 
Tt (7.6 ± 3.4) 18 NS 
D2Uwm171D2Ulb4 F3 9.6 ± 4.1 32 8.8 ± 3.5 32 0.8433 
D2Mgh21g2ULl-5 N3 3.4 ± 2.0 25 7.8±3.1 25 0.0001 
N3 (5.5 ± 3.6) 15 0.0413 
D2Ulb41ENSRlVOSNP 274 W2 6.0 ± 1.8 18 5.9 ± 3.2 9 0.8498 
D2Ratl161ENSRNOSNP27 U2 5.7 ± 3.9 6 6.3 ± 3.3 12 0.8866 
g2UL2-271D2Rat201 14 9.3 ± 3.0 19 7.9 ± 3.7 13 0.247 
D2Rat16/g2UL2-30 1b-ll 5.9 ± 2.2 12 6.4 ± 1.9 8 0.4179 
Abbreviations: WF, Wistar Furth; COP, Copenhagen; Chr, chromosome 
* P values from Mann Whitney tests 
tLine T phenotype published previously by Haag et al. Cancer Research, 63:5808-5812, 2003 
* 
Similarly, female rats homozygous for the 14 COP allele developed 9.3 ± 3.0 (N=19) 
tumors per rat compared to 7.9 ± 3.7 (N=13) for homozygous WF littermate controls 
again suggesting that the congenic 14 rats have the same mammary carcinoma 
susceptibility phenotype as homozygous WF rats. Conversely, female rats from line N3 
that were homozygous for the N3 COP allele developed 3.4 ± 2.0 tumors (N=25) per rat 
while rats homozygous for the WF allele developed 7.9 ± 3.7 (N=13) tumors per rat. 
This is a ~56% reduction in tumor multiplicity for animals bearing the N3 COP allele and 
is similar to the ~58% reduction exhibited by rats carrying the line T COP allele. 
Additionally, line N3 heterozygotes, only carrying one N3 COP allele, developed 5.5 ± 
3.6 (N= 15) tumors per animal suggesting that the N3 COP resistance allele exhibits no 
dominance over the WF susceptible allele. 
1 was unable to define a precise distal end to the Mcsl b interval. Comparison of 
microsatellite DNA and published rat SNPs located in the 0.66 Mb of genomic sequence 
between the distal and proximal ends of lines N3 and 14 yielded no genetic variation 
between resistant COP and susceptible WF alleles (Tables 3 and 4). It is possible that 
polymorphisms between WF and COP exist in this 0.66 Mb region and have yet to be 
found; therefore, there remains a potential area of recombination from marker g2ULl-5 
to marker g2Uwm65-18. Taken together these data delineate the Mcslb locus to a 1.7 
Mb region spanning from marker D2Rat142 at position chr2:42318464 to marker 
g2UL2-29 at chr2: 44325564. 
Targeted Resequencing of the WF and COP Mcslb Locus Reveals New Polymorphic 
Markers and Tightens the Mcslb Interval 
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Table 3: 
Primer Sequences for MkTosatel\ites in 0,66 NIb region of ~lcs1b locus 
Samuelson Lab ID Public ID EnsembllD Forward Primer Seguence Reverse Primer Seguence Position· Variant 
AU046380 AU046380 AU046380 GCCACCATTGTTATCTGACACA CTCAGTGTGAGACCATGGTTCA 43313765-43313989 WF"COPt 
g2llL2-22 12324055 CAAC~AACTGACruGAGATAC AGAGC~AATCAATTTGAA.GA 43531384-43531546 WFCOPt 
g2l'L2-13 12324048 GTGTATGTrTAGGGGGTGM CCCAAAGA'fA:JUGTGAAGM 43536766-43536909 WF-COPt 
g2t'L2-23 12324056 GGACACATGAGCCAGTATTT CTTGGAGACGACTGAAACTC 43541442-43541637 WF=CoPt 
g2UL2-1 12324044 TACACrrGAGCAAGGACACA ACMGCCTGTTG'lTGTAGGT 43598558-43598706 WF-COPt 
D2RAT267 D2RAT267 CGCAGGAGAAACOCCrrATA CCTCAmTITCATCA(iCCTG 43605867-43605989 WF=COPt 
D2Rat254 D2Rat254 AGCATGACCAAGACATTCCA CGCCATGGAGAGAGATGCTA 43624817-43625068 WF-COPt 
g2UL2-14 12324049 CGCICfCTCTCTCATACACAC CCTAAGACACTGGCTGAGAC 43659242-43659460 WF-COPt 
g21 :1,2-2 12324054 (j(3AGGrrCATTAT<flTGT<iG CTITC TC1TC TCrCC CCATr 43697612-43697849 WFCOP+ 
g21:1,2-15 12324050 rrGGACCTAAC ACCTAGC'AT ATAGGTCGAGATCj(JAAA4..CA 43704760-43704927 WF-COPt 
g21'L2-16 12324051 GCCAGATGTAGTGGCATATT GTTTGACTTTTGGGACAAAT 43753048-43753283 WF-COP+ 
g21:L2-3 12324061 GCACKiCAAAACATCTATACAC ACTATGGGTAGAAACGCAAA 43751704-43751942 WF-COPt 
VI g2{ 'L2-24 12324057 CTTCCATACCTGACACACCT :\AC ATG ACACK.'TITGGA,'\AT 43840761-43841043 WFCOP+ 
-....J g21'L2-4 12324062 GTAGGGGCTACAAAGGAAGT CCCAGGCTACACCAITAITA 43845450-43845697 WF COP+ 
g2l'L2-25 12324058 GCrroAcTCiGTOACAAAGATr GTCAGCTlTrGAAOGAACAC 43911826-43912026 WF-COP+ 
g2UL2-5 12324063 TCTGGTTC AAAGAA.GACCTG AGGAGTTTTGGAGTGTCCTT 43934522-43934761 WF=COPt 
g2t:L2-6 12324064 AATCCCCTTCTCA TTCTlTC C,{,'A TCTTAAGGTCTGGAGTG 43935644-43935818 WFCOPt 
g2U1.2-7 12324065 TCTGTrcAGTGAGAGATCCA AGTCAGGACAAAGATACACAAG 43951932-43951951 WF~COP+ 
g2t:L2-26 12324059 AGCAGCTGGTATAGAAAACKiT OCACACn'GAGAGTGAGTGA 43969019-43969339 WF~COPt 
g2UL2-9 12324066 OGGAAGGAAAGACTGACITC AGTCK.'TI'Gl'CJATGTCCTCrC 44024519-44024723 WF-COPt 
g2liL2-10 12324045 CGGATCTTTTGAGTlTGAAG GTCruAATGGGGAAACTA TTA 44033098-44033281 WF;COP+ 
g2UL2-18 12324052 TCGAGCTGTCTTCTGACTG TTCTCCCTTCATCATGTCTC 44089085-44089302 WFCOPt 
g2VL2-11 12324046 CGCTAAACCTGTCAACCTAC AATAAAACCCACCACACAAC 44118131-44118361 WF=COPt 
g2UL2-19 12324053 TTCCCACn'CTrCATrCCTA GTCTGAACCCTACCATGAA.A 44128126-44128291 WF~COPt 
D2Rat298 12324043 TCK.' AACTATCTATGCCAGTI'Cj(J CAGGACAGGCAGAJ\GATGCT 44149293-44149181 WF~COPt 
g2CL2-12 12324047 GACruAGTC ATCGAC'f(j(J'rJ'A CCTrGCTCTCT1-rCAAATTC 44164273-44164510 WF;COPt 
g2UL2-27 12324060 TAM TGTGGTITCCTrJ'OCT TCA4..CG'!·AGCTGAAATrGTG 44195286-44195382 WF,>COPt 
D2Oot27 D2Got27 ACCGTATGCACTTGATTTACAGAT CCATr.~\GTTGTCCTCTGCCC 44205860-44205910 WF<COPt 
B!\, Brown !\orway~ COP, Copenhagen~ WF, Wistar Furth 
*Position is Rattus nonregiCllS genome build version 3.4 
+Microsatellite D!\A genotypes were determined using 3°'0 high resolution agarose 
T ..... : 
S1\P markers tested on WI' and COP rats based on Ilublished datAofSNPs in the l>kslb inlerval 
Samudson lab ID PubliCID bnsemble ID Forward Primer S«I,",n." Reverse Primor Sequence Position" 
I:lN 
COP WI' 
(reference) 
R~02U1?:\12t -\AA.'\TGCAGACCCATGTG{' TGATGCCCTTTCATTGTCC 42142131 C C T 
R N02n ,-,\ 1211 ClCAAACi(lTrTCATCT(nnTC (iCT \(' <\A{;C A(iC An nOAA 42J10174 (' C '\ 
Rl'IJ2UI ,-A J 1\'+ ",63769957 E:-;SR~OSNP274{)1l54 GAOCI'G'I,('AO'IUr(j(JCAAA 'I'GGAOC,\,\A'IU(lCI"I'CAO,\ 4236415; A A C 
RN02l'L-AI2\\ ",64618233 AGTCCCTCACAAATGGTAGAA OGCCAOOAATAATGAGCAA 42421698 A 0 0 
RN02t'In\12x rs6441857K ENSR~OSNP2785536 ,\,\TOA TIGGCCCCAGTGT ,\. \TG. HCTC,\TCGGCCTGT 12514359 ,\ G G 
RN021'T?AI2y rs 105808796 ENSRNOSNPI1R2721 C,('CTIGGTGTTTACATOAC.c CAGC ,\ATIACCG:\G:\TnC:\C 426U911 C A A 
Rr...021'L-AI27 ",(,616254'1 ENSRNOSNt>27855J8 j"I('AlTGCrACClAlli(',\(iTlli A(iCTATCCC ACTGA'\'nCI'CC 4267'}()O6 (J ,.\ \ 
R.'1021'L-A 12aa rs 105703830 ENSR.'IIOSNP1382993 CTGTACC ArnCTGCCATGC CATCAnn,\ATJ-rroAOAAOCA 42782209 A T T 
VI R,,02l'I?AI2bb rs 1 05836290 ENSRNOSNPJ383048 CCGAGCTI'(ICTTGlTTGTT TG(J,\OACCC ACGCTC'ITr ~2822772 T C C 
00 RN02l'L·AI2cc N639~8035 F.NSRXOS'llP2i~ ~ ~41 (i('CT A TGATOnA TGCCC AOT CACATGTGTG,\TCOC;\T,\(JC 4286%64 T C C 
J{l\U21'I~AI2dd rs \1)70420115 ENSRNOSNl'2785542 GOn.'ATCJTO(iACAGlliAO Tl'OOATUGUU<.'AAAUACIA ,UU52!!9 A U U 
RN02l '1.."\ 12cc I'sl06693272 ENSRNOSNP2785543 TITC'IG<iGAIT(iA(J(iACCA C,\:\OCCG,\'!'Cn::AOCAU1T ·U2525115 C T T 
RN02I.L-A 121f ",64339116 ENSRNOSNP1383915 CT(ICCAGA,AGC XrCTAAA'\ACT AAGTGG(JTGCTCTUTCITC A 43523570 T C C 
RMJ2t:l .. ,\12gg ",107369228 ENSR.'<OSNP2785545 CTAArnOTfTCTGCTK ,\,\TCCTATCC,\AACTCrr 43544727 C C (' 
R'X021 'I-A 12hh ",66091~Rl E:\'SRNOS:\'PI384088 TOe <\A "'CTOTrAC "'AM; CC AlGA TL\CTCCTTTI 43660982 T C C 
RNII21 l~,"\lZii rs(,5K2484lJ ENSJ{NOSNt>271 X470 rrAOACCAOAAACCI'I"l' CI(iAACTI',\lrl"I"rll."l'Hi H1>9'1296 A (i (j 
RN02l'l ,-A 1 2ii 1>8143555 CCAGOAAATIAACACTI GCTCCATGATACATCC 43836007 C T T 
R}'021'L-,\12kk rs8171129 ENSR.\iOSNP2785549 ,\C, \AAGTCTT(.'TC, \;\GC OTCCCATG'rfTC!',\GTrA 43838288 C T T 
RN02t'lrA1211 rslO7117602 ENSRNosNP2785550 CTI'AOCAAC <\ TACC1TCT CTACGATGAGTJ'(iTCTn 43')1807') G A ;\ 
RMJ2UL-AI2mm ",65844~85 ENSRNOSNI'1384598 CA'rCAITAGTCA('TG("1T CCAACAGITrIAGTnCr 43987419 G A A 
Rl'021IJ ~A 12nn rs66189322 ENSRNOSNP2731297 OATOCA'r(IGTA,!'ATAGTGr GA1'O'IT\AA,\CCA1T,\(jO 44180666 C C C 
R;\02t'l?,,\12oo+ 1'8107066908 ENSRNOSNP2785553 GCATTG,\CACTIGTJ'T,\ :\(ICTA TOTOTA TTGGTIC 44210175 C C G 
Rl"02tJL-, \1 2pp rs6402 1638 ENSR.'IIOSNPJ384967 CGTOO'lTOT:\'ITCTAACT C :\OT AGTC:\CTCCACA TT 44242105 C T T 
Table 4 ~ontinuted 
Samuel""n lah JU PubliCJU Ensemble 1U l;orward Pnm..:r Sequence Reverse rrimcr Sequence Position-
RN 
COP WI' 
(rd,m:nc<) 
A48·ENSRNOSC'lP·1383684 ... 105214022 EC'lSRC'lOSNP1383684 AGCCTGCACTGCC AACGTA TGGT(,'(}A.A TGC ACCGCTAC 43294777 C T T 
".48·ENSRNOS'<P·13836% ... J(J6710684 F'<SR'IOSl\'P 13836% CTCTCC(,,oC,\GTCACAGGTT TOGAO ".CT(;(,'{'AA TOCAAA TO 43308266 T C C 
,\4!l·ENSRNOS'II'· IJ~JN'JG rs64N39!73 I.'1SR'IOSl\PI3113l196 I'CAGOGCG,\AC'I,(;A<.iAAAlK, (j{,'UII .. ·Al'Ala.:AAACAIC nce 435U7047 0 ,\ A 
A48 .. ENSRNOS:-IP .. 138435 1 ... 64812820 E'ISR'IOS1\PI384351 GAACCCCTTCCTCGCTTGA'j' TGTGOCTOTGGGTCACCA 43843704 A (j G 
:\48 .. ENSRNOS'IP .. 1384874 n;65209285 E:-ISR:-IOSNP 1384874 CTGTG<.'C.\GCi\GGCT.\AGGT ,\Crt::CI':\OGTGOC,\,j'OTO.\TOA 44159855 C T T 
".48·ENSRNOS'IP .. 13848S0 rs66201784 E'ISR'IOSl\'P 13848S0 C.UGTCGTGCTTCCTGTCCTT TCAGGA.\GTCA TGGAUGTGAGAC' 44164060 A fi (; 
A48 .. ENSRNOS:-IP .. 2645369 ... 107488981 DJSR'IOSNP2645369 nCAAUTGGCOOAGTOCn TCTOOOAG'rTCAOTGCTOTCTG 42712802 T C C 
,\48 .. ENSRNOS'IP·2654615 ... 64619323 DJSR:-IOSNP2654615 ,\-\T,\CAGGC(KiTGGATAATGi\o\(l,\ ,\OCCTGGTCCAGTGTCTC, \1\ TC 4366962~ \ G G 
,\4R .. ENSIINOS'II'·2657'7'J ",6~ltiH2ti E'ISR'IOSl\'1'2657179 TfC(i(l'f(HCT .\('GTCKi'lT '\{K~'\ ('('TOe A ,\'\T,,\TCT<K K:ATGT Acrrc 4,181544, '\ (; (1 
VI 
A4li .. ENSRNOS'II' .. 2685221 ",66162549 F'ISR'IOS1\P2685221 C AITOCI 'ACCTA'llK.' AGn'OOA OACOTG,\(K:GCATACAAAfC 42679006 <> A A 
1.0 ,'\48 .. ENSRNOS'IP .. 2686459 ... 63770151 DISR"IOSNP2686459 C AOTGTCTCC ,,\CCGACTGACC C-rITGCCCCGATACATCCAC 43529896 C T T 
'\48 .. ENSllNOS"II'·2705085 ",6546,1491' F '1SR 'lOS l\' 1'27050S5 A(iTCl<l<iCOCTACCTrCA,\C,\ G<lCCATTG!\(;TC(l(iT(l(,rL\ 4,1418586 C T T 
,\4S .. ENSRNOS,'i1'·27060U5 rs66268295 L'ISR:-.IOS1\P2706005 (JOAG(;'L\AOCOUIOTGAOOA AOCCI'rCAAOOA1OUUOAAU 43517914 G A A 
A48 .. ENSRNOS"IP·2706295 rs66174360 E'ISR'IOSl\'P2706295 .\A TGCeC AAC ATCCCTTCCT C A TGCC AC \CCCA,," \C A TTG 43377935 ,\ A ,\ 
A48·ENSRNOS"Ip .. 2708093 ... 65540697 E"ISR"IOSNP2708093 TAGOC ACCGAG AAGCC AC ,\ T ACiOGACTCCTGGAAC,oG A TG 43418057 lj C e 
A48·ENSRN(]S;o.!P·27441 JO rs64996390 E'ISR'iOS!\P274411O ,\(jCAllicnn UACTCTGAAT CAM 1.,\(;0 nlTH ;(irR TITC\ 43006{)I.' C T T 
A48 .. ENSRNOS:-II'·2769457 1'863803615 E:-.ISR'IOS~1'27694~7 ,\AGAG'I'CC,\OOT,\GOO'lUUAU O(,'ACTAAGCUATACCCXJ'GA 43376687 C C C 
:\48 .. ENSRNOS"lP·2753~29 ... 64232116 E'ISR:-IOS1\P2753529 TCTTOOOTAC\CTUCCCACA ,\CGU,\(J(JO'nTI'GCCTGI1T 43753769 ,\ T T 
-\4R .. ENSRNOS'<1' .. 2778924 ",106914580 F"JSR'IOSl\'P2778924 ".CTC,ciCTTGCiCTGTTGGTGT TGnTG(,OCT AAAA(l(;(;,-\C;(,T 43191996 T C C 
AbbreviatIons: 111\, Brown Norwav (reference) COl'. l'oponhascn; WI'. W,.tar Furth 
·Position IS based on RaUIH norveglclis ('hrt)mosomc 2. genome build versi(~n 3.4 
tlnionnative markers llsed in nam)\\IOO!vlcslb loem. 
Sources' R1\02l'L mark"r.<, '1ijman eTal. mdC'Genomics 2008; A48 mark""" STAR COI1S1ortmm databa." 
Up to this point, all mapping had been perfonned using microsatellite markers. 
SNPs between WF and COP have not been tested and new markers were needed in the 
region to effectively fine-map the Mcs1 b locus. I resequenced targeted regions in the 
newly delineated Mcslb interval from D2Ratl42 to g2Uwm65-18. Cuppen and 
colleagues published a panel of SNP markers for the rat genome consisting of 820 
different SNP assays tested in 34 different rat strains (Nijman et aI., 2008). SNPs assayed 
in the study were chosen based on being polymorphic between BN, Wistar and Dahl/Salt 
Sensitive (SS) rats. Of the 820 SNPs tested, 22 lie within the Mcs1 b locus, making this a 
good tool to identify polymorphisms between WF and COP alleles (Table 4). Although 
the Cuppen panel was tested on 34 different rat lines, the COP strain was not included. 
Further, WF rats were tested but they were not the Harlan (WF IHsd) strain used in my 
study. It was therefore, necessary to resequence WF and COP gDNA at these 22 sites to 
detennine if they were polymorphic. 
Additionally, a rat SNP map has been developed by the Specific Targeted 
Research Project (STAR) Consortium (Saar et aI., 2008). The consortium sequenced 
>100,000 SNPs in 60 different rat strains, including COP/Hsd; however, WF/Hsd was not 
included. To identify potential polymorphisms between WF and COP sequences I 
identified 20 non-redundant SNPs from the STAR Consortium database lying within the 
rat Mcs1b locus (Table 4). These were tested in WF and COP gDNA samples by Sanger 
sequencmg. 
Of the 22 Cuppen SNPs tested, 4 were identified to be polymorphic between WF 
and COP alleles. These were tenned A12t, A12u, A12v, and A1200. Markers A12t, A12u, 
and A12v lie relatively close to each other at positions chr2:42142131, chr2:42170174 
60 
and ehr2:42364155 (Figure 5). Marker A12oo, however, lies much further downstream 
near the proximal end of line 14 at position ehr2:44210175 (Figure 5). Sequence results 
of SNPs from the STAR Consortium database revealed no polymorphisms between WF 
and COP at any of these markers. All newly-identified markers will be useful in future 
mapping studies to narrow down the Ales 1 b locus. 
I also attempted to identify new micro satellite markers by amplifying regions of 
sequence containing di- and tri-nucleotide repeats, which are typical of microsatellite 
polymorphisms. Results of these studies uncovered no polymorphisms between WF and 
COP sequences. In addition, large regions of gDNA were resequenced in these areas 
across the Mes 1 b interval to identify potential SNPs. The results of this study showed no 
polymorphisms between the two rat strains (Table 5). 
The new SNP markers were tested on rats from congenic lines U2, W2, N3 and 
14. Lines U2 and W2 tested homozygous for the COP allele at A12v and homozygous for 
the WF allele at the more distal SNPs. Line 14 tested homozygous for the COP allele at 
A1200 and homozygous for the WI' allele at the proximal SNPs. Line N3 tested 
homozygous for the WF allele at a12oo. Taken together, these markers slightly shorten 
the Meslb interval to a region from A12v to A1200 (Chr2: 42364155 - 44210175). 
Backcrossing Line T Generates a Novel WF.COP Congenic Line: Jb-ll 
There are 10 annotated transcripts that lie in the newly-defined Mesl b locus 
(Figure 5). Also, there is a region of potential recombination between markers g2 ULl-5 
and A12oo. Further mapping could eliminate some of these transcripts and reduce the 
number of potential gene candidates that need to be tested. To do this, 1 attempted to 
61 
W2 
Actbl2*1 
Mcs1b - 1.05 Mb -0.66 Mb 
MCS1B 
i 
H-rs889312 
114 Gpbp1 Ankrd55 HI 
I ENSRNOGOOOOO013098* U6 so RNA * I 
Mier3 • IISst • 
I CSorf35" 1131ra II 
Map3k1 .-t Ddx4 • 
Slc38a9 tH 
Ppap2a hi 
I 
1t>-11 
1t>-14 
14 
__ ~ ____ 1_~_1_3 ______ ~ ____ ~ 
o 
o 
o 
, 0 
I , 
""h'~~-I:I-I880""'1 ~4 i~4_250....I OO_OO _____ 4_30_00001o.. _O ____ -I-j _43_5+i _OOO ______ 44_0000....lI...-00_rA_ .... : 44_ 14+[,_76_ 
62 
Figure 5: Genetic landscape of fine-mapped rat Mcsl b locus. and 0 represent 
regions with a COP genotype with resistant and susceptible Mcs phenotypes, 
respectively. 0 represents regions with the COP genotype where the Mcs phenotype is 
not known. • denotes regions of potential recombination where no markers are 
currently known. Red and blue lines demarcate the location of informative SNP and STS 
markers used to genotype the locus. The blue bar depicts the rat interval orthologous to 
the human breast cancer-associated locus; SNP rs889312 and SNPs in LD are shown. 
Annotated transcripts obtained from UCSC Genome database shown in black. 
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Table 5: 
Regions sequenced between Rat Chr2:43125940 and Chr2:43632545 to identify potential 
polymorphisms between WF and COP in the Mcs 1 b locus 
Total conserved regions attempted to sequence 194 
Regions Successfully Sequenced 142 
Regions successfully sequenced with results that match reference gDNA files 103 
% Regions sequenced resulting in both WF and COP sequences matching 
reference 24% 
% Regions sequenced resulting in either WF or COP sequences matching 
reference 54% 
Total potential polymorphic regions identified 86 
Potential Microsatellites 4 
Potential Insertion/Deletions 27 
Potential SNPs 55 
Potential Polymorphisms validated 0 
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generate a new congenic line containing a COP allele from the end of line N3 at 
micro satellite marker g2ULl-5 and spanning marker A1200 and beyond. I backcrossed 
line T heterozygous rats to homozygous WF rats to generate novel unique recombinants 
containing this region. 268 progeny were tested from these crosses and generated 3 new 
recombinants. These recombinant animals contained COP alleles spanning markers 
g2ULl-5 to g2UL2-30 and were termed lines 1b-11, 1b-13, and 1b-14 (Figure 5). These 
recombinants were backcrossed to expand the population and progeny were genotyped. 
Pups containing the recombinant COP allele were inbred to establish a homozygous fixed 
congenic line. Due to complications with attaining recombinant pups and insufficient 
litter sizes, only 1 b-11 was established as a new congenic line. This line was 
subsequently phenotyped as described. 
Mammary Carcinoma Susceptibility Phenotype of WF.COP Congenic Line lb-ll Is 
Not Different Than Homozygous WF Controls 
Female rats homozygous for the 1b-11 COP allele and homozygous WF controls 
were administered DMBA at 50-55 days of age and euthanized at 15 weeks post-DMBA 
administration. Female 1b-11 rats developed 5.9 ± 2.5 (N=12) tumors per rat compared 
to 6.4 ± 1.9 (N=8) tumors for WF controls (Table 2, Figure 6). The difference in tumor 
multiplicity between the two lines is not statistically significant (P=0.4179). These data 
suggest that there is no difference in the mammary carcinoma susceptibility phenotype 
between I b-11 congenic rats and WF rats. 
WF.BN Congenic Rat Strain/Line Is Resistant To Developing Mammary Tumors 
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Figure 6: Endogenous mammary tumors formed in congemc line 1 b-ll and 
homozygous WF animals. Tumors presented as box plots. Circles represent outlier 
datapoints. N value represents number of rats tested. 
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BN rats are almost completely resistant to chemical, radiation and oncogene-
induced mammary carcinogenesis. The Mcs 1 b locus was identified between WF and 
COP rat strains and it is not known whether this locus is functioning in the BN rat to 
reduce mammary carcinoma susceptibility. If it is, the BN rat may be another useful 
strain to study the Mcsl b QTL. 
To address this, I used a WF.BN congenic line. WF.BN congenic rats were 
developed by introgressing a BN allele at the Mcsl b locus onto a WF background using 
the method described previously. Female WF.BN N4FI homozygous rats were 
phenotyped along with homozygous WF controls. WF.BN N4FI homozygous rats 
developed 2.3 ± 1.5 (N=l1) tumors per rat while WF controls developed 5.4 ± 2.6 
(N=28) tumors per rat (Figure 7 A). The difference between these means is significant 
(P=0.0012) and it suggests that the mammary carcinoma resistance exhibited by the BN 
rat strain may be partly conferred by heritable elements lying within the Mcs 1 b locus. To 
be certain there was no difference between WF.BN N4FI rats carrying a WF allele at 
Mcsl b and inbred homozygous WF rats, these groups were also compared (Figure 7B). 
There is no statistical difference (P=0.2039) between congenic WF.BN N4FI rats 
homozygous for the WF allele at Mcs 1 b and inbred WF rats; therefore, these could be 
pooled as susceptible controls. 
With the knowledge that there are two other Mcs loci on rat chromosome 2, it was 
necessary to define the full interval of the BN allele. To determine the length of the Mcsl 
locus within the WF.BN locus, the N4FI rats were genotyped at markers along the 
original Mcsl locus (Figure 2, line B; Table I). WF.BN N4FI rats had a BN allele 
spanning markers D2Uwm17 to D2Rat210 (chr2:32051319-82193231) delineating a-50 
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Figure 7: Tumor multiplicity in WF.BN congemc lines. A; Average mammary 
carcinomas formed in congenic WF.BN N4Fl and homozygous WF control female rats 
after being administered DMBA. Error bars denote standard deviation. Data was 
analyzed using Mann Whitney test. B; Average mammary carcinomas formed in 
congenic WF.BN female rats compared to inbred WF female rats. C; Map of WF.BN 
congenic lines at N4 and N6 generations . • denotes a BN genotype with a resistant Mcs 
phenotype. • denotes regions of potential recombination. Black bars designate Mcs 
loci 1 a, I b, and 1 c previously identified by Haag et al. 
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Mb region (Figure 7C). There is a region of potential recombination at the proximal end 
of the interval that overlaps with the Mcsic locus; therefore, the Mcsic locus may be 
contributing to mammary carcinoma resistance in this line. Thus, 1 again attempted to 
reduce the interval by backcrossing the WF.BN congenic rats to WF rats up to the N6 
generation and these animals were again genotyped to identify the ends of BN allele. The 
N6 generation contained the BN allele spanning markers D2Rat116 to D2Rat2iO 
(chr2:33845498-82193231) shortening the interval to ~48 Mb and eliminating overlap 
with the Mcsic locus. 1 attempted to further breed these animals out to the NIO 
generation to eliminate the long stretches of BN genomic sequence flanking the Mcsi b 
locus; however, due to complications, the WF.BN congenic line was lost. It was decided 
that it was not feasible to pursue reestablishing the WF.BN congenic line. 
Discussion 
The Mcsib locus was previously delineated to a ~15 Mb interval bounded by 
markers D2Uwmi7 and g2UL2-30 on rat chromosome 2 (Haag et aI., 2003)(Figure). 
More than 50 transcripts lie in this region. To shorten this list and reduce subsequent 
comparative genetics work 1 sought to fine-map this locus using a combination of 
WF.COP and WF.BN congenic rats. 
Five congenic lines were developed using a similar approach to what was used 
previously to identify the Mcsi and its subloci: Mcsia, band c. Lines F3, U2, W2, 14 
and N3 all contain COP alleles spanning various portions of the original line T 
background genome (Figure 4). Testing these lines for mammary carCInoma 
susceptibility enabled me to narrow the Mcsi b locus. The tumor multiplicity data 
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Figure 8: Map of human Mcslb orthologous locus on human chromosome 5. Base 
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bar denotes 280 kb haplotype block containing SNP rs889312. The genomic position of 
SNP rs889312 is shown in red. Transcripts are shown with exons designated by vertical 
bars. 
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obtained from lines U2, W2, 14 and N3 delineate the Mesl b locus to a ~ 1.8 Mb interval 
on chromosome 2 between markers Al2v and Al2oo. This markedly reduces the number 
of transcripts to be functionally tested to thirteen. 
As anticipated, the rat ortho10g to the human breast cancer-associated 280 kb 
haplotype block lies within this 1.8 Mb region. It is likely that a heritable e1ement(s) 
lying in this region is controlling rat mammary carcinoma susceptibility in a manner 
potentially analogous to the human ortho10gous locus. Therefore, the rat may be used to 
identify the mechanism of action and translate this to human disease susceptibility. The 
human block contains 2 known transcripts, MJER3 and MAP3Kl, as well as a predicted 
gene transcript, C50RF35 (Figure 3). Nearby, but lying outside of the human haplotype 
block associated with rs8893l2, are approximately 7 other annotated transcripts (Figure 
8). The rat contains ortho10gs to these transcripts within the Mes 1 b locus although the 
orientation of the rat Mesl b locus is reverse of the human locus (Figure 5). I anticipate 
that one or a combination of the three transcripts lying inside the human haplotype 
ortho10g is causative for the mammary carcinoma susceptibility phenotype. However, all 
of the transcripts within the IIIesl b locus, including those lying outside the human 
haplotype block ortho10gous interval, must be tested as they cannot be ruled out as 
causa1. 
The Meslb locus was mapped with the use of polymorphic microsatellite markers 
published in the ROD public database (Dwinell et a1., 2009). However, many of these 
were not informative between WF and COP genotypes. Targeted resequencing of 
regions in the narrowed Mesl b locus uncovered 4 SNPs polymorphic between the WF 
and COP strains. Using these new SNP markers, the Mcslb locus was mapped to a 
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shorter interval between markers A12v and A1200. Also, short genomic regions rich in 
di- and tri-nucelotide repeats within the Mcsl b interval were sequenced; however, no 
polymorphisms were identified between WF and COP alleles. Taken together these data 
suggest that WF and COP share similar haplotypes. However, since these newly 
identified SNPs are positioned at the ends of the Mcsl b interval, it is unlikely that they 
are causative; therefore, more polymorphisms likely exist in this region. 
Breeding of line T led to the development of another congenic line, I b-ll. Line 
lb-ll has a COP genotype from marker D2Rat16 to marker g2UL2-30. This interval 
crosses the 0.66 Mb region from g2ULl-5 to A 1200 making it useful in identifying if this 
area of potential recombination is contributing to the resistance phenotype (Figure 5). 
Tumor multiplicity between homozygous I b-ll female rats and homozygous WF 
littermates was not statistically different (Table 2). These data imply that this 0.66 region 
from D2Ratl6 to Al200 does not contain the element responsible for the Mcslb 
phenotype. It stands to reason, then, that the element conferring resistance to mammary 
carcinoma development resides in the interval from Al2v to D2RatJ-6, thereby narrowing 
the Mcslb locus to ~1.01 Mb. 
These data signify that a more complex mechanism may be at work. Tumor 
multiplicity data for line 14 and WF littermate control rats was 9.3 ± 3.0 and 7.9 ± 3.7, 
respectively. Although the difference is not significant, it suggests a trend that may 
indicate that the mechanism controlling susceptibility in the Mcsl b locus is much more 
complex than originally thought. A resistant phenotype could be compensated for by the 
action of another risk allele lying outside of the Mcsl b locus on the distal side. Indeed, 
the OW AS by Easton et at. reported two additional alleles identified upstream of SNP 
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rs889312 and an additional breast cancer-associated allele was identified on human 
chromosome 5 in a subsequent breast cancer-GWAS (Easton et aI., 2007; Turnbull et aI., 
2010). SNPs rs981782 and rs30099 reported by Easton et al. are positioned on human 
chromosome 5 at bases 45321475 and 52454339, respectively. SNP rs981782 has a 
minor allele frequency of 0.47 in the SEARCH population studied and associates with a 
reduction in breast cancer incidence with an OR of 0.92 (95% CI=0.87-0.97) when 
homozygous for the minor allele (Easton et aI., 2007). SNP rs30099 has a minor allele 
frequency of 0.08 in the SEARCH population and associates with an increase in breast 
cancer incidence with an OR of 1.09 (95% CI=0.96-1.24) when homozygous for the 
minor allele (Easton et aI., 20(7). The magnitude of the affect associated with these loci 
is much smaller than what is seen for SNP rs889 312. Regardless, the results from the 1 b-
11 phenotype suggest that an additional risk allele may be present in the 1 b-l1 locus. To 
address this, I used a bioinformatics approach to identify rat orthologs of human SNPs 
rs981782 and rs30099. I determined that LD blocks associated with these SNPs have 
orthologs on rat chromosome 2 (Figure 9A). SNP rs981782 lies in a 56kb haplotype 
block on human chromosome 5 and is in LD with one other SNP, rs4866929 (Figure 9B). 
This haplotype block has a rat ortholog that spans from base pairs (bp) 49907723 to 
49954324 on chromosome 2 (Figure 9A). SNP rs30099 is also in LD with only one other 
SNP, rs30727 and lies in a 3kb haplotype block on human chromosome 2 (Figure 9C). 
The haplotype block has a rat ortholog that lies on chromosome 2 from bases 46916997 
to 46918680 (Figure 9A). SNP rs9790879 reported by Turnbull et al. lies within a 488 
kb haplotype block on the p arm of human chromosome 5 and is in LD with 
approximately 100 other SNPs (Figure 9D). There is a rat ortholog to this block 
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Figure 9: Additional breast cancer-associated loci identified in GW AS with rat 
chromosome 2 orthologs. A; Map of line 1 b-ll interval on rat chromosome 2 showing 
positions of blocks orthologous to human haplotype blocks in LD with other breast 
cancer-associated SNPs. B - D; Haploview images of human haplotype blocks 
associated with individual breast cancer associated SNPs. Lower panel shows pairwise ~ 
values for LD; light blue represents lower disequilibrium, white is intermediate, and red 
represents strong disequilibrium. An ~ threshold of 0.80 was used to determine SNPs in 
LO. SNPS in LD are shown for rs981782 and rs30099. There are too many SNPs in LO 
with rs9790879 to maintain resolution; therefore, these are not shown. 
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delimited by bp 49961197 and 50564367 (Figure 9A). When mapped to the rat genome, 
none of these rat orthologs lie within the 1 b-ll congenic region (Figure 9A). This 
negates the notion that there is a second allele that is offsetting the affect of the Mcs 1 b 
locus. However, this is based on the assumption that there must be a human ortholog. It 
is possible that a second risk allele is present in this region but is specific to the rat or that 
an ortholog to a human risk allele lies within the 1 b-ll locus yet unidentified in human 
studies. Testing this idea would require the development of new congenic lines 
containing varying portions of the distal end of line 1 b-ll to define the specific region for 
this phenotype. However, this would be meaningless to human breast cancer 
susceptibility if the effect is rat-specific. 
Another potential explanation for the susceptible phenotype seen in the 1 b-l1 line 
is that Mcs 1 b is a compound locus, i.e., resulting from the action of two or more variants 
working in concert to give rise to the phenotype. Line N3 shows a ~56% reduction in 
tumor multiplicity compared to WF controls (Table 1). This indicates that the N3 allele 
contains the necessary variants required to give rise to the resistant phenotype. The 1 b-
11 interval overlaps the distal end of the N3 interval. Therefore, the 1 b-ll allele could 
harbor a variant that is insufficient alone and requires an additional variant lying 
upstream. This variant would be present in N3 but lost in 1 b-ll, thereby eliminating the 
resistance phenotype in 1 b-l1 congenic rats. Work here is not conclusive, but other 
complex QTLs were identified that operate this way (Samuelson et al., 2007). To further 
study this potential mechanism would require modifying the current approach by 
incorporating cross-breeding of different congenic lines to determine whether the 
resistant phenotype can be restored, i.e., breeding of U2 or W2 rats to 1 b-l1 rats and 
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phenotyping offspring containing both U2/W2 and 1b-11 alleles. If Mcslb is a complex 
locus, these offspring should exhibit a resistant phenotype. 
Gould and colleagues show that line T heterozygous female rats average 7.6 ± 0.8 
(N=18) mammary carcinomas per rat (Haag et aI., 2003). This result was not statistically 
different from WF-homozygous littermates (8.3 ± 0.8, N=18) but was significantly 
increased (P<O.OOOl) compared to COP-homozygous line T rats (3.5 ± 0.5, N=21). 
These data suggest that the WF allele at the line T locus exerts a dominant phenotype in a 
Mendelian sense. On the other hand, Line N3 heterozygous and COP-homozygous 
littermates develop 5.4 ± 3.6 (N=15) and 3.4 ± 2.0 (N=25) carcinomas per rat, 
respectively (Table 1). Both of these values are statistically reduced compared to WF-
homozygous line N3 littermate female rats (7.8 ± 3.1, N=25). Tumor multiplicity in line 
N3 heterozygous rats is approximately half compared to COP-homozygous littermates 
signifying neither the WF nor the COP allele is acting dominantly. Taken together, these 
figures show that there is a decided difference between the line T and N3 alleles. This 
substantiates the notion that there is a more complex mechanism occurring at this locus. 
The simplest explanation is that there is an epistatic allele placed in either the proximal or 
distal regions flanking the N3 allele; however, other mechanisms may be at play. A 
compound locus could exist as described above. Moreover, it may be that there is a cis-
interaction requiring a second element that is present in the line T interval but is absent in 
line N3. My data are insufficient to favor one scenario over another but suggest that the 
mechanism of action at this locus is much more complex than originally anticipated. 
In addition to the COP rat, the BN rat strain is also almost completely resistant to 
developing spontaneous, chemically-induced, and oncogene-induced mammary 
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carcmomas. As previously mentioned, the BN sequence has been completely sequenced. 
It is currently not known whether the resistant phenotype exhibited by the BN rat is 
associated with the Mcsl b locus. The BN rat was tested to determine if the mammary 
carcinoma resistant phenotype is controlled in part by the Mcsl b locus. If it is, the BN 
could be an additional tool to help discover SNPs that may be involved in the COP 
Mcslb phenotype. A WF.BN }.,{cslb congenic line had been initiated and I attempted to 
establish this line in order to determine if the BN Mcsl b region confers resistance to 
developing mammary carcinomas in similar manner to the COP strain. 
Results of WF.BN phenotype studies were to be applied to further characterize 
the Mcslb locus in the COP line as well as determine whether the Mcslb locus is 
involved in controlling mammary carcinoma susceptibility in the BN line. By examining 
the phenotype of the BN allele a 3-way haplotype analysis would rule in/out specific 
polymorphisms in the Mcs 1 b locus for their contribution to the mammary carcinoma 
resistance phenotype. The BN haplotype carries a set of SNPs that is shared with the 
COP allele (BN=COP at A'12v and A12oo) and can, therefore, be used to develop the 
Mcsl b locus with a BN haplotype. Markers between WF and COP are infrequent in the 
Mcslb interval; however, the BN strain has been sequenced and many more markers have 
been identified. Therefore, these may be used to identify markers that may be used to 
narrow the Mcslb locus. 
Unfortunately, however, the line was lost before the NIO generation and the 
Mcslb region narrowed. Regardless, data from initial studies with the WF.BN congenic 
line at the N4FI generation imply that the mammary carcinoma resistance exhibited by 
BN rats is, at least in part, controlled by the Mcsl b locus. This cannot be stated with 
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complete confidence as the proximal end of the WF .BN rats contains a region of potential 
recombination that overlaps with the Mesic locus. Therefore, the Mesic locus could be 
involved. Additionally, these WF.BN congenics have large intervals ofBN sequence that 
flank the distal side of the Mcs I b locus. These rats potentially harbor other risk alleles 
that are controlling mammary carcinoma susceptibility, i.e. the rat orthologs of the human 
haplotype blocks associated with SNPs rs981782, rs30099 or rs9790879. With the loss 
of the WF.BN congenic line further investigation of the BN phenotype is not practical at 
this time. 
Overall, the data delineate the Mcsi b locus to a 1.01 Mb region flanked by SNP 
markers A12v and D2Ratl6. The variant(s) contributing to the Mcslb-conferred 
resistance phenotype likely lies inside this interval unless the mechanism is much more 
complex, as discussed. To determine the specific variant(s) contributing to mammary 
carcinoma susceptibility deep sequencing of this region is needed to identify new variants 
and test them accordingly. If no variant is identified lying inside the region delineated by 
A12v and D2ratI6, this strongly implicates that Mcsi b requires additional cooperative 
loci or that the 1 b-11 line contains an epistatic allele downstream. 
One of the goals for this project was to shorten the interval containing the Mcslb 
locus to minimize the list of potential gene candidates that would need to be functionally 
tested. This was achieved by mapping the Mcslb locus to 1.01 Mb. Within the 1.01 Mb 
Mcslb locus there are five potential gene candidates: Actbl2, GpbpI, Mier3, C50rj35 and 
Map3kI. Mier3, C50rj35 and Map3kI all lie inside the region orthologous to the 
rs889312 LD block. Although these three transcripts are the most likely candidates, any 
one or combination of the genes contained within Mcs I b may be involved in controlling 
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mammary carcinoma susceptibility and they must be tested further to determine their 
role. 
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CHAPTER III 
RAT MCS1B ACTS IN A MAMMARY GLAND CELL-AUTONOMOUS 
MANNER TO CONTROL MAMMARY CARCINOMA SUSCEPTIBILITY 
Introduction 
The etiology of mammary carcinogenesis is complex, involving events that occur 
within the mammary parenchyma as well as events that are external to the mammary 
gland. In both humans and rats, mammary tumors arise primarily in the cells that line the 
mammary duct, the ductal epithelial cells. One would expect, then, that genetic 
differences that give rise to sustained proliferation and carcinogenesis would originate in 
these cells. Likewise, it would be likely that anti-oncogenic properties, such as the 
phenotype conferred by the Mcsl b COP allele, also lie within these cells. Indeed, there 
are both oncogenes and tumor suppressor genes expressed in the ductal epithelia that 
affect tumor development; however, as mentioned previously, different groups have 
shown that other cell types external to the mammary gland can affect pathogenesis 
(Pollard, 2004; Sica et aI., 2006; Smits et aI., 2011b; Trimboli et aI., 2009). 
Consonant with data illustrating mammary tumors originating in the mammary 
epithelial cell (MEC) population, it has been shown previously that the effects of the 
Mcsl COP locus are generally intrinsic to the mammary gland (Zhang et aI., 1990). 
However, in these studies a slight mammary gland-external effect was observed, likely 
due to mixed effects of multiple QTLs: Mcsla, band c. It is necessary, then, to test the 
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Mcs 1 b allele independently of the other COP Mcs alleles. This is critical to functionally 
analyze potential candidate genes. For instance, results of these mammary gland 
autonomy studies will guide us as to what tissues or cell types to examine when assessing 
transcript levels or protein expression. Moreover, knowing the site of function of the 
Mcsl b allele may lend some insight into a viable gene candidate or a plausible role that a 
gene may be performing to control mammary carcinoma susceptibility. There are five 
potential gene candidates lying in the narrowed Mcslb locus; Actbl2, Gpbpl, Mier3, 
C50rj35 and Map3kl. Of these, only Map3kl has been fully characterized. Therefore, 
identifying the tissue or cell type that the Mcs 1 b locus is conferring resistance to 
mammary carcinoma development may provide leads as to potential functions of these 
transcripts in the context of mammary carcinogenesis. Further, these mammary gland 
cell-autonomy studies are critical in that they provide the basis for all functional studies 
of the Mcs 1 b locus and will potentially provide needed insight into the etiology of 
mammary carcinogenesis. 
Design and Methods 
Whole Mammary Gland Tramplant Assays 
Donor nulliparous female homozygous WF and line N3 WF.COP congenic rats 
(N=~25 animals per group) were euthanized at 30-35 days of age and their abdominal 
and inguinal mammary glands excised. The glands were scissor-minced and, using an 
IACUC-approved protocol, transplanted into the interscapular white fat pad of age-
matched nulliparous female rats in a reciprocal manner; i.e. WF into WF.COP and 
WF.COP into WF. Also, WF into WF and WF.COP into WF.COP transplants were 
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perfonned as controls. At 50-55 days of age, recipient animals were administered 
DMBA dissolved in sesame oil (20 mg/ml) by oral gavage (65 mglkg body mass) to 
induce mammary carcinogenesis. At 15 weeks post-DMBA administration, recipient rats 
were necropsied and interscapular fat pads were examined for tumor development 
(Figure 10). Fat pads were whole mounted onto glass slides and stored in 70% ethanol 
for two weeks to allow for clearing of lipids from the pad. After two weeks, the whole 
mounts were fixed with 1 part glacial acetic acid and 3 parts 100% ethanol for 1 hour, 
hydrated by serially-decreasing ethanol washes (70%, 50%, 40%, distilled water) for 15 
minutes each, and stained in aluminum cannine for four days. Aluminum cannine was 
prepared by dissolving 2.5 g alum potassium sulfate (Spectrum Chemical, New 
Brunswick, NJ) and 1 g Cannine stain (TCI America, Portland, OR) in 500 ml distilled 
water, boiling for 20 minutes and filtering out precipitate. Once stained, whole mounts 
were dehydrated again with serially-increasing ethanol washes (50%, 70%, 100%) and 
finally a xylene wash. Whole mounts were stored long tenn in mineral oil. To verify 
properly mammary gland development in the transplant site whole mounts were 
examined for proper mammary gland duct elongation and TEB fonnation. Whole 
mounted fat pads were examined microscopically for frank carcinoma, ductal carcinoma 
in situ (DCIS) and hyperplasia development. Tumor outcome was analyzed using 
logarithmic regression analysis. DCIS and hyperplasia multiplicity data were analyzed 
by Mann-Whitney rank test. 
Mammary Gland Cell Preparation and Injection into Interscapular Fatpad 
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Figure 10: Flow diagram of mammary gland grafting assay. 
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Donor nulliparous female homozygous WF and line N3 WF.COP congenic rats 
(N=~25 animals per group) were euthanized at 30-35 days of age and their abdominal 
and inguinal mammary glands excised. The glands were scissor minced and epithelial 
cells were enriched by enzymatic digestion in collagenase III (Worthington, Lakewood, 
NJ) for 3-4 hours at 37° C. Details of this method have been previously published 
(Gould and Clifton, 1985). The mammary epithelial cell-enriched suspensions (hereafter 
referred to as MEC preparations) were injected into the interscapular white fat pads of 
30-35 day old nulliparious WF female recipients (N=16 animals per group) at 1 x 106 
cells per animal in 100 III ofDMEM/F12 (Life Technologies,) media (1 x 107 cells/ml). 
Whole mammary gland transplants from WF donors were performed as positive controls. 
Tumor development in the ectopic mammary glands was examined 15 weeks 
following DMBA administration to determine the mammary carcinoma susceptibility of 
the ectopic mammary gland. Transplants that did not develop tumors were examined by 
whole mounting the fat pad and staining with aluminum carmine to confirm that the 
transplanted gland developed properly in the fat pad, as previously described. Fat pads 
that failed to develop mammary glands greater than 3 x 3 mm2 were excluded from 
further analysis. Previous studies utilizing this method have reported that a very small 
percentage of recipient rats develop multiple tumors in the transplant site. Therefore, 
tumor outcome was assessed as a binary response and analyzed by logistic regression. 
Mammary Gland Cell Injections supplemented with Adherent Cell Fraction 
Mammary gland cell preparations were made from WF donors usmg the 
mammary gland cell preparation protocol described above. Adherent cells left in the 
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flask were removed with Trypsin +EDTA (Life Technologies) for 5 minutes and placed 
into 15 ml centrifuge tubes. Approximately 250 Jll FBS was gently added to the bottom 
of each tube to form a distinct layer for the cells to be centrifuged into. The cell solution 
was centrifuged briefly to collect cells and the supernatant discarded. The cell pellet was 
resuspended in media and counted and herein referred to as adherent cell fraction (ACF) 
preparations. ACF preparations were added to MEC preparations at 1: 1 0 ratio resulting 
in a final MEC concentration of 1 x 107 cells/ml plus a final ACF concentration of 1 x 106 
cells/ml. MEC/ ACF preparations were injected into the interscapular fat pads of 
nulliparious WF female rats. MEC preps alone were injected into the fat pads of 
nulliparous WF female rats as a control. At 12 weeks of age all recipient rats were 
administered DMBA. Recipient rats were necropsied 15 weeks post-DMBA and 
examined for tumor development in the ectopic site. Fat pads were mounted and 
processed and stained with aluminum carmine. Stained fat pads were evaluated for 
proper mammary gland development and hyperplasia and DCIS development was 
assessed. Tumor, hyperplasia and DC IS data were analyzed using a Mann-Whitney rank 
test. 
Results 
Whole Mammary Gland Transplants Suggest Rat Mcslb Is Mammary Cell 
Autonomous 
To determine if the Mcsl b COP allele reduces mammary carcinoma susceptibility 
in a manner that is intrinsic to the mammary gland, rats were transplanted with whole 
mammary gland tissue into their interscapular fat pads and exposed to DMBA (Figure 
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10). All of the donor and recipient female rats used had a WF background and only 
differed at the Mcs 1 b locus having either a resistant COP or susceptible WF allele. We 
expected that there would be no rejection of the graft as both genotypes have the same 
major histocompatibility complex (MHC) type and, thus, have compatible immune 
systems. To verify this, we determined that recipients did not reject mammary tissue 
grafts from donors of different genotypes by microscopic assessment of whole mounted 
fat pads. There was no statistically significant association (P=0.1869) between the 
outcome of ectopic mammary gland development and donor or recipient genotype (Table 
6). 
Data from ectopic mammary gland-positive fat pad whole mounts were analyzed 
for associations of donor and recipient genotypes with ectopic carcinoma development. 
Ectopic mammary glands formed from mammary gland tissue from Mcsl b resistant 
donors, when grafted into either resistant or susceptible recipients, resulted in fewer 
ectopic tumors forming compared to ectopic mammary glands from susceptible donors 
when grafted into animals of either genotype (Figure 11). The genotype of the-donor was 
significantly associated (P=O.OO 19) with ectopic mammary carcinoma outcome while 
there was no effect seen from the recipient genotype (Table 7). These data signify that 
the resistant phenotype conferred by the Mcs 1 b COP allele is acting in a mammary gland-
autonomous manner. Based on this, future studies to functionally characterize the Mcsl b 
locus should be focused on the mammary gland. 
Enzymatically-Isolated Mammary Gland Cells Injected into the Interscapular Fat Pad 
Reconstitute a Normal Mammary Gland in the Ectopic Site 
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Table 6: 
Graft site MG development outcome (dependent) and Mcslb donor and recipient 
genotypes (independent) 
Coefficient P value 
Odds Ratio 
(95% CI) 
Donor Effect 0.99 0.1869 
2.69 
(0.62 - 11.68) 
Recipient Effect -1.31 0.116 
0.27 
(0.05 - 1.38) 
Intercept 2.7 0.0004 
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Figure 11: Rat Mcs 1 b is mammary gland autonomous, Percentage of mammary gland-
graft-positive recipients that developed ectopic mammary gland carcinomas are shown 
for each susceptible (S) and Mcs 1 b-resistant (R) donor:recipient group, Groups with S 
donors are shown as filled bars, and groups with R donors are shown as unfilled bars. 
The total number of mammary gland-graft-positive recipients that were evaluated for 
tumor outcome in each group were, respectively, 27, 22, 23, and 18 for S:S, R:R, S:R, 
and R:S, 
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Table 7: 
MG graft site tumor outcome (dependent) and Mcsl b donor and recipient genotypes 
(independent) 
Coefficient P value 
Odds Ratio 
(95% CI) 
Donor Effect 1.48 0.0019* 
4.4 
(1.73 - 11.18) 
Recipient Effect -0.04 0.9381 
0.96 
(0.39 - 2.36) 
Intercept -1.22 0.0045 
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The Mcsl b COP resistance effect is intrinsic to a mammary gland cell type. As 
mentioned, the majority of rat mammary tumors arise in the epithelial cells lining the 
duct. In addition to these ductal epithelial cells there are myoepithelial cells that 
surround the duct and TEB and multi potent cap cells that can differentiate into 
myoepithelial cells or move inward and differentiate into luminal cells (Williams and 
Daniel, 1983). Based on the fact that mammary tumors originate in the cells lining the 
mammary gland duct we hypothesized that one or more of these epithelial cell types are 
responsible for Mcsl b COP-conferred resistance. However, there is evidence that other 
cell types in the mammary mesenchyme affect tumor development (Pollard, 2004; Sica et 
aI., 2006; Smits et aI., 2011b). To test which cell type the Mcslb COP allele is acting on 
to control mammary carcinoma development I used a MEC-enriched c1onogen transplant 
approach that had been previously developed (Gould and Clifton, 1985). This method is 
used to enrich for MECs and non-adherent leukocytes and lymphocytes by removing 
mammary gland adipocytes, fibroblasts, and other strongly adherent cells by negative 
selection. These cells are injected into the interscapular fat pad of recipients to induce 
development of an ectopic mammary gland similar to the whole mammary gland 
transplantation experiments. 
Enzymatic preparation of mammary glands to enrich for MECs is the standard 
protocol. However, this method is time-consuming and I wished to decrease the time 
required to dissociate mammary glands. To do this, I compared cells dissociated 
mechanically using a Medicon tissue dissociator to cells from enzymatic preparations to 
determine whether they recapitulated a morphologically normal mammary gland in the 
transplant site. Rats receiving mechanically-dissociated MECs did not develop 
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mammary glands in the ectopic site while 75% of the rats injected with enzymatically-
isolated MECs developed ectopic mammary glands when a 1: 1 donor:recipient ratio was 
used (Table 8). Mammary glands grown in the ectopic site looked morphologically 
normal (Figure 12). Based on these results, subsequent MEC preparations were 
performed using the enzymatic method. 
To estimate the number of rats to use for these studies we used standard 
deviations (SD) data from previous mammary cell autonomy experiments resulting in SD 
of approximately 0.6 ectopic mammary tumors. For a 95% confidence interval and using 
a tolerable error of ± 0.15 of the mean ectopic mammary tumors with a SD of 0.6, 
approximately 60 animals must be tested. Given we achieved 75% transplant efficiency 
in the pilot study, to be successful 80 animals per group are required. 
Mammary Gland Cell Preparations Are Not Sufficient to Allow for Efficient Mammary 
Carcinoma Development at Ectopic Graft Sites 
Since injection of MECs into the interscapular fat pad resulted in mammary 
glands formed in the ectopic transplant site, I intended to use this method to determine if 
the Mcslb locus was controlling mammary carcinoma susceptibility in MECs. MECs 
isolated from susceptible WF (N=16) or resistant WF.COP (N=14) rats and injected into 
the fat pads of age-matched susceptible WF female rats to determine the effect of the 
genotype on tumor outcome in the transplant site. Upon inspection of stained whole 
mounts, all recipients (100%) exhibited mammary gland development in the ectopic site. 
However, tumor development was not significantly different (P=0.9221), as each group 
developed only one tumor each (Figure 13A). Tumor outcome in MEC-derived 
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Table 8: 
Mammary gland outcome in enzymatically-dissociated versus mechanically-dissociated 
mammary gland cell preparations. 
MEC isolation # Rats 
method Administered 
Medicon 3 
Collagenase Digestion 4 
# Ectopic Mammary Glands 
formed 
94 
o 
3 
% 
Positive 
o 
75 
Figure 12: Representative whole mounted interscapular fat pad from MEC pilot study. 
lOX magnified image of aluminum carmine stained mammary gland formed in the fat 
pad following injection ofMECs isolated via collagenase digestion. 
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mammary glands was determined to be significantly reduced when analyzed against 
whole mammary gland transplant controls (P=O.0007, Figure 13A). 
Since tumor development was considerably reduced in animals receIvmg 
mammary gland cell preparations compared to whole mammary gland transplants, I 
examined the fat pads microscopically to determine if there were any gross 
morphological changes compared to ectopic mammary glands developed from whole 
mammary gland transplants. There did not appear to be gross morphological differences 
in ductal branching or TEB formation at the microscopic level ; however, hyperplasia and 
DCIS formation was detected in the majority of whole mounts (Figure 12B). When 
quantified, hyperplasia were not significantly different (P=0.4884, Kruskal-Wallis test) 
between ectopic mammary glands from recipients of WF, WF.COP, or whole mammary 
gland transplants (Figure 12C). DCIS development was not significantly different 
(P=O.3545, Mann-Whitney test) between ectopic mammary glands formed from MECs 
from either genotype (Figure l3C). However, DCIS formation in whole mammary gland 
transplants was significantly greater (P=O.0003 , Mann-Whitney test) than for ectopic 
mammary glands formed from MECs of both genotypes. 
Injection of Mammary Gland Cell Preparations Along With Adherent Cell Fractions 
Does Not Allow for Mammary Carcinoma Development at Ectopic Graft Sites 
Since there was no distinction in tumor outcome between ectopic mammary 
glands from susceptible and resistant MEC preparations and the ability to form frank 
carcinomas was nearly ablated, I sought to determine what was missing in cell 
preparations that was necessary for tumorigenesis. The MEC isolation method I 
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Figure 13: Tumor outcome in ectopic mammary glands derived from MECs. A" , 
Proportion of interscapular fat pads with ectopic mammary glands exhibiting tumor 
development. P values based on logistic regression analysis. B; Microscopic images of 
aluminum carmine-stained normal TEB, hyperplastic TEB, and precancerous lesion 
stained from interscapular fat pad whole mounts. C; Quantification of hyperplasia and 
DCIS formed per mm2 in ectopic mammary glands. P values based on non parametric 
Mann-Whitney test. 
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originally employed enriches MECs by negative selection removing most adherent cells, 
i.e., fibroblasts , macrophages, mast cells, as well as, adipocytes, which remain on the top 
layer when centrifuged. These cell types play roles in mammary gland function ; 
therefore, we hypothesized that the absence of one or more of these cell types resulted in 
retarding tumor development. To test this I adapted the original MEC isolation method 
to include the ACF that was discarded in the original protocol. These ACFs were 
retained and injected along with MECs. MEC-only injections and whole mammary gland 
transplants were performed as controls. I was attempting to restore the DMBA-induced 
mammary tumorigenesis susceptibility phenotype seen previously with WF whole 
mammary gland transplants; therefore, resistant cells were not considered and only WF 
donor cells were used. 
I anticipated that co-injecting the adherent cells lost during dissociation along 
with MECs would restore mammary tumor development in the transplant site. 
Surprisingly, there was no difference (P=O.6664) in ectopic tumor outcome in WF rats 
receiving WF MECs (N=9) and WF MECs co-injected with the AHC (N=9) but, 
combined, these were significantly different from those receiving whole mammary gland 
transplants demonstrating that inclusion of the ACF was not sufficient to restore 
tumorigenesis (Figure 14A). Additionally, I quantified hyperplasia and DCIS formation 
microscopically by counting hyperplastic TEBs or DCIS foci . I noted no significant 
difference (P=O.8345, Kruskal-Wallis test) in hyperplasia formation between ectopic 
glands formed from MECs, MEC plus ACF cells or whole mammary gland transplants. 
DCIS development did not statistically differ between rats receiving WF MECs and those 
getting WF MECs plus the adherent cell fraction. However, DCIS formation was 
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Figure 14: Tumor outcome in ectopic mammary glands derived from MECs or MECs 
supplemented with adherent cells. A; Proportion of interscapular fat pads with ectopic 
mammary glands exhibiting tumor development. P values based on logistic regression 
analysis. B; Quantification of hyperplasia and DCIS formed per mm2 in ectopic 
mammary glands. P values based on nonparametric Mann-Whitney test. 
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significantly increased (P<O.OOOl) in whole mammary gland transplants compared to 
either cell injection (Figure 14B). 
DMBA Susceptibility Is Delayed In Ectopic Mammary Glands Formed from Injection 
of Mammary Gland Cell Preparations 
Injection of cellular components of mammary glands into the interscapular white 
fat pad failed to form tumors in the resulting ectopically-formed mammary gland. Co-
injecting the AHC along with MECs again showed no difference in formation of frank 
carcinomas, DCIS or hyperplasia suggesting that there was a more complex process 
taking place. Within the process of dissociation of the mammary gland for MEC 
enrichment adipocytes are removed. Adipocytes are critical in mammary gland 
development and could be the missing link in efficient tumor formation that is lost in the 
mammary cell preparation transplants. However, there is an adequate concentration of 
host adipocytes within the interscapular fat pad cellular milieu making this less likely. 
Additionally, extracellular matrix (ECM) proteins are removed during MEC enrichment 
by collagenase digestion. The ECM provides an essential substrate required for normal 
mammary gland development; therefore, ECM may be required for tumor growth in these 
ectopic mammary glands. However, reintegrating MEC preparations with the adherent 
cells would restore fibroblasts which are responsible for ECM deposition, making this 
scenario less likely as well. DMBA-induced mammary carcinogenesis in the rat has been 
established to be dependent on a distinct mammary gland developmental window of 50-
55 days of age; however, this window is based on fully developed mammary glands 
(Russo and Russo, 1994). We hypothesized that a different time span is required for 
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dissociated mammary gland cells to reconstitute a functional mammary gland than for 
whole gland transplants, i.e., the DMBA-susceptibility window is shifted. 
To test this idea I used the original MEC isolation protocol, including susceptible 
and resistant MEC preparations only and administered DMBA at 40-45, 50-55, 60-65, 
and 70-75 days of age days. By including susceptible and resistant donor MECs, I would 
be able to identify whether the Mcs 1 b COP resistant phenotype is acting in the MEC 
population. 
Interestingly, only 32% (8 of 25) of female rats receiving DMBA at the 40-45 day 
susceptibility window developed a mammary gland in the interscapular fat pad while 
those receiving DMBA at 50-55, 60-65, or 70-75 days of age developed 81 %, 74%, and 
68%, respectively (Figure 15A). This may suggest that administering DMBA too early 
after MEC injection may affect the efficiency of the graft to develop into a proper 
mammary gland. 
Tumor outcome in the ectopic site was higher at the 40-45, 60-65, and 70-75 day 
susceptibility windows compared to the 50-55 day window (Figure 15B). These results 
are without regard to genotype of the MEC transplant as no genotype effect was detected 
(Figure 15B, bottom). Results for the 40-45 and 60-65 day windows were not 
statistically different from that of the original 50-55 day window (P=0.2352 and 0.0659, 
respectively). However, fat pad whole mounts from rats that received DMBA at 70-75 
days exhibited a significantly higher tumor outcome when compared to the original 50-55 
day DMBA window (P=0.0041). Furthermore, tumor outcome for the 70-75 day window 
was not significantly different than what was observed in whole mammary gland 
transplants (P=0.2025). These results suggest a shift in the susceptibility window of 
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Figure 15: Results of DMBA susceptibility window studies with MEC injections. A; 
Mammary gland development outcome in the interscapular fat pad. Bars represent the 
proportion of rats injected that developed a mammary gland in the injection site. B; 
Tumor outcome in the ectopic mammary gland at varying windows of DMBA-
administration. P values are based on logistic regression analysis. 
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ectopic mammary glands derived from MECs compared to those from whole mammary 
glands. Also, since no genotype effect was observed it is likely that the action of the 
Mcs 1 b locus to control mammary carcinogenesis is not intrinsic to a mammary epithelial 
cell type. 
Discussion 
Carcinogenesis in the mammary gland is complex involving multiple cell types 
and signaling mechanisms. On these lines, we set out to determine if the resistance to 
mammary carcinoma development conferred by the Mcslb locus was acting in a 
mammary gland-intrinsic or extrinsic manner. The majority of mammary carcinomas 
arising in the rat originate in the ductal epithelium; thus, we hypothesized that the Mcsl b 
locus was acting within a mammary gland cell type to confer resistance. 
Transplanting immature mammary glands into the interscapular fat pad results in 
the development of a properly branched and formed mammary gland (Gould and Clifton, 
1985). We used this approach and induced mammary carcinogenesis with a single dose 
of DMBA. The results of these experiments supported our hypothesis that the Mcslb-
conferred phenotype is mammary gland intrinsic. 
Transcripts within the Mcsl b locus remain to be functionally tested and these 
results indicate that the mammary gland should be the focus of these assays, e.g., gene 
expression profiles and splice variant analysis. Moreover, these data focus on a cell type 
of interest. Cells from the immune system can have an effect on mammary 
carcinogenesis in the tumor microenvironment (Pollard, 2004; Sica et aI., 2006; Smits et 
aI., 2011b; Trimboli et aI., 2009). Herein, we have shown that this is not likely the case 
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and focused on the mammary gland cellular milieu. The mammary gland is composed of 
a variety of cell types all of which have roles in normal gland development as well as 
progression to a neoplastic and malignant state (Lanigan et aI., 2007). Therefore, 
identifying a candidate cell type will afford a greater understanding of the etiology of 
mammary cancer. 
Given that rat mammary tumors arise predominantly in the epithelial cells lining 
the ducts, I hypothesized that MECs were responsible for the Mcsl b-conferred 
phenotype. To test this I modified the original transplant protocol by injecting MEC-
enriched cell preparations and tracking the phenotype. I anticipated that approximately 
twice as many WF MEC-derived ectopic mammary glands would exhibit tumor 
development than glands developed from WF.COP MEC donors, similar to what was 
seen in whole mammary gland transplant assays. However, the ability to form tumors in 
the transplant site was lost, suggesting that there is a component missing necessary for 
tumor development. 
I estimated that 80 animals of each genotype would have to be tested to estimate a 
mean tumor outcome to within ± 0.15; however, I only tested 16 homozygous WF and 14 
resistant congenic WF.COP rats in these studies. Although this is below the target 
number, the ability to form tumors in the fat pad was nearly completely ablated in all 
animals. Moreover, the lack of tumor development was not an artifact of poor transplant 
efficiency since the majority of recipients (97%) developed mammary glands in the 
interscapular fat pad. These ectopic glands appeared to have developed normally and, 
upon microscopic inspection, exhibited hyperplasia and DCIS development suggesting 
that DMBA was sufficiently initiating carcinogenesis within the ectopic site. Hyperplasia 
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and DCIS were quantified to determine if there was a difference between the MEC and 
the whole mammary gland transplants. No significant difference in hyperplasia was 
identified between ectopic mammary glands formed by MECs from the two genotypes, 
nor were these different than hyperplasia in whole mammary gland transplants. 
Similarly, DCIS formation was not statistically different in ectopic glands formed from 
congenic WF.COP MECs compared to ectopic glands from homozygous WF MECs. 
However, DCIS formation in ectopic mammary glands from either genotype was much 
lower than what was observed in whole mammary gland transplants suggesting 
carcinogenesis was being initiated in the MEC-derived glands but something involved in 
the MEC-isolation process removed a component required for progression to a frank 
carcmoma. 
My hypothesis was that a cellular component was removed during MEC-isolation 
that was required for complete tumor-induction by DMBA. To address this hypothesis, I 
first attempted to restore the ability to form tumors by reclaiming the cells removed 
during MEC enrichment and re-introducing them along with MECs into the fat pad and 
following the phenotype. However, including these adherent cells with MECs had no 
effect on tumor outcome compared to MECs alone, suggesting that the mechanism is 
more complex. The loss of tumorigenisis could be explained by the absence of 
adipocytes since these were discarded during MEC-enrichment. However, this seemed 
unlikely since the recipient fat pad contains adequate adipocyte content and allowed for 
mammary gland development in the majority of recipients. Therefore, it appeared that 
this effect could not be explained simply by a single missing cellular component. 
Whole WF mammary gland transplants were performed as controls in these 
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experiments and these exhibited a nonnal ectopic tumor outcome. Also, hyperplasia and 
DCIS development was quantified in ectopic glands from MEC-, MEC plus adherent 
cell-, and whole mammary gland-induced grafts. All grafts exhibited hyperplasia 
development, but there was no statistical effect associated with MECs, MECs plus 
adherent cells, or whole mammary gland transplants. Moreover, DCIS fonnation was not 
statistically different between ectopic mammary glands fonned from MEC or MEC plus 
adherent cell grafts; however, again the level of DC IS fonnation in either cell-derived 
ectopic gland was significantly reduced compared to whole mammary gland grafts. 
Taken together, these data suggest that DMBA is driving neoplastic events to 
fonn hyperplasia and precancerous DC IS lesions but is insufficient for progression to 
development of frank carcinomas. We hypothesized that there was a developmental gap 
in these ectopic mammary glands affecting their susceptibility to DMBA-induced 
carcinogenesis. I sought to detennine if there was a difference in susceptibility to DMBA 
in WF MEC-grafted ectopic mammary glands at different developmental windows. 
DMBA was administered in previous experiments at 50-55 days of·age of the recipient 
rat; approximately 20 days after cell injections were perfonned. Rather than adjust the 
age at which cell injections were perfonned, we chose to keep this constant at 30-35 days 
and, instead, administer DMBA at 4 different time points: 40-45 days, 50-55 days, 60-65 
days, and 70-75 days. If there was an effect from the developmental stage of the ectopic 
mammary gland, it was anticipated that one ofthese windows would return the mammary 
carcinogenesis phenotype towards a level similar to that seen in the whole mammary 
gland transplant studies. One may predict that an earlier DMBA window would likely 
result in an increase in tumor fonnation as these cells would be expected to be more 
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mitotic and, therefore, more vulnerable to DNA damaging agents. However, outcomes of 
the susceptibility window tests showed that female rats receiving DMBA at the 70-75 day 
window developed significantly more tumors than rats receiving DMBA at the 40-45, 50-
55, and 60-65 day windows. Tumor outcome in the 70-75 day group was not statistically 
different than that observed in whole mammary gland transplants, suggesting a 
developmental dependency for mammary carcinogenesis induction by DMBA. This may 
hold true for other PHCs as well. 
In addition, efficiency of proper mammary gland development in the interscapular 
fat pad was retarded at the 40-45 day DMBA window. This implies that DMBA may 
have an effect on mammary gland development. At this time point, DMBA was 
administered only ten days following cell injections. DMBA causes acute 
immunotoxicity immediately after it is given (Gao et aI., 2005). It may be that immune 
cells necessary for appropriate ductal branching and elongation are not present, resulting 
in atrophy of the mammary gland in the ectopic site. However, the high dose of DMBA 
administered to rats is not physiologically relevant; therefore, this effect is not applicable 
to human health but has implications on future rat studies. More studies will need to 
assess the mechanism by which DMBA affects mammary gland growth in these studies, 
e.g. measure immunological cells in the plasma and in the ectopic mammary gland. 
The shift in the DMBA-susceptibility window suggests that at earlier stages of 
mammary gland development, DNA-damaging agents, such as PHCs, have less effect on 
mammary carcinogenesis. It is not clear what the implications of this are. These data 
may suggest a reduced role for mammary "stem" cells in progression to full carcinoma 
development. Cancer stem cells have been proposed to be principal mediators in primary 
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tumor development and relapse following therapy. My data suggest, however, at earlier 
stages the stem cell niche may not be capable of driving full carcinogenesis and, rather, a 
more differentiated cell type is requisite for tumor development. Still, it could be argued 
that these undifferentiated cells may require more than a single dose of DMBA to 
develop frank carcinomas. Indeed, DMBA-induced carcinogenesis relies on steroidal 
hormone activation, such as estrogens, as a "second hit" to drive carcinogenesis and 
potentially these stem niche cells lack ample ER expression. We currently have no 
information regarding the cell populations present or how they act within the 60-65 or 70-
75 day window. Therefore, there is no evidence for or against a role for a particular 
mammary gland cell type in DMBA-induced mammary carcinogenesis. 
Previous studies have demonstrated that the clonogen transplantation method is 
sufficient to induce mammary gland formation in an ectopic site; yet, to date, no one has 
shown a capacity to stimulate mammary cancer development in these ectopic glands. 
These experiments are important because they provide insight into mammary 
carcinogenesis III the context of environmental exposures. Herein, I show that the 
mammary carcinogenic effects of DMBA are dependent on a specific stage of mammary 
gland development. Although the data imply that the Mcslb-conferred phenotype is not 
intrinsic to a mammary epithelial cell population, work to identify a specific cell type 
responsible for Mcs 1 b-induced resistance, regrettably, remains inconclusive. Regardless, 
the initial goal of this aim was to identify a tissue type involved in Mcsl b-conferred 
resistance to mammary carcinoma development. My data show that the action of the 
Mcsl b COP allele is specific to the mammary gland. Future efforts to functionally test 
gene candidates within the Mcsl b locus will, consequently, be focused on the mammary 
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gland as a target tissue. Although these studies do not provide definitive answers as to 
what the specific factors are affecting tumor development, they afford a means by which 
to study these effects further. On the whole, my data identify that the Mcsl b COP allele 
is acting in mammary gland-autonomous manner and indicate that the effectiveness of 
DMBA to induce mammary carcinogenesis is dependent on the developmental stage of 
the mammary gland. 
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CHAPTER IV 
MIER3 IS A CANDIDATE BREAST CANCER-ASSOCIATED GENE 
Introduction 
There are thirteen transcripts annotated within the 1.8 Mb Mcslb locus delineated 
by lines N3, W2, U2, and 14 and six of these transcripts reside in the 1 Mb region 
delineated by addition of line 1 b-ll (Figure 5). All of these genes are also annotated to 
the human breast cancer-associated locus marked by SNP rs889312, and any combination 
of these transcripts could be the responsible gene(s) involved in Mcsl b COP-conferred 
mammary carcinoma resistance (Figure 8). The most plausible breast cancer candidate 
gene within this region is Map3kl. However, no direct evidence is available to support 
Map~kl as the causal gene. It is relevant, then, to test the transcripts annotated to this 
region. We hypothesize that a genotypic variant between WF and COP in the McsJb 
locus lies within the coding region of one or more of these transcripts and results in an 
amino acid change that gives rise to a differential mammary carcinoma susceptibility 
phenotype. This approach is important in that SNP haplotype maps in the rat are 
incomplete; thus, identifying variants will increase current knowledge of rat genetics and 
potentially identify causative SNPs. Many cancers are caused by detrimental mutations 
or variants that alter protein function and this may be the basis the Mcsl b phenotype. 
All of the human SNPs tagged along with rs889312 lie outside of annotated 
transcribed genes (Figure 3). Consequently, it is possible that the inherited element(s) 
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controlling the risk phenotype are non-coding regulatory elements. Indeed, many low 
penetrance alleles associated with disease phenotypes are now being found to involve 
non-coding variations. There may be additional SNPs not yet identified that lie in 
transcribed regions that may be causative; thus, it is important to first test for changes in 
the coding region. 
To not bias the approach towards any specific transcript(s), I first set out to 
resequence the open reading frames (ORFs) of each transcript lying in the 1.8 Mb Mcslb 
locus as it was delineated from marker A12v (ch2:42364155) to marker a1200 
(ch2:44210175). The mechanism by which the Mcslb locus is controlling mammary 
carcinogenesis susceptibility is not clear; therefore, including all of the transcripts in this 
interval reduces the probability of missing the causative factor. 
In the past decade there has been increasing interest in regulatory microRNAs 
(miRNAs) in cancer research. These miRNAs are short pieces of untranslated RNA 
transcribed by the cell that can recognize and bind specific target sequence sites on 
translated mRNAs and mark them for degradation. They regulate rrormal processes 
within the cell and have been shown to be dysregulated in some cancers. Differential 
effects can result either through sequence variation in the miRNA target sequence or 
through alterations in the sequence or the expression of the miRNA itself. These miRNA 
target sequences are principally located in the 3' untranslated regions (UTRs) of the 
mRNA to be regulated. Therefore, in addition to resequencing the ORFs, I also 
resequenced the 3' UTRs of these transcripts. 
Sequence differences between WF and COP sequence in any of the transcripts 
will be analyzed in silico to determine if the variation(s) disrupts the normal structure of 
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the protein, e.g., results in an amino acid change or introduces a premature stop codon. It 
may be that variation between the two rat lines results in differences in stability of a 
transcript. Efforts will be focused on determining transcript expression levels between 
susceptible WF and resistant WF.COP line T and N3 rats. Conversely, if no variation is 
identified in the coding region of any of these transcripts, it will be tacit that the 
mechanism of the Mcs 1 b-conferred phenotype is regulatory in nature. In this case, gene 
expression of all the transcripts will be tested. In each case, gene expression levels will 
be first assessed in mammary gland tissue as we found Mcsl b COP-conferred mammary 
carcinoma resistance to be autonomous to the mammary gland. Other tissues will be 
tested to establish whether the effect is mammary gland-specific. 
Design and Methods 
Resequencing Mcslb Transcripts 
Spleen or thymus tissue from WF/Hsd and WF.COP lines N3 and T rats was 
excised and total RNA was extracted using TriReagent (Molecular Research Center) and 
standard chloroform/isopropanol precipitation. RNA samples were treated with TURBO 
DNase (Life Technologies) to reduce DNA contamination and cDNA was made using 
Superscript III reverse transcriptase (Life Technologies). Sequences were not attainable 
from cDNA in some instances; therefore, genomic DNA, extracted from frozen spleen or 
liver tissues using standard phenol-chloroform/isopropanol precipitation, was used. 
Samples were PCR amplified using Accuprime HiFi Taq polymerase (Life Technologies) 
and, subsequently, cleaned with the QIAquick PCR Purification Kit (Qiagen) to remove 
unincorporated nucleotides. Amplified samples were sequenced using the BigDye 
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Terminator v.3.1 Cycle Sequencing Kit (Life Technologies and purified with Agencourt 
CleanSeq magnetic beads (Beckman Coulter). These were submitted for analysis to the 
University of Louisville Center for Genetics & Molecular Medicine DNA Core using an 
ABI PRISM 3130XL Sequence Detection System (Life Technologies). Primer sequences 
for amplifying and sequencing McsJh ORFs and 3'-UTRs are in Table 9. Nucleic acid 
sequences were submitted to NCBVGenBank and assigned accession numbers JQ013728 
through JQ013739. 
Gene Expression Assays 
Tissues were excised from WF/Hsd and WF.COP lines N3 and T rats that had 
been treated with DMBA or not and flash-frozen in liquid nitrogen. Total RNA was 
extracted with TRI-Reagent (Molecular Research Center) followed by standard 
chloroform/ethanol precipitation. To reduce possible solvent and DNA contamination 
RNA samples were further processed by a 1110 v/v 3M sodium acetate and 2.5x v/v 
100% ethanol wash on ice for 10 minutes followed by 80% ethanol wash followed by 
Turbo DNase (Life Technologies) treatment. Total RNA quantity and quality were 
measured with a Nanodrop 1000 (Fisher Scientific) and a Bioanalyzer with RNA 6000 
NanoChips (Agilent). cDNA was made by reverse transcription reactions using (20 III 
f.v.) 11lg total RNA 0.5x RNAsecure, 51lM random hexamers, 25ng/IlL 0Iigo(dTI8), and 
0.5 mM dNTPs were incubated 5 minutes at 65° C prior to adding 1 x first strand buffer, 
100mM DTT, and 11lL Superscript III (Life Technologies). Reactions were incubated 5 
mat 25° C, 1 hat 50° C, and 15 m at 70° C. TaqMan QPCR primers and MGB probes 
(Applied Biosystems) were designed by using Primer Express v 2.0 (Applied 
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Biosystems). Primer and probe sequences are provided in Table 10. One I.d of the 
dilution (;:::;12.5 ng of RNA-equivalent cDNA) was used in a 16-fll TaqMan QPCR. The 
reaction components were 1 x TaqMan Buffer A (Applied Biosystems); 5.5 mM MgCh; 
dATP, dCTP, dGTP, and dTTP at 400 flM each; experimental primers at 300 nM each; 
200 nM TaqMan experimental probe (Applied Biosystems); Rplp2 primers at 100 nM 
each, 200 nM rodent Rplp2 probe; and 0.4 units of Taq Gold DNA Pol (Applied 
Biosystems). Real-time QPCR was run on an ABI PRISM 7900HT real-time PCR 
machine. Real-time QPCR cycling conditions were 50°C for 2 min and 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. F AM (Mcs 1 b region target 
gene probe) and VIC (Rodent Rplp2 probe; Applied Biosystems) fluorescence values 
were measured by using Applied Biosystems SDS v 2.3 software; quantities of transcripts 
were measured by comparison of cycle threshold values with a standard curve calculated 
from serial dilutions. Sample measurements are an average of four replicates per sample 
and were standardized by dividing the quantity of rodent Rplp2. Data were analyzed by 
Mann-Whitney tests. 
Comparative Genomics 
Human and mouse sequences for genes annotated to the Mcsl b locus were 
obtained using the UCSC Genome Browser using the Homo sapiens verSIOn 
GRCh37/hg19, Rattus norvegicus version 3.4/m4, and Mus musculus verSIOn 
NCBI37/mm9 genome assemblies. Sequences were aligned using the DNAStar SeqMan 
sequence analysis program (DNAStar) to identify orthologous regions. Primers were 
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Table 10: 
Rat \1cs I b Target and Rplp2 Primers and Probe S~yuences Used for (JPCR 
Assay Name 
Rplp2 
Map3kl 
Ivlier3 
Gpbpl 
[]6st 
Ankrd55 
1I31ra 
Ddx4 
Slc389 
Ppap2a 
Forwam Prim .. r Sequefl('e (5' to 3') 
fGAACGACTCAACAAGOTCATCA 
TCCTCATATTGTCAGTACCGATGTC 
C(iAAA(i(lTAC)'(iCT<iTAATGGAAA 
GAGTAGAAGAGGAGCATGAAGATGAA 
GAC,\ACGCTGCTGOGAGfCI' 
ATGGTGCCAAGCACAACATC 
GCCAAAGAAA,\AGCrCCAACAT 
CTGGGAAGACGGCAGCTIT 
GGTTTGCGCC AAC AGA.yrIT 
TGTCAAGOGAATG ... \ACA(IAAGGT 
Reverse Primer Sequence (5' to 3') 
CAACACCCTGAGCGATGACA 
TI"GCA1\GGCAl\AGGCf AAGAG 
GCACTCCTCTrCACfTCCAAGCT 
TGGTGAGTACTATTGCTGTTATGCAA 
GGAG'ITAAAi\TrG'roCC1TGGG 
GATGAGAAGCCTCACATCAGGTr 
ACGGCTGTCTI'CAAACCAATG 
GCAGTfATTCCATCCCTCATC\TA 
CCCTGTC,\GCTGTGGAA .. \CTG 
AACAGCATGCAOTACATAGAGAATOA 
Probe Sequence (5' to 3') 
VIC-CTGAATGGAAAGAA TA TTGAG 
6 FA,\\·CCTGTTGAAA TCAGGTATAA 
6FA\f-C(fTCTC AAGAAOOAATG 
6F.-\M-CTCAGAGA-\GGA TGACGAC 
6FJ'-"1-AAAC,\CATCTGGCCGAAT 
6FAM-CAGATAAAAATGGCCGCCTG 
6FAM-TCCCAATACCACGGTGAA 
6FAM-CTCTTGCCTA TTTTGGCTC 
6FAM-TTGTACCAGAGATAAGAGC 
6FA1\I-AACKiCAGG1TGTCCIT 
)'IiCBI Gme Refel't'n~ ... ID 
:-1\f 0010300211 
NM 053887 
'-i\1 00 J J 68()OO. J 
'-i!\\ 001106410.1 
:-.IM_OO 1008725. 3 
X\I 342195.4 
XM 226759.4 
'-iM 001077647.1 
'-i!\1 00103525 J.I 
NM 022538,2 
designed against the rat orthologous sequence using Primer3 (Rozen and Skaletsky, 
2000) and used to test for alternate start sites for Mcsl b transcripts in rat cDNA samples. 
Genomics and Statistical Analysis 
Mammary carcinoma multiplicity phenotypes were compared by nonparametric 
Mann-Whitney tests. Results from mammary gland grafting experiments were analyzed 
using logistic regression. Donor and recipient genotypes were incorporated as dependent 
variables. In independent models, graft site tumor outcome and grafting ability were 
used as independent variables. Quantitative PCR (QPCR) data were analyzed using 
ANOVAs with log2 (Target quantity/Rp/p2 quantity) as the dependent variable. 
Independent variables for comparing mammary gland transcript levels were Mcslb 
genotype and DMBA exposure. Mcsl b genotype and tissue source were independent 
variables for mammary carcinoma and non-diseased mammary tissue QPCRs. Fisher's 
PLSD tests were used to compare groups following a significant F-test (a:S 0.05). 
Statview software (SAS Institute) was used. 
Cloning of Mier3 Splice Variants 
Splice variants for rat Mier3 were amplified from susceptible and Mcsl b resistant 
rat mammary gland cDNAs by standard PCR and cloned into a pCR® 2.1-TOPO® vector 
(Life Technologies) according to manufacturer specifications. Clones were transformed 
into chemically-competent DH5a E. coli cells, plated on Miller's LB Agar (Amresco) 
plates containing 50 Ilg/ml Kanamycin and coated with 40 III of 40 mg/ml X-gal, and 
incubated at 37° C overnight. White colonies were picked from each plate and inoculated 
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into individual wells of a 96 well plate containing 40 III Miller's LB broth (Amresco) and 
incubated for 2 hours while shaking. 0.2 III of inoculated media was amplified by PCR 
using M13 reverse and T7 promoter primers specific for flanking regions of the multiple 
cloning site within the pCR® 2.1-TOPO vector. PCR products were resolved on 1% 
agarose TBE gels and stained with SYBR Gold. Large and small bands corresponding to 
full-length and spliced Mier3, respectively, were counted for each sample. Analysis was 
performed on the proportion of full-length bands in the total number counted. 
Proportions were arcsine-transformed and analyzed by a student's t-test. 
Results 
Mcslh Potential Candidate Open Reading Frame Sequences Yields Are Not Different 
Between WF and COP 
As shown in Figure 5, rat McsJ b was found to contain thirteen potential candidate 
gene transcripts as well as sequence orthologous to human 5qll.2, a GWAS-identified 
breast cancer risk associated allele marked by SNP rs889312 (Easton et aI., 2007). To 
prioritize potential candidates, I resequenced conserved protein coding ORFs that were 
within the 1.8 Mb interval that delimited Mcslb, and based on RT-PCR gel 
electrophoresis, were expressed in mammary glands of susceptible WF and Mcsl b 
resistant females (lines N3 and T). Transcripts from Gpbpl, Map3kl, Mier3, Ankrd55, 
116st, Il31ra, Ddx4, SIc38a9, and Ppap2a genes were detected in mammary gland total 
RNA pools from each genotype by RT-PCR. No genetic variants were identified 
between susceptible WF and Mcsl b resistant genotype ORFs or 3' UTRs for these 
transcripts. Nucleotide sequences were submitted to NLM-NCBI and the GenBank 
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accession numbers are provided in Table 9. 
Four of the Mcsl b candidate genes are predicted transcripts based on sequence 
containing gene-coding properties, e.g. intron-exon boundaries and polyadenylation 
signals, or sequence similarity to known expressed transcripts: Actbl2, 
ENSRNOG00000013098, C50rj35 and U6 snRNA (labeled with asterisks in Figure 5). 
Rat Actbl2 was identified as a pseudo gene and is located outside rat genomic sequence 
orthologous to the human 5qll.2 haplotype block that associates with breast cancer risk. 
Predicted transcript ENSRNOG00000013098 was listed on the Ensembl genome browser 
(Flicek et aI., 2011). I found no evidence by RT-PCR of a transcript from Actbl2 or 
ENSRNOG00000013098 in total RNA samples from multiple susceptible and Mcslb 
resistant mammary glands or in rat mixed tissue total-RNA samples that included 
embryo, brain, testes, ovary, thymus, spleen, and liver. Since cDNA was not attainable 
and Actbl2 was predicted to be a single-exon transcript, we sequenced genomic DNA 
spanning this predicted pseudo gene and found no sequence differences between WF and 
COP alleles. 
Rat C50rj35 IS an ortholog of human C50RF35. This gene was recently 
identified to have a SET domain and renamed SETD9 (SET domain containing 9). SET 
family members are histone methyltransferases involved in regulating chromatin 
structure by methylation of lysine residues on tails of histones. Dysregulation of SET 
proteins plays roles in the progression of many cancer types. For instance, the SET 
member EZH2 has been implicated in the development of breast and prostate cancer 
(Kleer et aI., 2003; Yu et aI., 2007). Although the human C50RF35 protein has not been 
fully characterized it could be a potential candidate based on its sequence similarity to 
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SET proteins. However, rat C50rj35 was not present in any total RNA samples tested 
from various rat tissues. Additionally, I successfully amplified C50RF35 from human 
thymus, spleen, and ovary, but not human breast tissue cDNA (Figure 16A) suggesting 
that human C50RF35 is not highly expressed in the breast. However, in an Oncomine 
(Rhodes et al., 2004) database search I found that other groups have reported detection of 
C50RF35 in human breast carcinoma and non-diseased breast tissue. Using 
bioinformatic analysis I discovered that the annotated 5'- and 3'- UTRs of human 
C50RF35 are poorly conserved between humans and rodents (Figure 16B); therefore, we 
concluded that C50RF35 is a human, but not a rat transcript. 
A predicted small nuclear RNA (snRNA) at rat position Chr2:43765811-
43765918 named U6 or ENSRNOG00000034909 is estimated to be 108 bp on the 
forward strand. I noted that ENSRNOG00000034909 sequence aligned to approximately 
100 distinct regions of the rat genome using both NCBIIBLAST and UCSC/BLAT (den 
Dekker et al., 2012; van Boxtel et al., 2011) (Table 11). Because of the highly repetitive 
nature of the sequence, I was unable to design specific probes to determine if this 
predicted single exon gene was transcribed from rat Mcsl b. 
Mcslb Potential Candidate Gene Expression Levels Uncover Mier3 as a Potential 
Gene Candidate 
Rat Mcs 1 b did not contain any protein coding genetic variation between Mcs 1 b 
susceptible and resistant alleles; therefore, rat Mcsl b may contain variation in one or 
more non-protein-coding regulatory elements that differentially control gene expression 
between mammary cancer-susceptible and resistant genotypes. To test this hypothesis, I 
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Human _ .................... ; ................... .. 
• • 
Orangulan 97% 
Rhesus Macaque 93% 
Dog 89% 
Cow 0% 
Rat 0% 
Mouse 0% 
Sequence Similarity 
98% 99'J(, 97% 96% 
98% 97% 100% 97% 
93% 93% 0% 94% 
92% 0% 90% 97% 
92% 0% 90% 97% 
0% 0% 0% 0% 
-
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79% 
79% 
0% 
Figure 16: Predicted human C50RF35 is not conserved in rats. A; Predicted C50RF35 
transcript was detected in multiple human tissues by RT-PCR. B; Splice variants of 
C50RF35 detected in human tissue and sequence similarity between human C50RF35 
exons and other species. A C50RF35 splice variant that did not contain exon 2 was 
detected in human thymus and spleen samples. C50RF35 is not conserved between 
primates and rodents based on degeneration of 5' and 3 'UTR sequences in rodents. 
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Table 11: 
llLAT alig!1ment ofENSRNOUOO000034909 scguencc against l1eSe Cicnome 13rowscr Rat DNA build (llilylor 3.4,m4 assembl!Ll 
Tranlleript 10 Transcript OC'lK"ription Chromosome Start Position End Position Orientation Seo .... %10 Span (bps) 
No rat transcripts annotated in browser Chr:2 43765811 43765918 108 100.00 108 
RefSl,)q ID: NM 153738 Rat Prlpn intronic region Chr:r 43789233 43789333 82 88.20 101 
No rat transcripts annotated in browser Chr:6 136766481 136766580 79 88.70 100 
Ref Seq ID: NM ~ 001108397.1 Rat SfTS 14 intronic region Chr:!6 19667327 19667415 78 93.10 89 
RefSeq 10: NM_001191653.1 Rat Tanc2 intronic region Chr:!O 95198700 95198796 78 89.40 97 
No rat transcripts annotated in browser Chr:~ 98699371 98699471 77 91.10 101 
RefSeq ID: N M 17310 1.I Rat ~lyo Ie intronic region Chr:8 74882368 74882468 75 89.90 101 
No rat transcript. annotated in browser Chr.·4 110618884 110618978 75 92.80 95 
No ral transcript, annotated in browser Chr:1f 63198076 63198175 75 89.70 100 
No ral transcript, annotated in browser Chr:! 103440155 103440263 75 90.50 109 
No rat transcripts annotated in bf<)wscr Chr:1 75525663 75525763 75 89.90 101 
No rat transcripts annotated in browser Chr:3 69993031 69993128 74 90.70 98 
No rat transcript' annotated in browser Chr:2 19495997 19496085 74 90.70 89 
No rat transcripts annotated in browser Chr:1 245228475 245228564 74 91.20 90 
........ Ref Seq ID: NM 031337 Rat Siat9 intronic rcgion Chr:4 105395193 105395722 73 95.20 530 
N 
w No rat transcripts atmotatcd in browser Chr:~ 79649136 79649236 73 88.80 101 
No rat transcripts annotatcd in browser Chr:20 29978369 29978469 73 88.80 WI 
No rat transcripts annotated in browser Chr:/~ 25409944 25410031 73 90.60 88 
Ref Seq ID: NM OOWI1915 Rat Plilkhcl intronic region Chr:15 21384589 21384682 73 88.80 94 
RcfScq ill: NM 001011915.1 Rat Fcmlt2 intronic r~gion 
No rat transcripts annotated in browser Chr:2 173740365 173740453 72 89.60 89 
No rat transcripts annotated in bmw!;er Chr:9 112012955 112013153 71 94.00 199 
No rat transcripts annotatoo in browRer Chr:2 124284322 124284416 71 90.40 95 
No rat transcripts annotated in browser ('h,.: II 70013852 70013937 71 90.40 86 
RefSeq ill: NM 001135761.1 Chr:3 17548151 17548246 70 93.90 96 
No rat transcripts annotated in browser Chr: 7 135345735 135345826 70 88.10 92 
No rat transcripts annotated in browser Chr:!8 27228793 27228894 70 86.70 102 
No rat transcripts annotated in browser Chr:8 31027110 31027202 69 90.20 93 
No rat transcripts annotated in browser Chr:5 15608653 15608741 69 92.30 89 
No rat transcripts annotated in browser Chr:2 240633692 240633780 69 92.30 89 
Rat mRNA lrom GenB.1I1k, ID: OCI66504 Rat Faml89a2 intronic region Cllr:l 227408075 227408163 69 92.30 89 
No rat transcript~ annotated in browser Chr:! 18291369 18291554 69 92.70 186 
Ref Seq ID: NM 001170548. I Rat ·lbumpd3 intronic region Chr:4 148933048 148933143 68 85.60 96 
Rat mRNA from OenBank. ID: FQ230829 No identified bomolog Chr:19 41214051 41214136 68 84.40 86 
No ral transcript~ annotated in browser Chr:14 18935943 18936031 68 87.30 89 
No rat transcript~ annotated in browser Chr:9 47499507 47499595 67 91.00 89 
Table II c(mtinue<i 
Transcript ID Transcript Description Chromosome Start Position End Position Orientation Seo .... %ID Span (bps) 
RcfSeq 10: NI<.1 001197907.\ Rat Oll.TI intronic region Chr:- 77197714 77197802 67 91.00 89 
R~fSeq ID: NM.001171177.2 Rat Tmtc2 intronic r~gion Chr:' 43891984 43892076 67 84.50 93 
No rat transcripts annotatold in browser Chr:- 11235427 11235515 67 91.00 89 
RcfSeq ill: NM 031057 Rat Aldh6a1 intronic region Chr:6 108710588 108710676 67 91.00 89 
No rat transcript~ annotated in browser Chr:6 93546629 93546717 67 91.00 89 
No rat transcripts annotated in browser Chr:6 72766763 72766851 67 91.00 89 
RefSeq 10: NM.OOI134463.1 Rat Camkml intronic region Chr:6 8704054 8704142 67 91.00 89 
No rat transcripts annotated in browser Chr:5 151444756 151444844 67 91.00 89 
Ref Seq ID: Nt.IOOII08005.1 Rat Mast2 intronic region Chr-5 136630633 136630721 67 91.00 89 
No rat trlUlSCripts annotated in browser Chr:5 60215398 60215486 67 91.00 89 
No rat transcripts annotated in browser Chr:5 56854404 56854492 67 91.00 89 
No rat transcripts annotated in browser Chr:3 36733997 36734085 67 91.00 89 
No rat transcripts annotated in browser Chr:3 35650885 35650973 67 91.00 89 
No rat transcripts annotated in browser Chr:2 233090377 233090465 67 91.00 89 
No rat transcripts annotated in browser Chr:2 168539521 168539609 67 91.00 89 
Ref Seq ID: NM_OO103496I Rat Sohlh2 intronic region Chr.2 144422171 144422259 67 91.00 89 
No rat transcripts annotated in browser Chr:2 96996138 96996226 67 91.00 89 
No rat transcripts annotated in browser Chr:1 35329196 35329284 67 91.00 89 
tv 
.j::. No rat transcripts annotated in browser Chr.!8 13043912 13044000 67 88.90 89 
Ref Seq ID: NMOO!OO4020.1 Rat Tmprs.< lIb intronic region Chr:l.J 23014788 23014876 67 91.00 89 
No rat transcripts annotated in browser Chr:U 9590393 9590481 67 91.00 89 
No rat transcripts annotated in browser Chr:!O 60526129 60526217 67 91.00 89 
RIlISeq 10: NM.001191634.1 Rat Gbfl intronic region Chr:! 251394207 251394295 67 91.00 89 
Rat mRNA from GenBank, 10: FQ232940 No identified homolog Chr:f 23671516 23671604 67 91.00 89 
No rat transcripts annotated in browser Chr:1 18892950 18893050 67 85.40 101 
RcfSeq 10: NM 012774.1 Rat 0pe3 intronic region Chr:X 139315241 139315329 67 91.00 89 
No rat transcript, annotated in browser Chr:- 127637150 127637238 67 91.00 89 
No rat transcripts annotated in browser Chr:6 72766085 72766173 67 91.00 89 
RcfScq 10: NM 001134628.1 Rat RGDl564943 (Predicted) intronic region Chr:5 148336835 148336923 67 91.00 89 
No mt transcripts annotated in browser Chr:4 102436898 102436986 67 91.00 89 
RefSeq 10: NM.022217.1 Rat Amph intronic region Chr:1 ~ 53682453 53682541 67 91.00 89 
No rat transcripts annotated in browser Chr:r 48877826 48877914 67 91.00 89 
No mt transcripts annotated in browser Chr:f4 111622041 111622131 67 89.90 91 
No rat transcripts annotated in browser Chr:IO 89929380 89929468 67 91.00 89 
No rat transcripts annotated in browser Chr:X 132443461 132443547 66 91.00 87 
RefSeq 10: NM 001106706.1 Rat Tte27 intTOnic region Chr:6 20562368 20562456 65 89.70 89 
No mt transcripts annotated in browser Chr:4 26126909 26126997 65 91.80 89 
No rat transcripts annotated in browser Chr:2 216457973 216458061 65 89.70 89 
No rat transcripts annotated in browser Chr:18 33879457 33879556 65 92.40 100 
Table II continued 
Transcript 10 T ranscri pt Dt'lICription Chromosome Start Position Rnd Position Orientation Score %10 Span (bps) 
Reffieq II): N1\I 001007145 Rat Catnal intronic region Chr:i8 27639818 27639906 65 89.70 89 
No rat transcripts annotated in browser Chr:iR 265348 265436 65 89.70 89 
No rat transcripts annotated in browser Chr: 14 40179238 40179338 65 84.30 101 
No rat transcript~ annotated in browser Chr:il 32577174 32577262 65 89.70 89 
No I1It transcripts annotated in hrowser Chr:' 1 B696949 113697045 65 92.30 89 
No rat transcript~ annotated in browser Chr.:} 190279006 190279094 65 89.70 89 
;0.;0 rat transcript. 1mnotated in hrowser Chr:i8 16341735 16341823 65 89.70 89 
No rat transcripts annotated in hrowser Chr:f 231873185 231873266 65 86.60 82 
RatmRNA from GenBank. ID: FQ227174 "io identified hOlllolog ('hr.· i- 15279892 15279979 64 89.50 88 
No rat transcripts annotated in browser Chr:/4 77213446 77213534 64 89.50 89 
....... Rat mRNA frulll (~nBank. ID: DQI00481 I JNE- 1 retrotransposon nucleic acid hinding protein mRNA Chr: / 25793445 25793533 64 84.10 89 
N No rat transcripts annotated in hrowser Chr:6 116937744 116937821 64 91.10 78 VI 
"io rat transcripts annotated in browser Chr:14 32819567 32819654 63 89.10 88 
Ref Seq ID: N\I. 001107047.1 Rat Hall intronic region Chr:/{j 87362236 87362320 63 90.50 85 
Ref Seq ID: 1"1\1 001007630.1 Rat Zfand6 intronic regi<m Chr:i 140906354 140906442 63 88.40 89 
No rat transcripts annotated in browser Chr:/ 56584008 56584096 63 88.40 89 
No rat transcripts annotated in browser Chr:9 10.3107997 103108085 63 88.40 89 
No rat transcripts annotated in hrowser Chr:3 104572110 104572198 63 88.40 89 
~o rat trans.:ri pt~ annotated in hrowser Chr:! 194118835 194118923 63 88.40 89 
Reffieq ID: NM 001135718.1 Rat Prexl intronic region Chr:3 157849079 157849155 62 89.20 77 
No rat trans.:ripts annotated in browser Chr:/6 36604669 36604747 61 91.40 79 
No rat transcripts annotated in hrowser Chr:i4 54341337 54341425 60 90.00 89 
No rat transcript~ annotated in browser Chr:i 232461672 232461742 60 91.20 71 
RefSe9 ID: NM 001191669.1 Rat 1llsd7b intronic re~ion Chr:i] 42749088 42749194 60 97.00 107 
(Hit~ with score:> 60) 
measured mammary gland transcript levels of genes located at Mcslb in 12-week old 
virgin female rats that were exposed to DMBA at 50-55 days and age matched controls 
without DMBA. These studies focused on mammary gland transcript levels due to the 
mammary gland autonomous nature of Mcslb previously discussed. Twelve-week old 
animals were used because this is the age after the acute phase for DMBA-toxicity and 
before induced frank mammary carcinomas are detectable in susceptible strains. 
Differences in expression between genotypes were analyzed by non-parametric 
Mann-Whitney tests and the effects of Mcsl b genotype and DMBA exposure on 
candidate gene transcript levels were analyzed by two-way ANOVA (Table 12). 
Transcript levels of Ankrd55, 113 1 ra, Ddx4, SIc38a9, or Ppap2a were not significantly 
different between Mcsl b resistant and susceptible mammary glands exposed to DMBA or 
not. However, the effect of Mcsl b genotype was statistically significant (P < 0.05) for 
Gpbpl, Mier3, and Map3kl. Furthennore, there was a significant effect of DMBA 
exposure on Map3kl transcript levels (P=0.0003) and the interaction between Mcsl b 
genotype and DMBA exposure approached statistical significance for Map3kl 
(P=0.0588). Additionally, there was an effect of Mcsl b genotype on Il6st expression by 
ANOVA; however, there was no difference in expression between genotypes in 
mammary glands not exposed to DMBA (P=0.1137) and expression only approached 
significance in glands exposed to DMBA (P=0.0734). When Mcslb genotypes were 
compared by DMBA exposure, mammary gland transcript levels were significantly 
different for Gpbpl, Mier3, and k/ap3kl between Mcslb resistant and susceptible 
mammary glands that were not exposed to DMBA. However, significant expression 
differences between Mcs 1 b resistant and susceptible genotypes were sustained only for 
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Table 12: 
Analysis and statistics of M es 1 b potential candidate gene mammary gland transcript levels in.!v! esl b -resistant and susceptible genotypes at 12 
weeks of age 
Two-wa~ ANOV A F test Pvalues Log2 Ta~etIRl!l1!2 mean ± SD (II ) 
Target Mcslb Genotype Exposure GXE Exposure Susceptible Mcs 1 b Resistant P-value 
Gpbpl 0.0101 0.209 0.6422 Control 0.586 ± 0.600 (34) 0.044 ± 0.734 (29) 0.002 
DMBA 0.281 ± 1.309 (45) 0.097 :le 1.246 (42) 0.1716 
MJER3 0.0023 0.7911 0.6682 Control 0.115 ± 0.594 (34) -0.522 ± 1.278 (34) 0.0104 
DMBA 0.154 ± 1.557 (45) 0.688 i 1.943 (48) 0.024 
Alap3kl 0.0002 0.0003 0.0588 Control -0.092 ± 0.818 (34) -0.725 ± 0.767 (32) 0.0019 
DMBA 0.105 -t 0.564 (47) -0.104±0.651 (45) 0.1036 
Ankrd55 0.4694 0.2025 0.9019 Control -0.691 ± 0.678 (24) -0.826 ± 1.108 (22) 0.618 
DMBA -0.377 ± 1.296 (17) -0.567 ± 1.006 (22) 0.609 
Jl6st 0.0199 0.1744 0.8435 Control -0.066 ± 0.755 (36) 0.418 ± 1.054 (33) 0.1137 
DMBA 0.189 ± 1.006 (44) -0.227 ± 1.181 (48) 0.0734 
Il3lra 0.2869 0.8674 0.9928 Control -0.331 ± 1.072 (24) -0.559 -1 0.761 (23) 0.4072 
DMBA -0.368 ± 0.942 (20) -0.592 ± 1.159 (23) 0.4949 
Ddx4 0.0555 0.5442 0.4045 Control -0.107 ± 0.983 (36) 0.359 :t 0.911 (33) 0.2748 
DMBA -0.055 ± 1.122 (18) -0.690 ± 1.575 (17) 0.1769 
SIc38a9 0.1008 0.3929 0.973 Control -0.285 ± 0.600 (24) -0.575 ± 0.681 (23) 0.1284 
DMBA -0.144 ± 0.970 (20) -0.422 ± 0.954 (23) 0.3499 
Ppap2a 0.3918 0.8314 0.5788 Control -0.385 ± 0.632 (24) -0.447 ± 0.765 (23) 0.7629 
DMBA -0.315 ± 1.357 (20) -0.605 ± 1.029 (23) 0.4315 
3Pisher PLSD test P- values from comparing susceptible and Alesl b -resistant genotypes by exposure. 
3 
Mier3 when females gIVen DMBA were compared between genotypes (P=O.024). 
Transcript levels of Gpbpl and Map3kl were not different between genotypes when 
DMBA-exposed females were evaluated. 
Mammary gland transcript levels were lower in Mcslb resistant genotype females 
for all genes with a significant difference between genotypes: Gpbpl, Mier3, and 
Map3kl. Mier3 mean transcript levels were approximately 4.5-fold lower in Mcslb 
resistant compared to susceptible genotype mammary glands whether animals were 
exposed to DMBA or not (Table 12). Thus, exposure to DMBA had no appreciable 
effect on Mier3 differences between susceptible and Mcsl b resistant genotype females. 
No significant differences in Mier3 transcript levels were detected between Mcsl b 
resistant and susceptible genotypes in spleen, thymus, ovary, or brain tissues (Figure 17). 
This suggests that Mier3 transcript level differences between Mcsl b alleles may be 
specific to mammary gland tissue. 
Mier3 Is Expressed as Three Different Variants in the Rat Mammary Gland 
Gene expression studies identified Mier 3 as a potential rat mammary carcinoma 
susceptibility-related gene. Interestingly, I also noted that Mier3 migrated as 2 bands on 
electrophoretic gels suggesting that different variants of Mier 3 may be being expressed; 
therefore, I sequenced these variants. Moreover, I also sought to check if these Mier3 
variants were expressed in the mammary gland and whether they were expressed at the 
same level between WF and COP tissue. 
Mier3 was cloned into a TOPO vector and many clones were sequenced. 
Sequencing showed that both Mier3 variants were expressed in the mammary gland 
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Figure 17: Mier3 is not differentially expressed between WF susceptible and MesIb 
resistant WF.COP congenic females in rat ovary, brain, .spleen, or thymus tissues. 
Expression (QPCR) levels are represented as log base 2 mean quantities of rat Mier3 
relative to rat Rplp2 expression +/- SO for each tissue listed on the X axis. Comparisons 
between WF susceptible (.) and Mcs I b resistant (_) females for each tissue were not 
statistically significant in one-way ANOV A with post hoc Fischer's PLSD test (Ovary: 
P=0.4755, N=8 WF, N=13 MesIb resistant line N3; Brain: P=O.3788, N=ll WF, N=10 
MesIb resistant line N3; Spleen: P=O.8854, N=8 WF, N=13 MesIb resistant line N3; 
Thymus: P=O.9277, N=8 WF, N=12 AlesI b resistant line N3). 
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(Figure ISA). One sequence identified the full length Mier 3 transcript (Figure ISB). The 
other showed intra-exonal splicing of exon 1 from bp 5S7 to bb 950 resulting in a 3611 
bp splice variant. This variant disrupts the normal A TG start site for translation and 
results in a new start site at position 1013 in the transcript. This new start site is in frame 
and would result in a 23 amino acid truncation at the N terminus of the protein (Figure 
ISC). It is not clear what the consequences of this truncation are on the function of the 
Mier3 protein. Additionally, it is not known whether this splice variant is conserved 
between species. 
I attempted to design Taqman gene expression assays to test whether there is a 
difference in expression of these splice variants between WF and COP mammary gland 
tissue samples; however, due to the constraints of the Taqman assay design this was not 
possible. Instead, I resorted to cloning Mier3 amplicons and counting clones (Table 13). 
Mier3 amplicons were cloned into a pCR2.1-TOPO vector, clones were picked and 
amplified and run on agarose gels. 96 clones were counted per sample and analyzed as 
the proportion of·fulliength Mier3 clones out of the total number of clones (containing 
full length Mier 3 plus spliced Mier 3) counted. Clone assay results demonstrated there 
was not a significant difference in Mier 3 splice variant expression versus the full length 
variant expression between WF and resistant WF.COP mammary glands (Figure ISD). 
Overall, the full length Mier3 transcript expression was much higher than that of the 
splice variant (76% and 79% for resistant N3 and susceptible WF samples, respectively). 
Further bioinformatic analysis showed that Mier3 sequence in the mouse and 
human have an alternatively used exon upstream of exon 1 that results in an alternative 
start site. The alternate exon usage transcribes three short exons and excludes 
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Figure 18: Three different Mier3 variants are expressed in the rat mammary gland. A; 
Image of electrophoretic gel of full-length Mier3 and Mier3 splice variant. B; Diagram 
of gene structure of full-length, spliced, and alternative 5'-transcript start variant of 
Mier3. C; Amino acid sequence comparison of the three different variants at the N-
terminus. Molecular weights of each protein are predicted based on sequence. D; 
Expression levels of full-length Mier3 compared to total Mier3 expressed. Levels 
depicted as proportion of full-length Mier3 in total. P values based on t-test of Arcsine-
transformed proportion values. E; Expression levels of alternative 5' -transcription start 
Mier3 variant. Expression is relative to Rplp2 expression. P values based on results of 
ANOV A and Fisher PLSD post-hoc test. Abbreviations: C, 100 base pair DNA ladder 
standard; FL, full length rat Mier3; SV, rat Mier3 splice variant. 
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Table 13: 
Primer and Probe Sequences Used for Analysis of Rat Mier3 Variants 
Assay Name 
!vlier3 Splice Variant Cloning and Sequencing 
Mier 3 Alternate 5' Transcription Start Site Sequencing 
Primer/Probe Name 
Mier3-F3 
Mier3-R3 
Mier3-alt -5' -end-F3 
Mier3-alt-5'-end-R3 
lv1ier3 Alternate 5' Transcription Start Site Taqman Expression Mier3-alt5'-I-F 
Mier3-alt5' -1-R 
Mier3-alt5'-1-Probe 
Mier3-alt5'-2-F 
Mier3-alt5'-2-R 
Mier3-alt5' -2-Probe 
Primer/Probe Sequence 
AGCCCGTGTATTCCAGACAG 
TGCAACCGTTGGAATTGTAG 
CTGGCGATTGGCTCAGG 
TGTCTAGGACTTTTTCATTTCCA 
ATGGCGGAGGCTTCCTTT 
TCAAAATCATGATCCTCAGAAGACA 
AGCCCAGTTGGGTCT 
AGCCCAGTTGGGTCTTTGTCT 
TCATAGTCATGGACCAGCACTCA 
CTGAGGATCATGATTTTG 
exon 1 (Figure 18B). I designed primers to the orthologous rat sequence and amplified 
and sequenced these in rat mammary glands (Table 13). To further determine whether 
there were expression differences in the alternative start form of Mier 3 compared to full 
length Mier3, I designed Taqman assays (Table 13). The results indicate a differential 
expression of the alternative start end variant between WF and COP untreated mammary 
glands (P=O.OOI7) (Figure 18E). Moreover, differential expression of the alternative 5'-
start variant appears to be specific to the mammary gland as differential expression was 
not observed in ovary and spleen tissue (Figure 18E). The alternative start site variant 
results in a transcription start site beginning upstream of the normal start site; however, 
the alternate transcription start site stays in frame with the downstream coding of Mier3. 
Although, the amino acid sequence is slightly altered at the N-terminus of the protein, 
there is no evidence suggesting this change should disrupt translation (Figure 18C). It is 
not clear what the implication of this alternative sequence has for Mier 3 function, but 
expression differences may be implicated in the reduced expression of total Mier 3 seen in 
previous gene expression assays. 
Mcslb Genotype Exhibits Pleiotropic Effects on Body Weight 
GW A studies have identified several breast cancer susceptibility loci; however, 
little is known about how the relative risks associated with these regions are affected by 
the established reproductive, behavioral, and anthropometric risk factors for breast cancer 
(often referred to collectively as environmental factors, although some, such as height, 
are in part genetically determined). Travis et al. detected a significant association 
between human breast cancer risk associated SNP rs889312 and stature in women (Travis 
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et aI., 2010). To detennine if rat Mcsl b might also exhibit pleiotropy, we analyzed rat 
body weight, which is infonnation we routinely collect and relevant because body weight 
is genetically correlated to stature in humans (Czerwinski et aI., 2007). Significant 
effects of Mcslb genotype (P<O.OOOI) and DMBA exposure (P=0.0014) on body weight 
at 12 weeks of age were detected (Figure 19). The interaction between Mcslb genotype 
and DMBA exposure was also significant (P=0.0004). Females with the Mcsl b resistant 
genotype had mean ± SD body weights of 200 ± 11 grams with DMBA (N=47) and 201 
± 7.7 grams without (N=33), which were not significantly different (P=0.7880). 
Comparatively, mammary cancer susceptible females had higher (P<O.OOOI) mean ± SD 
body weight at 192 ± 11 grams with DMBA (N=45) than unexposed susceptible females 
(N=34) who had a mean ± SD body weight of 180 ± 12 grams. 
Rat Mammary Carcinomas Express Higher Mier3 Transcript Levels Compared to 
Normal Rat Mammary Gland Tissue 
There was a significant difference in expression of Mier3, Gpbpl, and Map3kl 
between untreated N3 and WF mammary glands. However, only Mier3 exhibited a 
significant effect after DMBA induction. Therefore, I next sought to detennine whether 
there was an effect of Mcsl b genotype on levels of any of these transcripts in mammary 
carcinoma tissue. Further, Il6st was also included because it had been reported to be 
higher in rat mammary carcinomas compared to nonnal mammary gland tissues although 
in our studies it narrowly missed statistical significance (Qiu et aI., 2003b). 
Mier3 mRNA expression was measured in DMBA-induced mammary carcinomas 
from Mcslb resistant genotype (N=25) and susceptible (N=28) mammary glands by 
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Figure 19: Rat Mcsl b-resistant genotype is associated with higher body weight. Lower 
body weight at 12 weeks of age was observed in mammary carcinoma susceptible (.) 
compared withMcslb-resistant females (_) with DMBA and without (P< 0.0001 
and P=0.0007, respectively). Body weight was significantly higher in susceptible females 
that received DMBA compared to females not receiving DMBA (P < 0.0001). 
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QPCR and compared to adjacent "non-diseased" mammary glands. We collected total 
RNA from DMBA-induced mammary carcinomas (N=l or 2 per rat) and adjacent non-
diseased mammary gland tissue from 21-23 week old females (N=6 per genotype). There 
were no statistically significant differences in mammary carcinoma transcript levels 
between Mcslb genotypes for any of the four genes tested (Figure 20A). However, 
Mier3 transcript levels were significantly higher (1.8-fold) in mammary carcinomas 
compared to non-diseased mammary tissue. We also observed that Il6st was potentially 
different between mammary carcinomas and non-diseased mammary glands but did not 
meet statistical significance (Figure 20A). 
To determine whether Mier3 expression differences had been recognized in 
human samples, I queried The Cancer Genome Atlas (cancergenome.nih.gov) gene 
expression database by using the Oncomine (Rhodes et al., 2004) data-mining platform. 
Results show that levels of human MIER3 were, respectively, 1.33 and 1.20 fold higher in 
invasive ductal (N=392) and invasive lobular (N=36) breast carcinoma samples 
compared to pathologically normal breast tissues (N=61)(P=2.8x10- 13 , ductal; P=6.3xlO-
4, lobular; t-tests, Figure 19B). Thus, both human/rat MIER3/Mier3 levels are higher in 
breast/mammary carcinoma compared to non-diseased breast/mammary tissues. 
Discussion 
Within the interval delineated by SNP markers A12v and A1200 lie thirteen 
transcripts on rat chromosome 2 (Figure 5). To determine the mechanism by which the 
Mcslb locus confers resistance to developing mammary carcinomas when induced with 
DMBA I sought to, first, determine if any SNPs in the coding regions of these transcripts 
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Figure 20: Rat Mier3 transcript levels were significantly higher in DMBA-induced 
mammary carcinomas compared to non-diseased mammary gland tissue and 
human MIER3 was significantly higher in breast carCInomas compared with 
pathologically normal breast tissues. A; Mean ± SD are graphed for each variable. 
Expression of Mier3 mammary carcinoma (A) is significantly different than in adjacent 
non-diseased mammary gland tissue (e; *, P=0.0120; t, P=0.0569). B, Oncomine 
(www.oncomine.org) was used to query The Cancer Genome Atlas 
(cancergenome.nih.gov) gene expression database. Box plots of 10g2 median 
centered MIER3 transcript levels are shown for invasive ductal breast carcinomas 
(IDBC, N=392) and invasive lobular breast carcinomas (ILBC, N=36) compared with 
pathologically normal breast tissues (Breast, N=61). MIER3 transcript levels are 
significantly elevated in both tumor types compared to normal tissue (*, P < 0.05). 
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existed between susceptible and resistant lines. Of the thirteen, 9 were amplified and 
sequenced in rat spleen and thymus tissue: Gpbp1, Map3k1, Mier3, Ankrd55, 116st, 
1l31ra, Ddx4, SIc38a9, and Ppap2a. The other four were predicted transcripts and had 
not been validated. These were identified to be pseudo genes upon further investigation 
using bioinformatic tools. Sequencing results showed that there was no variation 
between susceptible WF and resistant WF.COP cDNAs. This suggests that the basis for 
Mcs1b COP-conferred resistance is regulatory in nature; therefore, further studies would 
be needed to identify potential gene candidates. 
There are many mechanisms that could be responsible for the Mcs1 b-conferred 
mammary carcinoma resistance phenotype, e.g., a variant in a promoter or enhancer 
disturbing transcription or a variant in a splice site disrupting mRNA processing. To 
investigate this mechanism the most suitable starting point was to examine expression 
levels of the transcripts. Gene expression of the nine validated transcripts was measured 
in mammary glands from animals treated with DMBA or not. Three transcripts were 
differentially expressed "between susceptible and resistant untreated mammary gland 
tissue samples: Gpbp1, Mier3, and }.1ap3k1. However, only Mier3 was statistically 
different between susceptible and resistant mammary glands after DMBA was 
administered. Moreover, 1l6st was previously reported to be upregulated in mammary 
carcinomas versus non-diseased mammary gland tissue (Qiu et aI., 2003a) but missed 
statistical significance in my studies. The interaction between Mcs 1 b genotype and 
DMBA exposure approached statistical significance for Map3k1; however, Map3k1 
expression was not differentially expressed in DMBA-treated mammary glands. The loss 
in statistical significance between DMBA-exposed susceptible and Mcs1 b resistant 
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females for Map3kl was due to an increase in mean level of Map3kl (P=0.0003) in the 
Mcs 1 b resistant genotype females with DMBA compared to age-matched controls of the 
same genotype without DMBA (Table 13). Map3kllevels were not different (P=0.2038) 
between susceptible WF mammary glands with or without DMBA. Regardless, Map3kl 
expression was not different between genotypes in DMBA-exposed mammary glands 
suggesting it was not a likely candidate. Hence, Mier3 stood out as the most likely 
candidate. Indeed, further study of Mier3 in rat tumor samples showed that Mier3 
expreSSIOn was also increased in mammary carcinomas compared to adjacent non-
diseased mammary gland tissue. This was reinforced by Oncomine microarray data 
confirming significantly elevated MIER3 expression in human breast cancer samples 
compared to normal breast tissue. 
Mier3 (Mesoderm induction garly response 1, family member 1) has not been 
characterized. However, based on sequence similarity, human MIER3 has been 
identified as having two key domains: ELM2 and SANT (2012). The MIER3 ELM2 
domain is from amino acid position 174 to 272. The ELM2 (Egl-27 and MTA1 
homology 2) domain was initially identified in the protein MTA1 a component of the 
NuRD chromatin regulatory complex and is involved in recruiting HDAC leading to 
changes in chromatin structure and resulting in transcriptional repression (Ding et aI., 
2003; Solari et aI., 1999). The SANT domain is located from amino acid position 277 to 
329. SANT domains are present in nuclear receptor co-repressor proteins and in the 
subunits of many chromatin-remodeling complexes (Aasland et aI., 1996). Moreover, 
SANT domains are characterized by tandem repeats of three alpha-helices arranged in a 
helix-turn-helix motif, each alpha helix containing a bulky aromatic residue making them 
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similar to the DNA-binding domain of Myb proteins involved in DNA binding and 
transcriptional repression (Grune et aI., 2003; Vargova et aI., 2011). Taken together, the 
presence of these domains suggests that Mier3 may bind DNA or regulate chromatin 
structure. 
Another Mier family member, Mier 1, has also been implicated in breast cancer 
progression (McCarthy et aI., 2008a). Human and rat MIER3/Mier3 (GenBank re~ 
NP _689835.3 and NP _001161472.1) gene products share 93% amino acid sequence 
identity, and human MIER3 and MIERI (GenBank re~NP_00I071172.1) have 54% 
identical amino acids based on BLAST (van Boxtel et aI., 2011). Mierl IS a 
transcriptional regulator that was discovered during a screen for fibroblast growth factor 
response genes (Paterno et aI., 1997; Paterno et aI., 1998; Thome et aI., 2005). Notably, 
MIERI physically interacts with ERa, Spl, and Creb-binding protein (Blackmore et aI., 
2008; Ding et aI., 2004b; McCarthy et aI., 2008b). The impact of hormone receptors and 
co-regulators on breast cancer development has been noted. Of particular interest, 
MIERI contains a C-terminal LxxLL motif referred to as LXD (McCarthy et aI., 2008a). 
The LXD is a highly conserved sequence shown to interact with variety of hormone 
receptors (Heery et aI., 1997). Moreover, studies have shown that different arrangements 
of the LXD confer varying specificities for different hormone receptors. For example, 
whereas a single LXD is sufficient for activation by ERa, different combinations of two, 
appropriately spaced, LXDs are required for actions of the thyroid hormone, retinoic 
acid, peroxisome proliferator-activated, or progesterone receptors (McInerney et aI., 
1998b). Strikingly, MIERI contains a single C-terminal LXD while MIER3 contains 2 
LXDs. Concordant with this, studies demonstrate that loss of MIERI may contribute to 
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breast cancer progression while our data indicate that reduction in Mier3 expression is 
protective against mammary carcinoma development. Taken together, a potential 
functional difference between MIERI and MIER3 may be that a difference in the number 
of LXD motifs between them results in physical interactions with different nuclear 
hormone receptors. 
Amplification of Mier3 m rat thymus cDNA for sequencmg resulted in two 
distinct bands on agarose gel. I further examined these bands by, first, confirming their 
expression in mammary tissue and sequencing. Sequencing revealed a full-length 
transcript and a splice variant in which a 363 bp segment was internally spliced out of 
exon 1. Additionally, the human and mouse MIER3Imier3 annotated sequences indicate 
that additional exons may exist upstream of exon 1. To test this, I successfully amplified 
and sequenced the rat orthologous region. Sequencing identified alternative usage of 
three short exons upstream of the original exon 1 being transcribed and skipping exon 1. 
Further, I measured gene expression of both variants. No differences were identified 
between the full-length and splice variant forms; however, the alternative start site variant 
was specifically down-regulated in resistant compared to susceptible mammary gland 
tissue. This was similar to the gene expression for all Mier3 isoforms performed 
previously, suggesting that the differences in total Mier3 expression may be defined by 
expression of the Mier3 alternative transcription start site variant. 
Both Mier3 variants have different translation start sites compared to the original 
full length Mier3 transcript. This would change the N-terminus of the Mier3 protein for 
each of these variants; however, neither rat Mier3 nor its human ortholog has been 
characterized and it is not clear what the consequence of these variants may be on protein 
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function. Examining the N-terminus with The Eukaryotic Linear Motif resource (Dinkel 
et aI., 2012) (http://elm.eu.org) shows that full length Mier3 contains a USP7-binding 
motif that is lost in the intra-exonal splice variant. Additionally, the alternative 
transcription start variant retains this USP7 -binding domain and adds a Casein kinase I 
(CKI) phosphorylation site (Dinkel et aI., 2012). USP7 is a deubiquitinating enzyme 
most commonly involved in regulation p53 regulation by deubiquitinating it and 
protecting it from MDM2-mediated degradation (Li et aI., 2002). CKI is a 
serine/threonine kinase involved in a variety of cell signaling pathways with a myriad of 
targets; however, it has been recognized to be involved in the activation of the Wnt 
signaling pathway (Davidson et aI., 2005). Therefore, the alternative start site form of 
Mier3 may be more mitogenic compared to the other isotypes. Taking everything 
together, Mier3 emerges as a positive regulator of cell proliferation affecting 
carcinogenesis in the mammary gland. 
Travis et al. reported pleiotropic effects on stature in women associated with the 
breast cancer-associated SNP rs889312 (Travis et aI., 2010). During the course of our 
experiments we routinely gather data on body mass of the rats. I used this to test whether 
a correlation existed between body mass and Mcsl b genotype since body mass can be 
used as a proxy for stature in humans. Lower body weight was observed in susceptible 
female rats compared to resistant congenic rats at 12 weeks of age. These animals differ 
essentially only at the Mcs 1 b locus and resistant female rats express less Mier3 than 
female rats harboring a susceptible Mcs I b allele. Therefore, this seems counter-intuitive 
as it is believed that Mier3 is mitogenic and increased expression would result in 
increased weight gain. However, as previously mentioned, PR is known to attenuate 
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effects of ERa (Hsueh et aI., 1976; Tseng and Gurpide, 1975). What is more, loss of 
estrogen activity has been identified to associate with a reduction in catabolism and an 
increase in weight, femur length, and bone density in male mice (Ford et aI., 2011). As 
discussed earlier in this chapter, human MIER3 contains 2 LXDs which may confer 
affinity for PR (McInerney et aI., 1998b). Therefore, a likely scenario would be that in 
resistant congenic females expressing lower amounts of Mier3, there is less PR bound to 
Mier3 and more that is available to inhibit ERa activity. ERa inhibition in these animals 
results in higher body mass compared to susceptible animals expressing higher amounts 
of Mier3. However, this is based on an assumption that Mier3 is binding to PR supported 
only by sequence similarity to Mier 1 and the presence of 2 LxxLL motifs. Therefore, 
this is entirely speculative and more empirical work is necessary to determine the 
mechanism by which Mier3 is working. 
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CHAPTER V 
CONCLUDING REMARKS 
Rat mammary carcinoma susceptibility, like human breast cancer risk, is complex 
as both are controlled by multiple susceptibility alleles and environmental factors. We 
have mapped rat Mesl b to a 1.1 Mb region of rat chromosome 2 using multiple congenic 
lines. We found that rat Mesl b is highly relevant to human breast cancer susceptibility as 
it contains genomic sequence orthologous to a low-penetrance breast cancer risk allele at 
human chromosome 5qll.2. This human susceptibility allele was first reported by 
Easton et al.(2007) in the first population-based breast cancer risk GWAS. Human 
5qll.2 has been confirmed to strongly associate with breast cancer risk in multiple 
independent studies of European- and Asian-descent populations (Antoniou et aI., 2008; 
Broeks et aI., 2011; Campa et aI., 2011; Garcia-Closas et aI., 2008a; Han et aI., 2011; 
Zheng et aI., 2010). This is the first report of a rodent complex disease susceptibility 
QTL with a GW AS-identified concordant human ortholog that had a probability of 
association below a stringent significance level ofPS 10 -7, which is widely deemed to be 
required for genome-wide studies. 
An experimental organism with a segregating concordant susceptibility allele 
implies that functional genetic studies may translate directly to human biology and 
disease. For example, Gould and colleagues reported that rat Mes5a, a WKY strain 
resistance QTL that is concordant to human MeS5A, acted in a non-mammary cell-
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autonomous manner that involves immune cells (Smits et aI., 2011a). Here, we used rat 
genetic lines to show that Mcsl b controls mammary cancer susceptibility by an 
undetermined mammary gland cell autonomous mechanism. While our result is in 
agreement with previous work that concluded a majority, but not all, of the COP rat strain 
resistance to mammary cancer is mammary gland autonomous (Zhang et aI., 1990); it 
further highlights that the WKY and COP strains may achieve mammary carcinoma 
resistance through different genetically determined cellular and molecular mechanisms 
that are likely genetically determined in humans as well. 
Further, Gould and colleagues developed a clonogenic transplant assay using rat 
MEC preparations to reconstitute mammary glands in the intrascapular fat pads of 
recipient rats (Gould and Clifton, 1985). To date no one has demonstrated an ability to 
induce carcinomas in these ectopic glands. The window for DMBA to induce 
carcinogenesis in endogenous rat mammary glands and whole mammary gland 
transplants was established to be at 50-55 days of age. Herein, I show that glands formed 
from the injection of MECs have a longer latency'compared to whole mammary gland 
grafts since DMBA-induced carcinogenesis is delayed to 70-75 days of age. This is a 
significant result for future use of this protocol. 
Most common genetic variation associated with human complex disease 
susceptibility appears to be located in non-protein-coding DNA. Since we found no 
genetic variation between susceptible and resistant allele Mcs 1 b ORFs, we conclude that 
Mcsl b is likely a noncoding gene regulatory element(s), such as a transcription factor 
binding site or noncoding RNA. This would be similar to the hypothesized identity of the 
human 5qll.2 breast cancer risk associated element. Human polymorphisms that are 
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contained in public databases and highly correlated with human 5q11.2 breast cancer risk 
associated SNP rs889312 are in non-protein-coding DNA. There are no known 
noncoding RNAs in either the human or rat ortholog; therefore, another type of gene 
regulatory element is likely responsible for or associated to susceptibility differences. 
Our studies suggest that MIER3 is a strong candidate breast cancer susceptibility 
gene at human 5qll.2. We identified Mier3 as a strong Mcs1 b candidate gene in this 
study based on different Mier 3 mammary gland transcript levels between susceptible and 
Mcs1b resistant genotypes. Lower levels of Mier3 in Mcs1b resistant genotype females 
were genetically determined and not dependent on the induction of mammary 
carcinogenesis by DMBA. We also found Mier3 levels significantly lower in non-
diseased rat mammary tissue compared to mammary carcinoma. Further, we queried The 
Cancer Genome Atlas gene expression database and noted that human MIER3 levels were 
higher in both ductal and lobular breast carcinomas compared to breast tissue. 
MIER3 or mesoderm induction early response 1, family member 3 (GenBank 
re~NM~152622) is an uncharacterized gene. We determined that MIER3 localized to the 
nucleus. Human and rat MIER3/Mier3 (GenBank re~ NP _689835.3 and 
NP _001161472.1) gene products share 93% amino acid sequence identity, and human 
MIER3 and MIER1 (GenBank re~NP _001071172.1) have 54% identical amino acids 
based on BLAST (van Boxte1 et aI., 2011). MIER1 physically interacts with ERa, Sp1, 
and Creb-binding protein (Blackmore et aI., 2008; Ding et aI., 2004b; McCarthy et aI., 
2008b). MIER1 contains one, while MIER3 has two conserved LxxLL sequences, which 
is a motif that facilitates nuclear hormone receptor interactions (Heery et aI., 1997). A 
potential functional difference between MIER1 and MIER3 may be that a difference in 
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the number of LxxLL motifs between them results in physical interactions with different 
nuclear hormone receptors (McInerney et aI., 1998a). In addition, MIERI and MIER3 
harbor ELM2 and SANT domains. The ELM2 domain is involved in recruitment of 
HDAC activity, which leads to changes in chromatin structure and results in 
transcriptional repression (Ding et aI., 2003). Likewise, the MIERI SANT domain 
functions in gene repression by interacting with Sp 1 and interfering with its ability to 
bind to its cognate site on responsive promoters (Ding et aI., 2004a). The presence of 
two LxxLL motifs along with the ELM2 and SANT domains suggests that MIER3 is a 
potential transcriptional repressor whose activity is mediated by interaction with nuclear 
hormone receptors. To test this idea, more functional studies are necessary to determine 
the mechanism by which Mier3 is controlling mammary carcinogenesis in the rat. 
In addition to MIER3, MAP3Kl and C50RF35 reside within the human 5qll.2 
haplotype block that associates with breast cancer risk. Even though there are no 
published studies in support, MAP3Kl is often considered the candidate breast cancer 
susceptibility gene at 5qll.2 due to its location within the breast cancer risk associated 
haplotype block and known function as a serine/threonine kinase. In our rat studies, 
Map3kl was differentially expressed between susceptible and Mcs 1 b resistant congenic 
rats that had not been induced to undergo mammary carcinogenesis; however, mammary 
glands that had been exposed to mammary carcinogen did not show a difference in 
Map3kl levels between Mel b alleles. An interesting result in our study with respect to 
Map3kl, which may have important implications for human studies of potential 
genotype-environment interactions, is exposure to mammary carcinogen resulted in 
increased mammary gland Map3kl levels for the Mcsl b resistant, but not the susceptible 
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genotype. We found no evidence of a rat orthologous transcript to human C50RF35 in 
multiple rat tissues. Further, exonic elements of C50RF35 have not been conserved in 
the rat. Therefore, we conclude that MAP3Kl and C50RF35 are not as likely as MIER3 
to be breast cancer susceptibility genes. 
I also identified multiple variants of Mier 3 expressed in the rat mammary gland. 
One of these variants exhibits alternate exon usage compared to the annotated Mier3 
transcript (GenBank re~NM _152622). Similar to what was observed in the original 
Mier3 gene expression studies, expression of the alternate exon variant is reduced in 
resistant Mcs 1 b mammary gland tissue compared to susceptible controls. The sequence 
of the variant differs only at the 5' end of the transcript, but is predicted to introduce a 
casein kinase phosphorylation site at the N-tenninus. However, the implications are not 
clear and more study is necessary to detennine whether differential expression of this 
variant affects mammary carcinoma susceptibility. Regardless, differential expression of 
this variant adds to our evidence that Mier3 is the most likely breast cancer gene. 
We noted that both rat Mcslb and human 5qll.2 exhibit pleiotropy. Travis et at. 
reported that carriers of the increased risk allele at human 5qll.2 were significantly 
shorter in height than non-carriers (Travis et aI., 2010). In our study, high risk female 
rats had lower body weight than Mcs 1 b resistant females. There is a predicted rat body 
weight QTL named Bwl that overlaps Mcslb and is associated with mesenteric body fat 
amount (Ogino et aI., 2000). Both human and rat study results are counter intuitive as 
one might expect taller women and heavier rats to be at greater cancer risk. Thus, it is 
important to note that, as expected with low-penetrance alleles, the quantitative 
difference between the means for each human genotype were subtle with overlapping 
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distributions. Mean height difference was 7 mm between non-carriers and carriers of the 
increased risk allele. In our study, we analyzed only body weight, and not specific 
components of body weight, such as bone density or fat. Thus, better descriptive traits 
would likely be more informative. It is notable that the pleitropic effects of these alleles 
opens the possibility that other experimental organisms, approaches, and study designs 
without focus on breast or mammary cancer may be useful to functionally characterize 
breast cancer risk associated genetic variation at 5qll.2. 
In conclusion, rat Mcsl b contains a mammary gland-autonomous allele and a 
non-protein-coding genetic element that is orthologous to the GW AS-identified human 
5qll.2 breast cancer susceptibility locus. We propose that MIER3 is a strong candidate 
breast cancer susceptibility gene. 
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Introduction 
During the course of my dissertation work some supporting experiments were not 
completed or were omitted into dissertation chapters as to not distract from the focus of the 
project. Despite this, some of the experiments and resulting data not included in the main 
body of this dissertation contributed to the conclusions of the work presented here and 
therefore are shown in the appendix. Below, these data will be explained in the context of 
the previous work described. 
Endogenous Control for Taqman Gene Expression Studies 
Introduction 
Early attempts to measure gene expressIOn of rat Mcsl b transcripts were 
performed using Gapdh as an endogenous control. However, the variability in Gapdh 
expression was high between samples and this was believed to be due to poor RNA 
quality. RNA quality was within acceptable limits (-1.8) for absorbance ratios at 260 nm 
and 280 nm when analyzed on a Nanodrop 2000 (Thermo Fisher Scientific); regardless, 
attempts were made to improve RNA isolation times and conditions but resulted in no 
change in the high variability in Gapdh expression between samples. I further analyzed 
RNA quality using RNA Pico Chips and an Agilent Bioanalyzer (Agilent, Santa Clara, 
CA). Based on RNA Integrity Numbers (RIN) determined by Bioanalyzer data, RNA 
was determined to not be compromised and that variability was due to variations in 
Gapdh expression itself and was not a good endogenous control candidate. Thus, I 
sought to identify a better endogenous control by measuring a panel of endogenous 
control gene candidates in WF and resistant WF.COP mammary glands. 
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Materials and Methods 
RNA clean-up using sodium acetate 
As stated above, Gapdh expression was highly variable between samples in initial 
gene expression assays. I initially believed this was due to degraded or contaminated 
RNA. To improve RNA quality I made some changes to the RNA isolation protocol. 
First, fewer samples were isolated in individual sessions to reduce the amount of time the 
RNA isolates were on ice. Total RNA was extracted with TRI-Reagent (Molecular 
Research Center) followed by standard chloroform/ethanol precipitation. To reduce 
possible solvent and DNA contamination RNA samples were further processed by a 1110 
v/v 3M sodium acetate and 2.5x v/v 100% ethanol wash on ice for 10 minutes followed 
by 80% ethanol wash followed by Turbo DNase (Life Technologies) treatment. Total 
RNA quantity and quality were measured with a Nanodrop 1000 (Fisher Scientific) and a 
Bioanalyzer with RNA 6000 NanoChips (Agilent). 
Endogenous Control Array 
To determine a good endogenous control candidate for the Mcs 1 b gene expression 
studies, I used an endogenous control array micro-fluidic card (Life Technologies). The 
card contains 16 different endogenous control probe/primer sets (Table S 1) preloaded 
into the card. cDNA was prepared from four mammary carcinoma resistant WF.COP and 
four susceptible WF mammary gland samples and normalized to 2 Ilg. They were 
loaded in triplicate into the endogenous control array card according to manufacturer 
specifications, centrifuged and run on an ABI Prism 7900 HT using standard conditions. 
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Statistical Analysis 
Endogenous control data were analyzed using SDS software (Life Technologies) 
and StatView (SAS Institute). Geometric means were calculated for each sample and 
Mann-Whitney tests were used to analyze expression between genotypes. 
Results 
3M sodium acetate results in higher quality RNA 
Total RNA had higher RIN and 28S and I8S bands were stronger when analyzed 
with the Bioanalyzer. However, differences in Gapdh expression between WF and 
resistant mammary gland samples did not change following reducing time on ice or by 
sodium acetate cleanup. 
Rplp2 is a good endogenous control gene for gene expression assays in rat mammary 
gland samples 
- Expression levels were highly variable between the genes in the panel (Figure 
S 1). Ct values for most of the Mcsl b target transcripts were in a range of ~20 - 25 cycles 
(data not shown). Therefore, genes with mean Ct values outside the range of 20 - 25 
cycles were omitted from further analysis. Candidate control genes were further 
analyzed for variance between replicates and between samples. Samples with SD higher 
than 0.5 Ct were excluded. 
Seven genes in the panel fell inside the allowable Ct range: Actbl2, Arbp, B2m, 
Ppia, Ppib, Rplp2, and Ubc (Table S2). Of these, only Rplp2 and Ubc had SDs below 
0.5 cycles for both genotype groups. Ubc was differentially expressed between WF and 
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Table SI: 
Endogenous control genes contained on ABI Endogenous Control Array MicroFluidic Card 
Name (Alternate Name) 
18S 
Beta-actin 
Attachment region binding protein 
Beta-2 microglobulin 
Glyeeraldehyde-3-phosphate dehydrogenase 
Beta-glucuronidase 
Hydroxymethylbilane synthase 
Hypoxanthine phosphorihosyltransferase 1 
Phosphoglycerate kina<;e 1 
Peptidylprolyl isomerase A (Cyclophilin A) 
Peptidylprolyl isomerase B (Cyclophilin B) 
Ribosomal protein, large, P2 
TATA box binding protein 
TransfelTin receptor (p90, CD71) 
I Tbiquitin C 
Tyrosine 3-monom .. ygenase i tryptophan 5-monooxygenase activation protein, ze!l:I.polypeptide 
Gene Symbol ABI product reference number 
18S Hs99999901 
Actb RnOO667869 
Arbp RnOO821065 
B2m RnOO560865 
Gapdh Rn99999916 
Gusb RnOO566655 
Hmbs RnOO565886 
Hprt Rn01527840 
Pgkl RnOO821429 
Ppia RnOO690933 
Ppib RnOO574762 
Rplp2 Rn014799271 
Tbp Rn01455648 
Tfrc Rn01474695 
Ubc Rn017898121 
Ywhaz RnOO755072 
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Figure SI: Mean Ct Values for Genes tested in ABI Endogenous Control Array. The 
geometric mean of the Ct value for each genotype is plotted. Error bars represent SD. 
The dashed line delineates the Ct value range desired for an optimal endogenous 
control. 
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Table S2: 
Results of ABI Endogenous Control Array Micro-Fluidic Assay 
Mean Ct value ± S.D. 
Gene Symbol WF WF.COP P valuea 
18S 21.5 ± 2.3 17.9 ± 1.8 0.0433 
Actb 22.2 ± 1.3 21.0± 1.3 0.2482 
Arbp 24.8 ± 1.2 24.6 ± 0.8 0.3865 
B2m 21.6 ± 0.6 21.3 ± 0.8 0.7728 
Gapdh 26.0 ± 1.1 24.4 ± 1.2 0.1489 
Gusb 29.0 ± 1.2 28.8 ± 1.2 >.9999 
Hmbs 28.0 ± 0.9 28.1 ± 1.5 0.7728 
Hprt 26.1 ± 0.7 26.4 ± 0.9 0.7728 
Pgkl 26.9 ± 1.0 26.7± 1.1 0.7728 
Ppia 22.2 ± 0.7 22.5 ± 0.8 0.7728 
Ppib 23.6 ± 0.7 24.0 ± 0.7 0.3865 
Rplp2 20.7 ± 0.5 20.8 ± 0.4 0.7728 
Tbp 28.9 ± 0.7 28.4 ± 1.3 >.9999 
Tfrc 33.3 ± 1.6 31.5 ± 1.8 0.1489 
Ubc 22.4 ± 0.5 23.0 ± 0.2 0.0433 
Ywhaz 26.2 ± 1.3 25.7 ± 1.0 0.7728 
a Non-parametric Mann-Whitney test 
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resistant WF.COP samples (P=0.0433); however, Rplp2 was not different between 
genotypes (P=0.7728). Therefore, Rplp2 was used in all subsequent gene expression 
experiments. 
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17~-HSD 
18S 
ACF 
ACI 
Actb 
AI 
Ankrd55 
Arbp 
B[a]P 
B2m 
BAC 
BC 
BN 
bp 
BPA 
C50rj35 
cDNA 
gDNA 
Chr 
CI 
LIST OF ABBREVIATIONS AND SYMBOLS 
17~-hydroxysteroid dehydrogenase 
18S 
Adherent cell fraction 
ACI rat strain 
Beta-actin 
Aromatase inhibitor 
Ankyrin repeat domain 55 
Attachment region binding protein 
Benzo( a )pyrene 
Beta-2 microglobulin 
Bacterial artificial chromosome 
Backcross generation 
Brown Norway rat strain 
Base pairs 
Bisphenol A 
Chromosome 5 open reading frame 35 (SET domain-
containing protein 9) 
Complementary DNA 
Genomic DNA 
Chromosome 
Confidence Interval 
182 
CKI 
cM 
CNV 
COP/Hsd 
CYP 
DCIS 
Ddx4 
DES 
DMBA 
DMEM 
DNase 
dATP 
dCTP 
dGTP 
dTTP 
dNTP 
El 
E2 
E3 
ECM 
EDTA 
ELM2 
Casein kinase 1 
CentiMorgan 
Copy number variant 
Copenhagen (Harlan Sprague Dawley) rat strain 
Cytochrome P450 
Ductal carcinoma in situ 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 
Diethylstilbestrol 
7,12 Dimethylbenz(a)anthracene 
Dulbecco's Modified Eagle Medium 
Deoxyribonuclease I 
Deoxyadenosine triphosphate 
Deoxycytidine triphosphate 
Deoxyguanosine triphosphate 
Deoxythymidine triphosphate 
Deoxynucelotide triphosphate 
Estrone 
Estradiol 
Estriol 
Extracellular matrix 
Ethylenediaminetetraacetic acid 
Egl-27 and MTAI homology 2 domain 
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ERE 
ERa 
ER~ 
Gapdh 
Gpbpl 
Gusb 
GWAS 
HCA 
HDAC 
Hmbs 
Hprt 
HR 
HRT 
IACUC 
IDBC 
Il31ra 
Il6st 
ILBC 
indel 
LD 
LTR 
LxxLL 
Estrogen Response Element 
Estrogen receptor alpha 
Estrogen receptor beta 
Glyceraldehyde-3-phosphate dehydrogenase 
GC-rich promoter binding protein 1 
Beta-glucuronidase 
Genome-wide association study 
Heterocyclic amine 
Histone deacetylase 
Hydroxymethylbilane synthase 
Hypoxanthine phosphoribosyltransferase 1 
Hazard Ratio 
Hormone replacement therapy 
Institutional Animal Care and Use Committee 
Invasive ductal breast carcinoma 
Interleukin 31 receptor A 
Interleukin 6 signal transducer 
Invasive lobular breast carcinoma 
Nucleotide Insertion/Deletion variant 
Linkage disequilibrium 
Long terminal repeat 
Leu-Xaa-Xaa-Leu-Leu domain 
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MAF 
Map3kl 
Mcs 
MEC 
MHC 
Mier3 
miRNA 
MMTV 
MTAI 
MWS 
NCI 
nitro-PAH 
NMU 
NSABP 
NuRD 
OR 
ORF 
PAH 
PCB 
PCR 
Pgkl 
PhIP 
Minor allele frequency 
Mitogen-activated protein kinase kinase kinase 1 
Mammary carcinoma susceptibility locus 
Mammary epithelial cell 
Major histocompatibility complex 
Mesoderm induction early response 1, family member 3 
MicroRNA 
Murine mammary tumor virus 
Metastatic tumor antigen 1 
Million Women Study 
National Cancer Institute 
Nitrated polycyclic aromatic hydrocarbon metabolite 
N-N itroso-N-methylurea 
National Surgical Adjuvant Breast and Bowel Project 
Nucleosome remodeling and histone deacetylase complex 
Odds ratio 
Open reading frame 
Polycyclic aromatic hydrocarbon 
Polychlorinated biphenyl 
Polymerase chain Reaction 
Phosphoglycerate kinase 1 
2-amino-l-methyl-6-phenylimidazo( 4,5-b )pyridine 
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PI3K 
Ppap2a 
Ppia 
Ppib 
PR-A 
PR-B 
PyVmT 
QPCR 
QTL 
R 
RF 
RIN 
Rplp2 
RR 
S 
SANT 
SD 
SERM 
SETD9 
SIc38a9 
SNP 
snRNA 
Phosphatidylinositol 3' kinase 
Phosphatidic acid phosphatase type 2A 
Peptidylprolyl isomerase A (Cyclophilin A) 
Peptidylprolyl isomerase B (Cyclophilin B) 
Progesterone receptor A 
Progesterone receptor B 
Polyoma virus middle T antigen 
Quantitative polymerase chain reaction 
Quantitative trait locus 
Resistant mammary carcinoma phenotype 
Radiofrequency/microwave radiowave emissions 
RNA integrity number 
Ribosomal protein, large, P2 
Relative Risk 
Susceptible mammary carcinoma phenotype 
Swi3, Ada2, N-Cor, and TFIIIB domain 
Standard deviation 
Selective Estrogen Receptor Modulator 
SET domain containing 9 
Solute carrier family 38 , member 9 
Single Nucleotide Polymorphism 
Small nuclear RNA 
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SS 
STAR 
Tbp 
TEB 
tet 
Tire 
U 
U6 
Ube 
UTR 
WF/Hsd 
(WF X COP) FI 
WHI 
WKy 
WMG 
Ywhaz 
Dahl/Salt-Sensitive rat strain 
Specific Targeted Research Project 
TAT A box binding protein 
Terminal end bud 
Tetracycline 
Transferrin receptor (p90, CD71 ) 
Undetermined mammary carcinoma phenotype 
Spliceosomal small non-coding nuclear RNA component 
Ubiquitin C 
Untranslated region 
Wistar Furth (Harlan Sprague Dawley) rat strain 
First generation from a Wistar Furth/Copenhagen mating 
Women's Health Initiative 
Wi star Kyoto rat strain 
Whole mammary gland transplant 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide 
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